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Remodeling
Abstract
Following myocardial infarction (MI), left ventricular (LV) remodeling initiates a series of maladaptive
events that may induce heart failure (HF). The use of injectable biomaterials is an attractive approach to
attenuate negative remodeling; however, optimal properties for these systems have not been identified.
The general hypothesis is that the properties of injectable hydrogels control the magnitude and duration
of stabilization in the weakened myocardium and the ability to attenuate LV remodeling. To test this
hypothesis, three specific aims were developed.
Increased stress due to geometric alterations is thought to exacerbate LV remodeling, causing infarct
expansion. Aim 1 utilized methacrylated hyaluronic acid (MeHA) hydrogels to demonstrate ex vivo that
macromer modification and oxidation-reduction (redox) initiator concentrations influence the mechanical
properties of hydrogel/myocardium composites and their distribution in tissue. Experimental data
incorporation into a finite element model of the dilated LV validated previous in vivo geometric outcomes
and generally demonstrated the largest stress reduction with higher mechanics and larger volumes.
Aims 2 and 3 evaluated the influence of temporal mechanical support on LV remodeling in an in vivo MI
model. Hydroxyethyl methacrylate groups were coupled to HA to produce hydrolytically degradable
hydrogels (HeMA-HA) polymerized via redox reactions. In Aim 2, hydrogel gelation, mechanics, and
degradation properties were varied by altering HeMA modification to yield low and high HeMA-HA with
similar gelation and initial mechanics but accelerated degradation kinetics compared to previously
studied low and high MeHA. High HeMA-HA was more effective than low HeMA-HA treatment in limiting
remodeling; however, high HeMA-HA only limited LV dilation for 2 weeks, while its high MeHA counterpart
sustained support up to 8 weeks. In Aim 3, a hydrogel/microsphere composite system was evaluated as
an alternative approach to enhance temporal support via collagen bulking through controlled macrophage
responses. The composite treatment increased myocardial thickness and decreased chamber volumes
compared to hydrogel alone.
This work demonstrates the significance of the magnitude and duration of mechanical support in
attenuating LV remodeling and provides insight on optimal material properties for injectable biomaterials
to develop better therapies to prevent HF.
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ABSTRACT

TUNABLE ACELLULAR HYALURONIC ACID HYDROGEL SYSTEMS TO
ATTENUATE LEFT VENTRICULAR REMODELING

Elena Tous
Jason A. Burdick, Ph.D.

!

Following myocardial infarction (MI), left ventricular (LV) remodeling initiates a

series of maladaptive events that may induce heart failure (HF). The use of injectable
biomaterials is an attractive approach to attenuate negative remodeling; however,
optimal properties for these systems have not been identified. The general hypothesis is
that the properties of injectable hydrogels control the magnitude and duration of
stabilization in the weakened myocardium and the ability to attenuate LV remodeling. To
test this hypothesis, three specific aims were developed.
Increased stress due to geometric alterations is thought to exacerbate LV
remodeling, causing infarct expansion.

Aim 1 utilized methacrylated hyaluronic acid

(MeHA) hydrogels to demonstrate ex vivo that macromer modification and oxidationreduction (redox) initiator concentrations influence the mechanical properties of
hydrogel/myocardium composites and their distribution in tissue.

Experimental data

incorporation into a finite element model of the dilated LV validated previous in vivo
geometric outcomes and generally demonstrated the largest stress reduction with higher
mechanics and larger volumes.
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Aims 2 and 3 evaluated the influence of temporal mechanical support on LV
remodeling in an in vivo MI model. Hydroxyethyl methacrylate groups were coupled to
HA to produce hydrolytically degradable hydrogels (HeMA-HA) polymerized via redox
reactions. In Aim 2, hydrogel gelation, mechanics, and degradation properties were
varied by altering HeMA modification to yield low and high HeMA-HA with similar
gelation and initial mechanics but accelerated degradation kinetics compared to
previously studied low and high MeHA. High HeMA-HA was more effective than low
HeMA-HA treatment in limiting remodeling; however, high HeMA-HA only limited LV
dilation for 2 weeks, while its high MeHA counterpart sustained support up to 8 weeks.
In Aim 3, a hydrogel/microsphere composite system was evaluated as an alternative
approach to enhance temporal support via collagen bulking through controlled
macrophage responses. The composite treatment increased myocardial thickness and
decreased chamber volumes compared to hydrogel alone.
This work demonstrates the significance of the magnitude and duration of
mechanical support in attenuating LV remodeling and provides insight on optimal
material properties for injectable biomaterials to develop better therapies to prevent HF.
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CHAPTER 1

An Introduction to the Heart, Myocardial Infarction and Cardiac Tissue
Engineering

1.1 The Heart
The heart is the muscular organ that is central to the cardiovascular system (e.g.,
the heart, blood vessels and blood); it serves the role of circulating oxygenated blood
throughout the body by continuously beating (approximately 100,000 times daily) [1].
Due to the heart’s crucial role in maintaining the body’s overall physiological function,
hindrance of its efficient pumping can lead to insufficient oxygenation of tissues, and in
extreme cases, death. To prevent this and/or treat cardiac complications, it is important
to understand the anatomy and physiology of the heart, both in healthy and diseased
states; this will lead to the development of more specialized clinical treatments to better
address pathological problems. To this end, this dissertation will focus on designing
treatments to attenuate the negative outcomes of left ventricular (LV) remodeling after
myocardial infarction (MI).
!
1.1.1 The Heart: Wall Structure and Function
The heart wall surrounding the outer portion of each cardiac chamber (right and
left atria and ventricles) is responsible for executing contraction to facilitate
transportation of oxygen and nutrients throughout the body [1, 2]. It is comprised of
three tissue layers surrounded by a protective fibrous membrane (i.e., the pericardium)
to prevent overextension [1]. The outermost layer is the epicardium and consists of both
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connective and mesothelial tissue, the myocardium is the middle and thickest layer and
is primarily made up of muscular tissue, and the inner most layer is the endocardium and
is composed of endothelial tissue [1, 3].

All three layers play significant roles in

maintaining the viability of the heart; however, the myocardium is the most relevant for
controlling cardiac function. The myocardium is composed of two primary cell types:
cardiac fibroblasts, which are responsible for producing and maintaining the cardiac
extracellular matrix (ECM), and cardiomyocytes, which are the cardiac functional units
and are responsible for initiating contraction [1-3].

1.1.2 The Heart: Myocardial Extracellular Matrix Structure and Function
The unique structure of the native myocardial ECM is a determining factor of its
biological signaling, mechanical properties and contractile function [2, 4-6].

It is

comprised of cardiomyocytes embedded in a matrix primarily composed of collagens I
and III, which facilitate cell alignment and cell interconnection to form cardiac fibers to
mediate contraction of the myocardium.

Specifically, this fiber network allows

cardiomyocytes to bear most of the wall load during systole (i.e., contraction), while
collagen struts transmit force. In diastole (i.e., relaxation), as collagen fibers uncoil they
resist further expansion, which prevents cardiomyocytes from overstretching [2].
On a macroscopic tissue scale, muscle fibers, oriented with their long axis, spiral
around the heart, and meet at the apex in a vortex conformation (Figure 1.1) [7-9]. The
distinct fiber orientation maintains the normal prolate elliptical geometry of heart, and is
energy efficient in cardiac function, allowing for uniform stress and strain distributions
throughout the heart [7-9]. This suggests that ECM structures both on micro (e.g.,
cellular/collagen fibril) and macro (e.g., tissue/fiber spiral) levels are essential to maintain
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normal heart function. This will be discussed in more detail regarding myocardial injury
in Section 1.2.

!
Figure 1.1 Muscle fiber spiral network of the heart (A) and apical view of the apical
vortex (B). Adapted from Buckberg [7].

1.1.3 The Heart: Coronary Vessels
The myocardial wall, like any other living tissue, requires nutrients and oxygen to
properly function. As blood enters the heart chambers during contraction, it is unable to
diffuse efficiently through the endocardium to the cells in the myocardium.

To

compensate, the heart has its own vessel circuit (the coronary vessels), which feeds off
the primary circulation system. Specifically, the coronary arteries branch from the aorta
and the coronary veins empty into the right atrium [1]. Given that these vessels are
crucial for delivery of nutrients and oxygen to the cardiomyocytes of the myocardium,
their obstruction can have negative repercussions including cell necrosis, ECM
disruption, and function (as discussed further below) [3, 4, 7, 10-13].
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1.2 Cardiac Complications: Myocardial Infarction (MI)
Approximately 6 million Americans suffer from heart failure (HF); ~70% of these
cases are associated with coronary artery disease (CAD), which causes MI [14, 15]. It is
estimated that these numbers will increase with time with approximately 600,000
Americans suffering their first MI and ~300,000 others having a recurrent attack within
the next year [15]. In general, MI triggers LV remodeling which involves a series of
maladaptive events that alter the ECM structure of the myocardium and consequently
the geometry of the heart, changing it from a prolate elliptical shape to a spherical (i.e.,
dilated) geometry (Figure 1.2) that is unable to recapitulate the function of the normal
myocardium [3, 4, 10-13, 16, 17]. These changes, particularly geometric alterations,
eventually may lead to significantly compromised function and HF [16]. This will be
discussed in greater detail in the next section.

!
Figure 1.2 Schematic illustrating infarct expansion and geometric alterations that occur
during LV remodeling. Adapted from Jessup et al. [17].
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1.2.1 Left Ventricular (LV) Remodeling: Micro-Scale Alterations
MI occurs following the occlusion of a coronary vessel, which leads to the
depletion of oxygen and nutrients to the myocardial tissue, cardiomyocyte necrosis and
initiation of LV remodeling [3, 4, 10-13, 16]. LV remodeling is a dynamic process that
involves both biological and mechanical changes and can be broken down into three
main phases: 1) acute ischemia and necrosis, typically during the first week post-MI, 2)
fibrosis generally ensuing the following 3 weeks, and 3) remodeling which can progress
for months [16].
Generally, the first stage of remodeling (i.e., acute ischemia and necrosis) begins
immediately after the onset of MI and is typically when the most dramatic alterations in
the ECM composition occur [4, 10, 11, 16].

Cardiomyocyte necrosis initiates an

inflammatory reaction in which cells infiltrate the infarct region to remove necrotic
cardiomyocytes and debris and latent matrix metalloproteinases (MMPs) are activated
[4, 10, 11, 16, 18]. MMP activation has been detected as early as 10 minutes post-MI
(porcine model) [19] and results in an imbalance between MMPs and tissue inhibitors of
metalloproteinases (TIMPs) (Figure 1.3). This imbalance precipitates a break down of
ECM proteins, including the collagen network responsible for structural support of the
aligned cardiomyocytes [4].

As will be discussed in more detail in Chapter 6,

fragmentation of cardiac ECM proteins is not limited to collagen and also includes
glycosaminoglycans such as hyaluronic acid (HA), which can facilitate the wound
healing events that occur during this phase of remodeling [10, 11]. As the collagen
network is disrupted, the cardiomyocytes that were embedded within slip out; ECM
disruption and loss of cardiomyocytes weakens the myocardial wall and renders it
susceptible to global geometric changes including chamber dilation and wall thinning.
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These changes can then lead to expansion of the infarct, increased global stress, and
ultimately HF, which will be discussed in more detail in Section 1.2.2 [3, 16, 20-22].

!
Figure 1.3 An imbalance of MMPs and TIMPs is present 8 weeks post-MI [18].

The fibrosis and remodeling stages comprise primarily the production and
remodeling of collagen to counteract the break down that occurs in the initial phase.
Fibrosis begins approximately 1 week after MI when the infarcted tissue is infiltrated by
fibroblasts and myofibroblasts (i.e., differentiated fibroblasts that can also contract the
scar) that initiate collagen production in an attempt to recover wall stability [4, 10, 11,
16]. Collagen deposition and stiffness of the infarct region increase in parallel during this
period [16, 23]. Remodeling begins ~4 weeks after MI and involves the remodeling and
crosslinking of collagen produced during fibrosis to generate a mature scare [4, 10, 11,
16]. There is no defined “end point” to this process as the “healing scar” is dynamic;
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however, studies suggest that by this point a thin non-functional scar has replaced the
once contractile healthy thick myocardium [4, 10, 11].

1.2.2 LV Remodeling: Macro-Scale Alterations
In addition to causing destructive alteration of the myocardial ECM at the
micro/cellular scale, the disruption of the native ECM, as briefly discussed above,
initiates global changes, including alterations in ventricular geometry and systolic and
diastolic function [4, 7-11]. When the distinct fiber spiral that ensures a prolated elliptical
geometry in the normal heart is disrupted, thinning of the myocardial wall into a spherical
(dilated) geometry can occur, causing increased global stress and inefficient function [7,
20-22]. Geometric changes may decrease normal ejection fraction (EF) by 50% [7].
Additionally, contractile deficiencies caused by collagen scarring force the adjacent
borderzone (BZ) region to compensate by increasing its workload, which can induce
cardiomyocytes to hypertrophy, stretch and decrease their contractile function [16, 24,
25]. To counteract this, BZ expansion may ensue, causing the mechanical burden to
extend to remote healthy regions of the heart [16, 24-26]. This process can propagate a
positive feed back loop and result in further infarct expansion, geometric alterations, and
increased stress until the onset of HF and heart function is severely compromised.

1.3 Current Treatments for MI
Current clinical treatments for MI are limited to either pharmacological
interventions and/or invasive surgical approaches.

Pharmacological approaches

generally aim to either restore blood flow to the ischemic tissue (e.g., blood thinners,
fibrinolytic drugs) or reduce the stress on the heart by decreasing blood pressure and/or
heart rate (e.g., ACE inhibitors, beta blockers) [27, 28]. Surgical procedures, in cases
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where the heart can still function, include bypass surgery and stent implantation to
restore blood flow [29, 30]. In cases of end stage heart failure, cardiac transplantation
still remains the gold-standard [31]. Due to a limited supply of donor hearts, left/ right
ventricular assist devices can also be implanted to improve function of the failing left or
right ventricle; however, their implantation is costly and requires an invasive implantation
procedure [32, 33]. Most of these interventions fail to directly treat the altered structural
state of the damaged myocardium; specifically, they do not replace the lost
cardiomyocytes nor do they stabilize the weakened myocardial wall, both of which could
assist in restoring cardiac function. Whole heart transplantation, the only one of the
described interventions that does achieve these goals, suffers from the extremely limited
donor supply, the need for invasive surgery, and life-long immunosuppressive therapy.

1.4 Tissue Engineering Approaches for LV Remodeling
Recent advances in tissue engineering (TE) are attempting to design better
treatments to target specific aspects of damaged myocardium post-MI. There are two
main TE approaches to treat MI: (1) cellular approaches that aim to replace the noncontractile scar with contractile tissue and (2) acellular mechanical strategies, which aim
to stabilize the wall to limit the destructive geometric changes that ensue during
remodeling.

1.4.1 Tissue Engineering: Cellular Strategies
Cardiomyocytes lack a regenerative capacity; this becomes a concern in MI
when approximately 1 billion cardiomyocytes (~20% of cardiomyocytes in the
myocardium) are lost, contributing to loss of contractile function [1, 34]. To address this,
groups have aimed to restore contractility of the infarct region by delivering cells to
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impart this function [3, 34, 35].

Endogenous cells have been homed to the injured

myocardium via delivery of growth factors such as stromal derived growth factor (SDF-!)
[36, 37].

Furthermore, a number of cell types including somatic cells (e.g.,

cardiomyocytes and skeletal cells) and stem cells (e.g., bone marrow-derived
mesenchymal stem cells, hematopoietic stem cells, adipose-derived stem cells,
embryonic stem cells) have been delivered via direct injection, seeding upon/within
implanted scaffolds, and/or cellular grafts to restore cardiac function [34, 35, 38-51].
While some improvements (e.g., remodeling and/or function) have been observed with
cellular approaches, it is unclear whether the source of improvement is due to the
direct/intended activity of the delivered cells. Reports have suggested that cells may
form a passive graft or induce paracrine signaling, leading to indirect cardiac benefits
[52, 53]. Cellular approaches are also limited in that most studies report low viability,
retention and engraftment of injected cells [3, 34, 35]. Although advances are being
made to better address engraftment issues, overarching concerns of cellular therapies
are the timing of their delivery, cell “dosage”, and cell source. No phase of remodeling
provides an ideal environment for cell survival due to high inflammation and limited
vasculature. Additionally, regeneration takes time and several maladaptive changes that
predispose the heart to HF occur early on in remodeling. To circumvent these limitations
recent efforts have focused on developing acellular approaches to mechanically stabilize
the disrupted injured myocardium to limit maladaptive geometric remodeling that occur
post-MI.
It should be noted that cell approaches are not limited to direct delivery of
cardiomyocytes and stem cells. Less direct approaches have also been investigated to
restore blood flow to the infarct through growth factor delivery (e.g., vascular endothelial
growth factor, VEGF, and platelet derived growth factor, PDGF) and cell delivery (e.g.,
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fibroblasts and endothelial cells) and with the delivery of cardioprotective cytokines to
decrease cell apoptosis (e.g., insulin-like growth factor, IGF-1) [45, 54-57].

These

approaches, however, are subject to the same general limitations as current clinical
treatments and the aforementioned cellular studies.

1.4.2 Tissue Engineering: Mechanical Strategies
Mechanical approaches to attenuate LV remodeling have recently gained interest
because they do not focus on regeneration, which as described is limited in the infarct
region. Instead they focus on providing mechanical stability to the weakened tissue to
prevent geometric alterations and limit increases in stress immediately following MI,
which are thought to be the primary cause of pathological processes that result in HF.
Non-conventional approaches to achieve normal myocardial geometry include surgical
procedures such as partial left ventriculectomy (the Batista procedure), which
reconstructs the dilated ventricle into a more elliptical shape that better represents a
healthy heart [58].

Data from FE modeling has demonstrated that removal of even

dysfunctional myocardium is detrimental to heart function; in addition, the procedure is
invasive and will probably not be performed in the United States again [59]. Polymeric
restraints have also been designed for direct placement around (Figure 1.4A) or
anchoring to a portion (Figure 1.4B) of the heart to physically prevent dilation (Figure
1.4C-E) by mechanically stabilizing and forcing it to maintain its original shape.
Polypropylene Marlex [60, 61] and polyester Dacron (e.g., CorCap cardiac support
device (CSD)) [62, 63] restraints have been employed in in vivo ovine MI models and
were effective in limiting geometric changes. Furthermore, clinical trials of patients with
HF demonstrated that treatment with the nitinol Paracor Medical Heart Net ventricular
support system limited remodeling [64]; more recently, five-year follow up results from
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the CorCap CSD “Acorn clinical trial” also showed that patients with HF treatment with
the Corcap had decreased ventricle chamber dilation [65].

While restraint

implementation has improved with time, they generally require an invasive surgery,
which is particularly not ideal for older patients.

!
Figure 1.4 Corcap CSD restraint wrapped around modeled heart (A) [63]. Marlex patch
placed over infarct region in ovine heart (B) [61]. Normal ovine heart (C), Marlex-treated
infarcted heart (D), and control infarcted heart (E) [60]. Images adapted from their
respective reference.

1.5 Summary
Motivated by the aforementioned studies, injectable biomaterials have recently
become a more appealing TE treatment to attenuate LV remodeling via myocardial wall
stabilization; their injectable nature allows for non-invasive delivery, potentially via
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catheter. A variety of natural and synthetic hydrogels have been investigated to provide
mechanical stability to the myocardium post-MI; a comprehensive review of these
techniques can be found in Chapter 3 [66]. While several materials have been studied,
there remains a lack of understanding of the mechanism involved in their success in
limiting remodeling. As discussed, myocardial function is dependent on the physical
properties of the myocardium, which are altered during dynamic remodeling; local
changes to the ECM may lead to increased susceptibility of the myocardium to global
geometric changes (e.g., dilation and thinning of the myocardial wall) making it difficult to
maintain normal function. It is important to consider the alterations that occur throughout
the progression of remodeling when engineering a treatment including: 1) the degree of
mechanical support needed and 2) the duration of treatment to limit maladaptive
alterations. This dissertation will focus on material design to fulfill these requirements by
designing novel hydrogel systems with tunable mechanical and degradation properties,
and investigating their efficacy in attenuating LV remodeling toward the prevention of
maladaptive changes and HF following MI.
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CHAPTER 2

Research Overview

2.1 Specific Aims and Hypotheses
Heart disease continues to be the leading cause of death in the United States;
approximately 82.6 million Americans suffer from cardiovascular disease with ~10%
suffering from myocardial infarction (MI). MI leads to left ventricular (LV) remodeling,
which involves a series of maladaptive events that can result in the onset of heart failure
(HF). Geometric alterations resulting from LV remodeling, specifically myocardial wall
thinning and dilation, are thought to be the root cause of exacerbated remodeling and
eventual impairment of cardiac function.

Despite advances in restraint technologies

targeted to prevent these maladaptive changes, these approaches are invasive and
have not been translated clinically.
To address this, there has been a recent focus in the development of acellular
biomaterials to impart stability to the weakened myocardium with the goal of limiting
geometric changes and subsequently decreasing global stress and maintaining heart
function. Although a range of materials have been investigated towards this strategy,
there is a lack of information on the specific material properties that lead to the best
outcomes.

Recently, a study was performed to independently evaluate the role of

material properties in mitigating negative remodeling.

Specifically, treatment with

methacrylated hyaluronic acid (MeHA) hydrogels demonstrated that material mechanical
properties play a critical role in stabilizing the infarcted myocardium as indicated by
increased thickness, decreased ventricle dilation, and limited infarct area measurements
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in an in vivo ovine MI model. This study initiated the work proposed and completed in
this dissertation. To elaborate on these findings, the general goal of this dissertation is
to further evaluate the role of material properties (including mechanics and degradation)
on the efficacy of injectable agents in attenuating LV remodeling.

The global hypothesis encompassing the work of this dissertation is as follows:
Engineered injectable hydrogels with tunable properties can provide enhanced control of
both the magnitude (via tunability of material mechanics and distribution) and duration
(via tunability of degradation) of stabilization in the weakened myocardium to provide
insight on design criteria for targeted therapies to attenuate LV remodeling.

This

hypothesis will be systematically tested in the following three Specific Aims.

Specific Hypothesis 1: Stress reductions in the dilated LV are dependent on the
mechanical properties and distribution of the injectable material.
Specific Aim 1:

To theoretically examine different formulations of MeHA

hydrogels with various mechanics and volume distributions to determine their
influence on stress reduction in a finite element model of the dilated LV. Similar
formulations (i.e., modification percent, initiator concentration) of MeHA hydrogels as
those investigated in previous MI work will be formed via oxidation-reduction (redox)
initiation reactions when injected into ovine cardiac explants to simulate in vivo injections
and then characterized in vitro as hydrogel/tissue composites. Biaxial testing will be
performed to assess the mechanics of each hydrogel/tissue composite formulation and
magnetic resonance imaging (MRI) will be employed to examine their distribution within
myocardial tissue. The mechanical and volume distribution data will be incorporated into
a finite element (FE) model to assess their influence on stress in the dilated LV; previous
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experimental geometric outcomes (e.g., increased thickness and decreased dilation)
from MeHA treatment will be correlated to stress reduction data for validation. Similar
studies will be performed with higher initiator concentrations to assess the influence of
gelation on hydrogel distribution and mechanics, and consequently, on stress reduction,
and will allow for relative comparisons between MeHA formulations.

Specific Hypothesis 2:

The magnitude and duration of mechanical stabilization by

injectable materials influences their efficacy in limiting LV remodeling.
Specific Aim 2:

To synthesize and characterize hydrolytically degradable HA

hydrogels and select formulations to assess the temporal role of mechanical
support in attenuating LV remodeling in an in vivo ovine MI model. HA will be
functionalized with varying amounts of the hydrolytically degradable functional group,
hydroxyethyl methacrylate (HeMA), to yield HeMA-HA macromers with a range of
modification efficiency. HeMA-HA hydrogels will be formed from these macromers by
redox initiation and characterized for mechanics (via compressive testing), gelation (via
rheometry) and hydrolytic degradation (via a uronic acid assay) to determine the
tunability of material properties. Two formulations of hydrolytically degradable HeMA-HA
hydrogels will be selected for investigation in an ovine in vivo MI model, and compared
to the previously studied only enzymatically degradable MeHA hydrogels for their
efficacy in attenuating LV remodeling.

Each HeMA-HA formulation will be tuned to

exhibit similar initial mechanics and gelation, but different degradation kinetics (based on
modification percent and initiator concentration) relative to its respective MeHA
counterpart. The influence of temporal mechanical support on LV remodeling will be
measured by myocardial thickness, end diastolic volume, end systolic volume, and
infarct area and compared to previous MeHA hydrogel results.
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Specific Hypothesis 3: Collagen bulking, induced by stimulatory hydrogel/microsphere
composites, to attenuate LV remodeling is dependent on the composite carrier and
particle formulation.
Specific Aim 3: To design various hydrogel/microsphere composites to evaluate
their influence on collagen production and macrophage response in a
subcutaneous model, and to identify an optimal composite formulation to
attenuate LV remodeling in an in vivo ovine MI model. Poly (DL-lactide-co-glycolide)
(PLGA) microspheres will be fabricated via a glass microfluidic device to form
microspheres that meet criteria to promote collagen production for constructive healing.
The same candidate HeMA-HA formulations selected in Aim 2 will be employed as
carriers for microspheres to form hydrogel/microsphere composites (via redox initiation)
with varying concentrations of microspheres.

Composites will be characterized for

mechanics, gelation, and degradation, similar to Aim 2. In vivo evaluation of the tissue
response to the composites will be performed in a murine subcutaneous model; the
influence of macromer properties and microsphere concentrations on the temporal
presentation of microspheres to the in vivo milieu and on the extent of bulking will be
evaluated

via

histological

(for

temporal

and

spatial

immunohistochemical (for spatial examination) assessments.

examination)

and

A selected composite

system (based on the timing and extent of collagen bulking from subcutaneous work) will
be assessed in an in vivo ovine MI model to analyze its ability to induce in situ collagen
bulking and attenuate ventricular remodeling with the same metrics as in Aim 2.
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2.2 Research Overview
The motivation for improving the design of injectable materials to treat LV
remodeling, specifically by optimizing their material properties, was already established
in Chapter 1. Chapter 3 will review natural and synthetic injectable materials that have
been evaluated to date in limiting LV remodeling and will introduce the described report
by Ifkovits et al. that demonstrated the significance of injectate (e.g., MeHA) material
properties (e.g., mechanics) on attenuating LV remodeling.
Chapters 4 and 5 will focus on in vitro data acquisition and FE modeling.
Theoretical modeling will be performed 1) to elaborate on the in vivo findings from MeHA
hydrogel treatment from the aforementioned study by translating experimental findings to
stress reductions and 2) to assess treatment of two additional MeHA formulations with
higher initiator concentration to examine stress between conditions of varied hydrogel
mechanics and distribution. Specifically, Chapter 4 will explore imaging modalities (e.g.,
x-ray and MRI) to determine the optimal method to accurately assess hydrogel volume
distribution in ovine myocardial explants. Radiopaque HA polymers will be synthesized
by addition of an iodinated moiety and imaged with a fluoroscope to assess their
radiopacity. MeHA hydrogels will be visualized via MRI with a contrast agent approach
involving the addition of iron oxide nanoparticles to impart hydrogel contrast and a noncontrast agent approach involving the alteration of imaging parameters to enhance
contrast. One optimized approach (i.e., non-contrast MRI) will be employed to quantify
volume distributions for each MeHA formulation. Chapter 5 will describe the mechanical
testing of MeHA hydrogel/tissue composites via compressive and biaxial techniques.
Biaxial methods will be optimized for hydrogel/tissue composite testing and used to
generate mechanical data that is physiologically representative of cardiac loading.
Chapter 5 will conclude by incorporating both volume data from Chapter 4 and biaxial
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mechanical data into an established FE model (collaboration with Dr. Jonathan Wenk at
the University of Kentucky) to simulate injections of each MeHA formulation into a dilated
LV and determine their respective influences on LV remodeling via stress simulations.
The next portion of this dissertation will investigate the influence of material
temporal mechanical support (e.g., treatment duration) with respect to the evolving
events of LV remodeling. An in vivo ovine MI model will be employed to assess the
efficacy of treatment with two hydrogel systems: 1) a hydrolytically degradable HA
hydrogel and 2) a hydrolytically degradable stimulatory HA/microsphere composite.
Chapter 6 will introduce a hydrolytically degradable version of methacrylated HA (HeMAHA) and detail macromer synthesis, purification, and hydrogel formation. The influence
of HeMA addition on hydrogel material properties (e.g., mechanics, gelation, and
degradation) will be assessed to determine the extent of system tunability. In Chapter 7
two HeMA-HA formulations will be selected for direct comparison to previously studied
MeHA hydrogels (i.e., featuring similar initial mechanics and gelation, but different
degradation profiles) to assess the importance of the duration of stabilization in
attenuating LV remodeling in a clinically relevant in vivo ovine MI model via
measurements for global ventricular geometry and infarct area.
Chapter 8 will describe an alternative material design to address the time
sensitivity of LV remodeling, where the timing and extent of wall stabilization are
dependent on the exposure and concentration of microsphere stimuli, respectively,
which induce collagen production through an inflammatory response.

PLGA

microspheres will be incorporated within HeMA-HA formulations similar to those selected
for Chapter 7 to form hydrogel/microsphere composites.

These composites will be

characterized in vitro to determine the influence of microspheres on properties including
mechanics, gelation, and degradation, and implanted in an in vivo subcutaneous model
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to examine the biological response elicited by each composite.

Based on this

characterization, a composite providing optimal bulking (e.g., timing and amount) will be
selected for analysis in an in vivo ovine MI model; the efficacy of the stimulatory bulking
agent in limiting LV remodeling will be assessed using similar metrics as in Aim 2.
Finally, Chapter 9 will summarize conclusions and major findings and discuss
future directions and limitations of each Aim.
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CHAPTER 3

Injectable Acellular Hydrogels for Cardiac Repair: A Review

(Adapted from: E Tous, B Purcell, JL Ifkovits, and JA Burdick, "Injectable Acellular Hydrogels for
Cardiac Repair," J Cardiovasc Transl Res, 2011, 4:528–542.)

3.1 Introduction
As described in Chapter 1, early geometric alterations and infarct expansion due
to extracellular matrix (ECM) break down have been associated with poor long-term
prognosis and have been identified as the mechanical phenomena that initiate and
sustain the process of adverse post-myocardial infarction (MI) left ventricular (LV)
remodeling that may lead to heart failure (HF) [1-10]. These changes cause abnormal
stress distributions in myocardial regions outside the infarction, especially in the adjacent
borderzone (BZ) region, putting this region at a mechanical disadvantage and causing
the infarct to further spread. With time, increased regional stress initiates a positive
feedback loop, propagating and exacerbating maladaptive biologic and mechanical
processes, which inherently alter the contractile properties of normally perfused
myocardium [11, 12]. Once initiated, these processes lead to a HF phenotype that is
difficult to reverse by medical or surgical means.
Over the past decade it has become clear that maladaptive mechanical
alterations are vital to consider when developing post-MI therapies [13-16]. Globally, LV
remodeling results in a change in the shape of the heart, shifting it from a prolated
ellipsoidal geometry to a more spherical shape with reduced transmural wall thickness.
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The Law of Laplace (Equation 3.1) illustrates how the resulting dilation (increased
radius) and thinning of the myocardium post-MI leads to increased stress; where stress
(T) is directly proportional to pressure (P) and the radius of curvature (R), and inversely
to the thickness of the myocardial wall (h).

T=

PR
h

(3.1)

As discussed in Chapter 1, previous work has demonstrated that the use of

!

ventricular restraints reduces infarct expansion by mechanically stabilizing the heart and
physically forcing it to maintain its normal shape [10, 17-20].

However, these

approaches are limited by the invasive procedure in which they are applied and clinical
adoption has not occurred. In order to circumvent the invasive surgical placement of
restraining devices early post-MI, our group and others have begun to explore the use of
injectable materials, and specifically hydrogels, to limit infarct geometric changes and
normalize the regional stress distribution [21-37].
Hydrogels are water-swollen polymer networks that exhibit many tissue-like
properties and have been explored for numerous tissue engineering applications [38-40].
Hydrogels can form through numerous techniques, including via self-assembly, through
non-covalent interactions with ionic species, through covalent crosslinking via chemical
reaction, and through thermal transitions that lead to gelation [38-40]. These methods
are advantageous in that they may be applied in a non-invasive manner (liquid to solid
transition) and can potentially translate to catheter delivery for minimally invasive,
percutaneous therapies.

This chapter will focus on common natural and synthetic

hydrogels that have been investigated to mechanically stabilize the myocardial wall via
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bulking (or thickening), as well as comment on the underlying mechanisms of therapy.
The reader should refer to Table 3.1 throughout this chapter, which summarizes the
various materials that have been investigated in animal models of MI.

Table 3.1 Summary of injectable hydrogels and their assessment in models of MI.
Hydrogel Type

Animal/Model

Inject
Time

Gelation
Mechanism

Injection
Volume

End
Point

Fibrin [21, 41, 71]

Rat: LAD ligation/ reperfusion

1 wk

Peptide-self
assembly

50 µL

6 wks

Fibrin, collagen, matrigel
[26]

Rat: LAD ligation/ reperfusion

1 wk

Peptide-self
assembly/Thermal

50 µL

6 wks

Fibrin and Alginate [37]

Rat: LAD ligation/ reperfusion

5 wks

Peptide-self
assembly/Ionic

10 wks

Alginate [44]

Rat: LAD ligation/ reperfusion

5 wks

Ionic

10 wks

Alginate [34]

Rat: Ligation of proximal left
coronary artery

1 wk

Ionic

130 µL

9 wks

Alginate [29]

Rat: Ligation of proximal left
coronary artery

1 wk and 2
months

Ionic

100 to 150 µL

2 and 4
months

Alginate [43]

Swine: Transient balloon
occlusion of LAD

4 days

Ionic

1,2, and 4 mL

2
months

Alginate/fibrin composite
[32]

Swine: Ligation of OM1 and
OM2

1 week

Peptide-self
assembly/Ionic

200 µL x 25

4 wks

Chitosan [61]

Rat: LAD ligation

1 wk

Thermal

100 µL

5 wks

Hyaluronic Acid [36]

Rat: Ligation of left circumflex
arteries

2 wks

Michael-type
addition

50 µL

6 wks

Hyaluronic Acid [54]

Sheep: LAD ligation and 2nd
diagonal coronary artery

30 min

Redox initiation

300 µL x 20

2
months

Collagen [22]

Rat: Ligation of proximal left
coronary artery

1 wk

Thermal

100 µL

6 wks

Matrigel [28]

Mouse: LAD ligation

Immediately

Thermal

50 µL

2 wks

Matrigel [55]

Rat: LAD ligation/ heterotopic
transplant

Immediately

Thermal

125 µL

2 wks

Naturally Derived ECM [33]

Rat: no infarct

N/A

Thermal

90 µL

N/A

Naturally Derived ECM [56]

Rat: no infarct

N/A

Thermal

90 µL

N/A

Dex-PCL-HEMA/PNIPAAm
[35]

Rabbit: Ligation of the
proximal left coronary artery

4 Days

Thermal

50 µL x 4

34 days

poly(NIPAAm-co-AAc-coHEMAPTMC) [25]

Rat: LAD ligation

2 wk

Thermal

100 µL x 5

10 wks

!CD-MPEG-PCL-MPEG [64]

Rat: LAD ligation

5 min

Self assembly

100 µL x 3

1 month

!CD-MPEG-PCL-MPEG [27]

Rabbit: LAD ligation

1 wk

Self assembly

200 µL

5 wks

PEG-VS [24]

Rat: LAD ligation

2 min

Redox reaction

100 µL (2 or 3)

13 wks
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3.2 Natural Hydrogels
3.2.1 Fibrin
Christman and colleagues pioneered the field of acellular injectable biomaterials
by exploring the effects of fibrin glue as a bulking agent [21, 26, 37, 41].

Fibrin has

natural binding domains for soluble growth factors and cellular integrin receptors,
motivating its use for wound healing applications. Although fibrin is commonly utilized
for these biological properties, it can also be used as a mechanical support for the
myocardium [21, 32, 37, 41]. Specifically, fibrin forms a crosslinked hydrogel in the
myocardium upon injection with a dual-barreled syringe. One barrel contains fibrinogen
and aprotinin, a fibrinolysis inhibitor, and the second barrel contains thrombin, factor
XIIIa, and CaCl2 [21, 26, 32, 41]. Following a similar mechanism to that involved in the
normal clotting cascade in vivo, when fibrinogen and thrombin are mixed, fibrinogen is
converted to fibrin which self assembles and is crosslinked via the factor XIIIa.
Christman et al. injected these fibrin hydrogels into the ischemic LV 1 week
following induced MI in rats (reperfusion-MI model) and animals were sacrificed 5 weeks
later. Echocardiograph and explant data showed that fibrin is capable of maintaining
fractional shortening (FS) and preserving infarct scar thickness after the material was
resorbed [21]. In later studies, using the same model, Christman et al. demonstrated the
ability of fibrin to substantially decrease infarct size and increase arteriole density in the
infarct area compared to control BSA injections [41]. These results imply that in addition
to its bulking effects, fibrin may also elicit a bioactive response that influences LV
remodeling.

Significant increases in neovasculature formation (capillary density)

following fibrin injection in rat models of MI were later confirmed by Huang et al. [26].
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3.2.2 Alginate
Natural materials that are relatively bioinert such as alginate have also been
explored as injectable hydrogels to treat MI.

Alginate is a linear seaweed-derived

copolymer consisting of linked "-D-mannuronate (M) and !-L-guluronate (G) residues
and can be crosslinked into hydrogels with the addition of divalent cations [42]. Unlike
fibrin, alginate must be modified with adhesive peptides to facilitate cell binding. Both
non-modified alginate and alginate modified with adhesive peptides such as Arg-Gly-Asp
(RGD) or Tyr-Ile-Gly-Ser-Arg (YIGSR) have been explored as bulking agents [29, 34, 37,
43, 44] and comparisons have been performed between the two [34, 44]. Yu et al.
compared modified alginate to non-modified alginate using a rat reperfusion-MI model
with injections 5 weeks post-MI, more indicative of a chronic response [44]. Five weeks
after hydrogel injections, both alginate groups improved FS, reduced LV dimensions and
significantly increased myocardial wall thickness compared to control BSA injections.
Although both non-modified and modified groups also increased the number of arterioles
in the infarct area, modified alginate resulted in higher densities, indicating the ability of
adhesive peptide modifications to promote angiogenesis following MI. Tsur-Gang et al.
also observed improved geometry and function following injection of non-modified
alginate hydrogels; however, they observed conflicting data with modified alginate
hydrogels [34]. Specifically, modified alginate showed a reduced benefit compared to
non-modified alginate in terms of LV diastolic and systolic dimension (LVDD and LVSD),
LV diastolic and systolic areas (LVDA and LVSA), FS, and fractional area change,
although no significant differences in relative scar thickness or blood vessel densities
were observed.
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3.2.3 Fibrin and Alginate Composite
Utilizing a large animal swine model, Mukherjee et al. injected composite
hydrogels containing both fibrin and alginate to prevent geometric LV remodeling [32].
One week post-MI, 200 µL injections (25 total) were applied to the infarct area via a
double barreled injection device; one component was comprised of fibrinogen,
fibronectin, factor XIII, plasminogen and gelatin-grafted alginate dissolved in an aprotinin
solution, while the second consisted of thrombin and 40 mM CaCl2.

Therapeutic

outcomes included increased posterior wall thickness 1 week post-injection and a
reduction in infarct expansion 21 and 28 days post-MI; however, no functional
improvements were observed. Other interesting findings included a significant reduction
of soluble collagen in the treatment groups, suggesting that collagen was less vulnerable
to protease degradation. This observation was supported by a significant decrease in
protease levels (e.g., MMP-2) in the composite hydrogel injection group, which could
favor infarct stiffening in the future.

3.2.4 Chitosan
Chitosan is a linear polysaccharide that is biocompatible and biodegradable and
therefore has been used in a wide variety of tissue engineering applications [45].
Chitosan hydrogels can be formed upon mixing commercially produced chitosan with a
glycerol phosphate and glyoxal solution. These gels exhibit a thermoresponsive gelation
that is tuned to occur at 37 °C by changing the glyoxal concentration, while hydrogel
degradation is controlled by the degree of deacetylation [46, 47]. In a rat infarct model, a
thermally responsive chitosan was injected 1 week post-MI [31].

Four weeks after

hydrogel injection, the myocardium thickness was significantly increased compared to
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PBS controls, even though the amount of chitosan present in the myocardium after 4
weeks had substantially decreased due to hydrogel degradation.

There were also

significant improvements in infarct size, FS, ejection fraction (EF), end systolic diameter
(ESD), end diastolic diameter (EDD), and microvessel density. Although the material
was not completely degraded at the end of this study, like fibrin, this is an example of a
degradable material that was effective in not only preserving thickness but also function.

3.2.5 Hyaluronic Acid
Hyaluronic acid (HA) is a polysaccharide that is abundant in the body and can
play several biological roles that include angiogenesis, cell migration, and scar reduction
depending on its molecular weight and the addition of function groups allows for
tunability in material properties [48-53]. In one example, acrylated-HA was mixed with a
thiol-terminated PEG crosslinker (PEG-SH4) and crosslinked via Michael-type addition;
the mixture was injected into a rat MI model 2 weeks post-MI [36]. Four weeks after
treatment, heart function was evaluated; HA treatment led to significantly decreased
infarct size, increased EF and increased arteriole and capillary density. Interestingly,
results showed significant increases in infarct thickness while histology showed
complete degradation of the HA gels. Improvements in this work were attributed to the
biological role of HA, which like fibrin has proven to play a large role in wound healing
applications. Additional work with engineered HA hydrogels [54] will be discussed in
Section 3.8 on modulating hydrogel properties.

3.2.6 Collagen
Collagen is a natural ECM protein that has been applied for LV remodeling
therapies due to the ability to inject as a liquid, which subsequently gels at 37 °C [22,
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26].

Collagen injections in 1 week old rat infarcts substantially increased infarct

thickness, stroke volume (SV) and EF compared to saline inject controls; there was also
a trend for improved end systolic volume (ESV) [22]. While this study did not show any
evidence of angiogenesis or cell infiltration, Huang et al, using a reperfused model, were
able to demonstrate both increased angiogenesis and myofibroblast infiltration in the
infarct zone compared to controls [26].

Contradicting results may be attributed to

variables in methodology (Table 3.1) or differences in collagen types and concentrations
used. Dai et al. used a mixture of collagen I (95%) and collagen III (5%) at 65 mg/mL,
while Huang et al. used a collagen I at 1 mg/mL.

3.2.7 Matrigel
As an alternative to hydrogels composed solely of isolated collagen, Matrigel is
commercially available hydrogel derived from the ECM that is primarily composed of
collagen, but also contains numerous other molecules derived from the basement
membrane.

Studies with Matrigel alone in a mouse model showed trends towards

increased scar thickening and improved function compared to infarct controls [28];
thickening and improved EDD were also observed in a rat model [55]. In addition,
studies by Huang et al. showed significantly increased capillary density with Matrigel
injection [26].

3.2.8 Extracellular Matrix Hydrogels
Extracellular matrix (ECM) components isolated from healthy myocardium have
been recently explored to treat MI. Singelyn et al. decellularized and solubilized the
ECM from porcine hearts for use as an injectable scaffold [33].

The isolated ECM

material maintained a complex composition including collagen and glycosaminoglycan
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content and exhibited a natural thermoresponsive behavior as it self-assembled into a
nanofibrous gel at 37 °C from a liquid precursor at 25 °C. Interestingly, the cocktail of
isolated ECM components stimulated the migration of human coronary artery endothelial
cells (HCAEC) and rat aortic smooth muscle cells (RASMC) in vitro.

For in vivo

application, 90 µL hydrogels were successfully pushed through a catheter into the noninfarcted myocardium of rats where they induced a significant increase in arteriole
formation 11 days post-injection. In later work, Seif-Narahi et al. isolated both porcine
and human pericardial ECM (PPM and HPM respectively) to evaluate their potential as
autologous scaffolds for treating MI [56].

Similarly, these gels polymerized under

thermal stimulation and maintained native components of the pericardial ECM. While in
vitro results demonstrated that PPM was more effective in promoting migration of
HCAEC, RASMC, and rat epicardial cells (RECs) compared to HPM, in vivo data 2
weeks post-injection (90 µL) indicated that both PPM and HPM similarly promoted
neovascularization (76 ± 13 arterioles per mm2 and 51 ± 42 arterioles per mm2,
respectively). Interestingly, stem cell evaluation revealed that although very slight, c-kit+
cells were present within the injection regions, suggesting a role in endogenous homing
of these materials. These studies demonstrate that providing cardiac-specific cues to
the injured myocardium via decellularized ECM injectable hydrogels provides a useful
strategy to promote cardiac-specific tissue formation.

3.3 Synthetic Hydrogels
Natural materials may provide numerous important cellular-interactive cues (e.g.,
adhesion and cell-mediated degradation), but are generally limited in the extent that their
properties can be adjusted (i.e., mechanics, degradation, and viscosity). In contrast,
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synthetic materials provide additional potential in engineering a variety of gelation
mechanisms and physical properties.

3.3.1 Poly(N-isopropylacrylamide)
One synthetic thermosensitive polymer, comprised of dextran (Dex) grafted
poly(caprolactone)-2-hydroxyethyl methacrylate (PCL-HEMA) and copolymerized with
poly(N-isopropylacrylamide)

(PNIPAAm)

termed

Dex-PCL-HEMA/PNIPAAm,

was

developed to gel in situ. Material injections were performed 4 days post-MI in a rabbit
model and resulted in significant reductions in infarct scar and improvement in EF and
LV end diastolic and systolic diameter (LVEDD and LVSD) compared to PBS control
injections when assessed 30 days after injection [35].

Significant thickening was

observed despite no histological evidence of material remaining.
Similarly, Fujimoto et al. synthesized a biodegradable, temperature responsive
hydrogel composed of N-PNIPAAm, acrylic acid, and hydroxyethyl methacrylatepoly(trimethylene

carbonate)

(poly(NIPAAm-co-AAc-co-HEMAPTMC))

with

slower

degradation than the previously discussed polymer (Figure 3.1) [25]. Like Dex-PCLHEMA/PNIPAAm, poly(NIPAAm-co-AAc-co-HEMAPTMC) was engineered to undergo
gelation at body temperature. In this particular study, a hydrogel with a maximum tensile
strength of 6.1 kPa and complete hydrogel degradation after 5 months was evaluated for
its efficacy in preventing LV remodeling in a rat MI model. The polymer was injected 2
weeks post-MI; after 8 weeks the myocardium thickness, EDA and fractional area
change were significantly improved compared to PBS injection controls.
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Figure

3.1

Chemical

structure

of

poly(NIPAAm-co-AAc-co-HEMAPTMC)

representative images of PBS (B) and gel

(A),

(C) injected hearts at 8 weeks, and

hematoxylin and eosin stained section of PBS control (D) and gel treatment (E) hearts at
8 weeks. Scale bar: 5 mm in (B, C), 500 µm in (D, E). Figure adapted from [25].

3.3.2 !"Cyclodextrin
Another synthetic material consisting of !#cyclodextrin (!-CD) and poly(ethylene
glycol) (MPEG-PCL-PEG) triblock polymer that has the ability to gel in situ has also
demonstrated therapeutic benefits when injected to target LV remodeling [27, 35].
Degradation can be controlled by the PCL block and hydrogels were formed upon mixing
the linear MPEG-PCL-MPEG polymer with !-CD. When injected 5 minutes post-MI in a
rat model, the hydrogel-treated groups showed a significant reduction in infarct size,
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!
!

LVEDD, LVESD, and an increase in FS compared to PBS inject controls. No increase in
neovascularization was observed [35].

In 1 week old infarcts in a rabbit model,

significant improvements in thickness, infarct size, LVEDD, LVESD, and EF were
observed with no increase in microvessel density [27].

3.3.3 Poly(ethylene glycol)
The aforementioned synthetic materials have all been degradable. In contrast, a
non-degradable vinyl sulfone derivatized poly(ethylene) glycol (PEG) (PEG-VS) has also
been investigated to treat MI [24]. PEG-based hydrogels are bioinert and can be tailored
to have high mechanical properties. PEG-VS was polymerized upon combination with
dithiothreitol (DTT) and injected into a rat MI model 2 minutes post-MI.

PEG-VS

significantly increased the wall thickness at 4 weeks, and although no longer significant,
was still thicker than saline controls at 13 weeks.

Despite PEG-VS thickening the

myocardial wall, echocardiograph analysis showed significant improvements in EDD
only 4 weeks after MI; this was not maintained at 13 weeks. FS was also not improved
in treatment groups. Here, in this small animal model, it is observed that prolonged
material presence (or stabilization) is not sufficient to attenuate LV remodeling.

3.4 Biological Cues
3.4.1 Stimulatory Agents
Likewise, the biological activity of materials cannot be overlooked.

A study by

Ryan et al. injected a stimulatory dermal and soft tissue filler (Radiesse) composed of
calcium hydroxyapatite microspheres suspended in an aqueous gel carrier of water,
glycerin, and carboxymethylcellulose [57].

The uncrosslinked gel carrier allows

endogenous cells to access the encapsulated microspheres to promote collagen
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synthesis [57]. Radiesse was injected into the myocardium 45 minutes after ligation in
an ovine MI model and analyzed at 4 weeks; injection resulted in a thickened myocardial
wall, increased global EF and reduced LV end systolic volumes compared to controls.
Unlike the previously mentioned hydrogel systems that directly bulk the myocardium
through hydrogel crosslinking, this approach provides an effective means to induce
tissue bulking by promoting the biological response to materials for attenuated LV
remodeling and preserved cardiac function [58-63]. A similar approach to stabilize the
infarcted myocardium will be discussed in more detail in Chapter 8.

3.5 Limitations of Experimental Assessment of Bulking Agents
From the above reviewed results, it is clear that bulking agents may attenuate
remodeling post-MI; however, the mechanism involved in their success still remains to
be elucidated. If anything, these results reveal the complexity in the material interaction
with the myocardial tissue, including both the biological (e.g., material remodeling,
inflammatory response) and mechanical (e.g., stress reduction) responses.

Variable

results from these studies indicate that myocardial thickness [24, 29, 32, 37], infarct size
[37], and/or increased angiogenesis [22, 27, 64] do not necessarily correlate directly with
improved heart function.

However, discrepancies in results could be due to

inconsistencies in methodology (Table 3.1) (e.g., animal models, infarct, amount of
material injected, timing of injection) and material properties, and their importance
should be considered when investigating LV remodeling. Specifically, several animal
models have been used to study the efficacy of bulking agents. The most popular model
is by far the rat model, possibly due to costs and ease of implementation; however, this
model has several limitations.

The most obvious is the lack of clinical relevance

associated with a small animal model, as well as infarct consistency. In the clinical
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setting, factors such as the LV volume and structure, material injection volume, and
method for injection will be very different than in the rat.
Material injection of bulking studies has been performed as early as immediately
post-MI [28] and as late as 8 weeks post-MI [29].

In separate studies with fibrin,

injection at 1 week was more effective in improving myocardium function [21] versus
injection 5 weeks post-MI [37]. Utilizing a permanent ligation rat model, Landa et al.
directly compared injections into new (1 week post-MI) and old (2 months post-MI)
infarcts and demonstrated the efficacy of alginate in both (although to different extents)
[29]. Recent infarcts resulted in improvements in wall thickening and LV dilation; while
older infarcts also showed improvements, results were less pronounced, implying that
post-MI therapies are more effective when applied early in the LV remodeling process,
potentially before irreversible processes have occurred. Similar to injection time, data
collection time points are also important to consider. The longest study evaluated in this
review was 3 months post-treatment [24] and 4 months post-MI [29].

3.6 Material Optimization: Theoretical Evaluation
Theoretical models have implied that material properties, specifically mechanics
and volume, are important to consider when selecting the type of bulking agent to
ameliorate dilation and increased stress in the myocardial wall [15, 65-67]. Using a finite
element (FE) model to simulate the effects of injecting a non-contractile material into the
myocardium, Wall et al. showed that bulking the myocardium was sufficient to decrease
stress in the myocardial wall post-MI [15]. More specifically, they demonstrated that
injections of 4.5% of the LV wall volume and 20% of the stiffness of the natural
myocardium into the BZ were able to decrease the fiber stress by 20% compared to
control simulations with no injections. Other approaches have validated the importance
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of infarct compliance using FE, as well as lump-parameter models and results reveal
similar overall beneficial outcomes [15, 65, 66]. FE models have also been employed to
evaluate the effects of material volume and distribution in the myocardium and showed
that they influence the extent of stress reduction (Figure 3.2) [15, 67]. After testing
several injection patterns it was determined that the maximum number of injections
leads to the highest reduction in fiber stress [67]. These simulations provide insight to
the relevance of bulking material properties, specifically mechanics and volume
distribution, and present more evidence to pursue injectable material therapies to control
LV remodeling. FE modeling will be employed in this dissertation to further understand
the role of injectable biomaterial treatment on attenuating LV remodeling; this will be
discussed in more detail in Chapters 4 and 5.

!
Figure 3.2 Reference FE model for infarcted canine heart (A) and modified FE model
with polymeric inclusion injection pattern into dilated LV (B). Figure adapted from [67].
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3.7 Material Optimization: Comparing Different Materials
Only two studies have directly compared different materials and their efficacy in
preventing LV remodeling [26, 37].

Utilizing an infarct-reperfusion rat model, Yu et al.

compared non-modified alginate to fibrin with injections applied 5 weeks post-MI [37].
Two days after injection, both materials were similarly effective in improving FS, LV
dimensions and wall thickness. However, 5 weeks post injection, alginate demonstrated
greater improvements than fibrin in FS, LV dimensions, and wall thickness. This could
be attributed to the extended presence of alginate in the myocardium while fibrin was no
longer detectable; however, fibrin treatment did result in thicker myocardial walls when
compared to BSA control injections.

Interestingly, while unable to promote cell

adhesion, alginate, like fibrin, resulted in significantly higher arteriole density. Despite
alginate’s superiority in long-term functional outcomes, fibrin treatment groups had
significantly smaller infarcts compared to controls. This comparison highlights potential
differences in the efficacy of material stabilization in preventing LV remodeling, due to
differences in material degradation and biological activity. In another study, Huang et al.
compared the extent of angiogenesis between fibrin, collagen and Matrigel post-MI and
determined that while all three polymers significantly increased capillary density, only
collagen significantly increased the degree of myofibroblast infiltration [26].

3.8 Material Optimization: Comparing Properties
Few studies have experimentally evaluated the role of material properties (e.g.,
volume and mechanics) on LV remodeling. A review of injectable materials illustrates
that a wide range of volumes have been injected as bulking agents (Table 3.1). As a
single example of differences in injected volumes, Leor et al. injected an alginatecalcium solution into the LAD 4 days post-MI via a coronary catheter in swine [43].
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During this time post-MI, the vasculature of the infarcted myocardium is leaky, allowing
the alginate mixture to be delivered to the infarct site. Due to inadequate levels of
calcium in the vasculature, the alginate solution does not crosslink until released into the
myocardium where levels of calcium suffice to stimulate gelation. Various volumes of 1,
2 and 4 mL were injected; 2 and 4 mL injections led to superior LVDA and LVSA with 2
mL injections resulting in significant thickening (despite material degradation) and more
pronounced trends for functional improvements. These findings illustrate the importance
of injection volume in stabilizing the myocardial wall [67]. Other parameters, such as
number and pattern of injections, although relevant through theoretical analysis [67],
have yet to be investigated in a clinically relevant model.
The influence of material properties may also be an important parameter to
control, yet few studies have investigated this, particularly in a controlled manner. This
may be due to limitations in material systems where various important properties can be
decoupled. For example, fibrin properties can be varied by adjusting the concentration
of fibrinogen and thrombin [68] and Martens et al. adjusted these parameters to optimize
fibrin viscosity and gelation for catheter delivery [69]. Similarly, alginate properties can
be adjusted by varying weight percent and the ratio of M and G units [70]. However, in
both of these systems viscosity may be changed during injection and lead to differences
in not only final mechanics, but also material dispersion and biomaterial concentration.
A recent study by Ifkovits et al. was the first to explore how the mechanical
properties of injectable materials influence LV remodeling (Figure 3.3) [54]. A highly
modified HA polymer (methacrylated HA, MeHA) with a high compressive modulus (43
kPa) was directly compared to lower modified MeHA with a low compressive modulus
(7.7 kPa) similar to that of native myocardium. This study demonstrated that although
both materials similarly thickened, or bulked, the infarcted myocardial wall, high MeHA
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was able to also decrease infarct size and dilation as well as improve function under
stress compared to the infarct control.

!
Figure 3.3 Chemical structure of methacrylated hyaluronic acid (A) and a representative
Masson’s Trichrome stain of the gel in myocardium 8 weeks post-MI (B). G= Gel. Scale
Bar= 50 µm. Figure adapted from [54].
!
This provides evidence that the mechanical properties of the injectable material
are important to consider for attenuating LV remodeling. Studies with tunable injectable
materials will broaden the understanding of factors, such as mechanics and degradation
that should be regarded to target LV remodeling via bulking agents. This dissertation
will elaborate on the work of Ifkovits et al. [54], to further understand the optimal material
properties for injectable materials to treat and limit LV remodeling.
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3.9 Summary
Although only in its infancy, it is clear that the field of injectable hydrogels to treat
the mechanical implications of LV remodeling has high potential as a translatable
therapy.

The lack of a cell source needed for transplantation will only accelerate

development of percutaneous delivered hydrogels as tissue bulking agents.

A wide

range of both natural and synthetic materials have been investigated and each has
unique properties, including mechanics, degradation, and cellular interactions. Due to
the variety of materials and models employed, however, it is still unclear as to what type
of material design is most effective in treating LV remodeling. Future work should further
investigate the various mechanisms in which these materials act, both biologically and
mechanically, and focus on clinically relevant parameters, such as the animal model and
mode of delivery.

Motivated by the advances and limitations of current injectable

materials, the remainder of this dissertation will focus on furthering our knowledge on
material design criteria to better treat patients with maladaptive remodeling due to MI.
Chapters 4 and 5 will, specifically, elaborate on the work of Ifkovits et al. [54] (discussed
in Section 3.8) and translate their in vivo outcomes to stress reduction data (as implied
by the Law of Laplace) from FE model simulations.
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CHAPTER 4

Optimizing Imaging Modalities to Visualize Hyaluronic Acid Hydrogel Distribution
in Cardiac Tissue

4.1 Introduction
The next two chapters will elaborate on the work of Ifkovits et al. (discussed in
Section 3.8), which employed injectable methacrylated hyaluronic acid (MeHA)
hydrogels as bulking agents to attenuate left ventricular (LV) remodeling [1].
Specifically, theoretical modeling based on data generated from different formulations of
MeHA hydrogels will be performed to examine how alterations in material properties
influence stress levels in the LV after infarct. This chapter will focus specifically on
developing and optimizing imaging techniques to quantify hydrogel distribution in the LV.

4.1.1 Theoretical Models
As discussed in Chapter 3, several theoretical models have been developed to
assess the extent of negative remodeling in the infarcted LV [2-6] and, more recently, to
test the theoretical efficacy of injectable materials as therapies [7-9].

Using a finite

element (FE) model to simulate the effects of injecting a non-contractile material into the
myocardium, Wall et al. showed that bulking (i.e., thickening) the myocardium was
sufficient to attenuate stress in the myocardial wall post-myocardial infarction (MI) [7].
Further investigation demonstrated the relevance of injectate properties such as volume,
injection distribution within the LV, and mechanics on the degree of stress reduction [7,
8]. As previously discussed and shown in Figure 3.2, Wenk et al. developed a FE model
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where inclusion (or injection) volume, geometry, and distribution in the LV could be
adjusted and were determined to influence stress levels [8]. Additionally, as described in
Chapter 3, passive material (e.g., mechanical) properties of injection regions can also be
varied in FE modeling [3, 7]. This chapter will focus on the experimental generation of
injection volume data in LV explants, while Chapter 5 will focus on the acquisition of
mechanical properties of hydrogel/tissue composites. Volume distribution patterns will
be used as previously reported [1]. This experimental information will then be employed
for FE modeling to investigate stress levels based on experimentally derived, rather than
theoretical input values.

4.1.2 Hyaluronic Acid (HA): Synthetic Versatility
Hyaluronic acid (HA) is a negatively charged non-sulfated glycosaminoglycan
that has been extensively employed in the field of tissue engineering (TE) [10-23] due to
its synthetic versatility and natural benefits in vivo, which will be discussed in more detail
in Chapter 6 [24-28]. HA is readily functionalized with reactive moieties at the carboxyl
and hydroxyl groups on each repeat unit for subsequent crosslinking into hydrogels [23,
29, 30]. Our group, as well as many others, have exploited this versatility to modify HA
using a range of chemistries (e.g., thiols [31], aldehydes [32], dihydrazides [33, 34], and
methacrylates and acrylates [1, 11, 22, 29]) to enable modulation of material properties
towards specific applications. In addition to the type and degree of modification, the HA
macromer molecular weight and weight percent can also be altered to achieve a wide
range of hydrogel properties [1, 11, 22, 29]. This dissertation will, however, focus on
evaluating the effects of the added reactive group; specifically, methacrylate and
hydroxyethyl methacrylate chemistries will be added to HA to form a range of percent
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modified MeHA and HeMA-HA macromers, respectively. Application of MeHA will be
first discussed in the next two chapters, and HeMA-HA will be introduced in Chapter 6.

4.1.3 Hydrogel Crosslinking for Cardiac Applications
HA macromers can be chemically crosslinked to form hydrogels via numerous
mechanisms (e.g., addition reactions and radical polymerization) that are defined by the
added reactive groups [35]. Radical polymerization of MeHA into hydrogels has been a
widely investigated system for both TE engineering applications and use in animal
models [1, 10-15, 29, 35].

In these systems, initiators and a stimulus such as

temperature, light, or oxidation-reduction (redox) forms radicals that propagate through
the methacrylate vinyl groups to form kinetic chain crosslinks. The result is a hydrogel
whose bulk properties are dependent on macromer properties including percent
functionalization and macromer concentration and, also, on initiator efficiency. Several
studies with MeHA hydrogels have shown that their mechanical properties can be
controlled by altering the extent of methacrylate modification [1, 35], since an increase in
reactive group concentration results in increased crosslinking and higher mechanics.
Additionally, initiator concentration has been demonstrated to influence mechanics, as
well as gel onset time based on the efficiency of crosslinking due to the availability of
free radicals [1].

Photopolymerization is commonly used to form these hydrogels ex

vivo for in vivo implantation or directly in situ where light can polymerize the macromer
within the intended tissue; however, these approaches are not practical for delivery of
material to the myocardium after MI [10, 11, 13, 29, 35]. To address this, hydrogels are
formed from methacrylated HA macromers using redox chemical initiation [1, 36] to
enable delivery of pre-polymer solutions with catheters and facilitate more controlled
delivery, which is critical for dynamic organs such as the heart.
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4.1.4 Experimental Versus Theoretical Work with HA Hydrogels
Ifkovits et al. employed two formulations (low and high percent modified) MeHA
polymerized by the redox initiators ammonium persulfate (APS, A) and N,N,N,N’,N’tetramethylethylenediamine (TEMED, T) where hydrogel dispersion and degradation
were the same and only hydrogel mechanics was varied [1]. This system was unique in
that the influence of one variable (mechanics) on the attenuation of LV remodeling could
be independently studied. The results concluded that mechanics did impact the extent
of LV remodeling.

Both MeHA formulations (7.7 kPa vs. 43.0 kPa) thickened the

myocardial wall to a similar extent, but only high MeHA (43.0 kPa) treatment limited
dilation of the ventricular wall (i.e., normalized end diastolic and normalized end systolic
volume, NEDV and NESV, respectively) and decreased the expansion of the infarct area
(Table 4.1) [1].

Table 4.1!Summary of hydrogel material properties and experimental outcomes from the
work of Ifkovits et al. [1]. Values presented as mean ± SD.

While Ifkovits et al. used in vivo experimental outcomes to demonstrate that a
hydrogel with higher mechanics provided the most benefits in attenuating LV remodeling
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[1], theoretical modeling can also be used to correlate this data with stress levels in the
heart wall [8].

In addition to those used in the described report [1], two additional

formulations crosslinked with higher concentrations of redox initiators will also be studied
to further examine the influence of crosslinking parameters on stress reductions; past
work has shown that increasing initiator concentration both increases mechanics and
accelerates the gel onset, influencing the hydrogel distribution in explants [1].

4.1.5 Imaging HA Hydrogels
While our group has previously shown that in MeHA hydrogels, redox initiator
concentrations influence gel onset (evaluated with rheometry) and distribution (assessed
in explants) [1], the employed technique was not adequate to acquire data for FE
analysis.

Distribution was analyzed in a non-quantitative manner (on the bench);

explants were simply sliced in half and rhodamine labeled HA (methacrylated rhodamine
attached to HA could be grossly visualized in explanted tissue) was macroscopically
distinguished and traced [1].

However, this is not an optimal technique to directly

compare hydrogel distribution between groups, since hydrogel/tissue samples would
need to be collected, prepared for histology, and sequentially sliced to construct a
representative three-dimensional (3-D) image. Other imaging techniques can address
these drawbacks. Specifically, x-ray and magnetic resonance imaging (MRI) modalities
will be compared for their ability to assess MeHA hydrogel distribution in the myocardium
and generate FE model inputs.

4.1.6 X-Ray Imaging
X-ray imaging can be utilized to acquire two-dimensional (via standard x-ray) and
3-D images (via x-ray computed tomography, CT); it is commonly used in the clinic as a
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diagnostic tool and has recently been used to image polymers [37-44]. In general, x-ray
generation occurs after high voltage is applied to accelerate electrons from the cathode
portion of the x-ray tube to the anode; it is here that x-rays are formed as high voltage
electrons strike. After filtration, the x-rays are delivered to the object to be visualized.
Image generation is dependent on the amount of x-rays that exit the object (Equation
4.1), where I is the number of x-rays exiting, I0 is the number entering, t is the thickness
of the object, and µ is the mass attenuation coefficient (an intrinsic property of the
material). Image contrast (C) is dependent on the differences between the exiting rays
of the area of interest and the background as defined in Equation 4.2 [40, 41].

I = I0e " µt

(4.1)

C = 1 " e "#µ#t

(4.2)

!
! The mass attenuation coefficient is important in determining the radiopacity of an object.
While it is dependent on several properties (coherent scattering, photoelectron
scattering, and Compton scattering), the photoelectron scattering is of most significance
in this work [40].
Photoelectric scattering is primarily dependent on both the atomic number (Z) of
the elements that comprise the tissue and on the photon energy (E) used to image.
Specifically, it is proportional to the cube of Z and inversely proportional to the cube of E
[40, 41]. In general, a higher atomic number results in more rapid electron absorption for
a given density and, thus, results in a brighter signal [40, 41].

Most soft tissues,

however, are comprised of smaller atoms (hydrogen, nitrogen, oxygen, and carbon),
thus larger atoms are typically used as agents to enhance contrast between the
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background tissue and region of interest [45]. For best contrast with these agents, it is
also important to consider the photon energy that is employed to image. The targeted
atom’s K edge energy, which is the energy above the binding energy of the K shell
electrons interacting with the photon (i.e., where mass attenuation is optimal) should be
accounted for when selecting a photon energy range for imaging [41].
X-ray detectability of conventional polymers is limited by their atomic make up, or
density, which is similar to that of soft tissue [46]. In order to distinguish polymers from
tissue, contrast agents with higher atomic number are often incorporated into the system
[40, 45, 46]. While contrast agents can be integrated into polymer systems by simply
mixing them in or via chelation, covalently binding the radiopaque entity enhances
control and eliminates concerns of leaching.
Iodinated agents have an atomic number of 53, which is much higher than any
natural element found in tissue; they have consequently become particularly popular as
a contrast agent [40, 45, 46] and been covalently bound to polymer backbones to
introduce intrinsic radiopaque material properties [37-39].

Blakley et al. conjugated

PEG-acrylate with 4-iodobenzene chloride to form the radiopaque moiety (IPEGA). This
was incorporated into the polymerization reaction with pentaerythritol tetrakis 3mercaptopropionate (QT) thiols and poly(propylene glycol) diacrylate where gels were
formed and the agent was introduced via Michael-Type Addition [37]. X-ray imaging of
gel samples revealed that radiopacity was achieved at 10% IPEGA.

Others have

introduced more dense iodinated functional groups into polymers to increase their
sensitivity in x-ray. Leon et al. modified N-isopropylacrylamide (NIPAAm) with 2,3,5triiodobenzoic acid (TIBA) with three times the amount of iodine used by Blakely et al.
[37, 39]. Their work successfully showed conjugation that resulted in radiopacity. These
studies demonstrated the ability to tune material radiopacity by altering the amount of
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iodinated substrate bound to the polymer as well as the type of radiopaque molecule
used. Motivated by these studies, for x-ray assessment to visualize HA, an iodinated
contrast molecule will be added for contrast.

4.1.7 Magnetic Resonance Imaging (MRI)
Due to its high temporal and spatial resolution, MRI is widely used in the clinic
and has also been a useful tool to experimentally assess LV remodeling [47, 48]. MRI
exploits the permanent magnetic moment of atomic nuclei or protons. In the absence of
a magnetic field, protons are naturally randomly organized, transitioning the orientation
of their spin (known as precession). To obtain an MR image of an object, the object is
placed in a constant (static) magnetic field B0, causing the protons to align in the
direction of the magnetic field; the protons precess about B0 at a frequency ($0)
proportional to the applied field of strength, where $0 is the Larmor frequency and % is the
gyromagnetic ratio (Equation 4.3).

(4.3)

" 0 = #$0

! This alignment creates a macroscopic magnetic moment that is referred to as
magnetization (M).

In the MR scanner, the imaged object is surrounded by a

radiofrequency coil (RF coil) that is tuned to the natural resonance frequency of the
protons so they can be specifically energized. The RF coil applies a series of B1 pulses
perpendicular to B0 that cause the protons to change orientation away from alignment
with B0.

When the RF signal is removed, the protons realign such that their net

magnetization M is again parallel with B0, in a process referred to as relaxation. During
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relaxation, protons lose energy and emit a signal in the form of a free-induction decay
(FID), which is detected and reconstructed to obtain 3-D MR images [47].
In order to generate a 3-D image, the FID signal must be encoded in three
dimensions. While the RF pulse is running, gradient coils embedded within the bore of
the MR scanner turn on to control the portion of the material that is analyzed. These
gradients encode phase and frequency information within each slice, resulting in data
that is generated in a series of slices to provide optimal spatial resolution and enable
reconstruction of a 3-D image.

Mathematical data from the MRI signal are later

converted to images by a Fourier Transform for interpretation by the user [47].
The MRI scanner interface controls parameters (e.g., the type of pulse sequence
and length of the pulse), which influence the magnetized protons and hence, the tissue
contrast generated by MRI. Specifically, the type (e.g., spin echo, gradient echo) of
pulse sequence influences proton orientation, echo time (TE) determines the time until a
signal or echo is generated, and repetition time (TR) is the time for a pulse to complete.
In combination with these parameters, MRI contrast also depends on the composition of
the imaged tissue, specifically its proton density and intrinsic relaxation properties.
These innate properties include the material’s longitudinal (T1) and transverse (T2)
relaxation times, which are the time required for protons to return to equilibrium or
rephase, respectively, after the application of a RF pulse; differences in proton density
and relaxation between different tissues differentiates them from one another.

The

dependence of magnetization M on these intrinsic properties and the gyromagnetic ratio
is illustrated by the Bloch equation (Equation 4.4), where Mxy is the transverse
magnetization and Mz is the longitudinal magnetization [47].
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(4.4)
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A major advantage to MRI is its sensitivity; the RF pulse is required to influence
the precession of only a few protons to successfully produce a 3-D image. However,
contrast agents can also be applied in small amounts to alter the intrinsic relaxation
properties (T1 and T2) of the imaged tissue or polymer [49-54]. Typical contrast agents
(e.g., gadolinium and iron oxide particles) possess paramagnetic properties that
influence surrounding protons and shorten their relaxation times to enhance contrast
with surrounding tissue [50-53]. Iron oxide nanoparticles are a particularly attractive
contrast agent in that they are superparamagnetic (e.g., elicit stronger effects on
surrounding protons) and can readily be chemically modified with functional groups,
including amines and carboxylic acids [45, 49, 54]. Iron oxide nanoparticle addition
leads to a shortened T2 relaxation time due to the accelerated dephasing of protons;
consequently, areas with iron oxide particles can be easily distinguished from those
without [45, 49, 54]. Additionally, chemical functionalization of iron oxide nanoparticles
provides a means to potentially facilitate binding with other polymers either through
electrostatic or covalent interactions.

This dissertation will exploit the electrostatic

interactions between positively charged aminated iron oxide particles with negatively
charged HA.
In addition to directly altering the proton makeup of the imaged object with the
incorporation of contrast agents, imaging parameters such as the type of pulse
sequence and length of pulse (e.g., TE and TR) can be adjusted.

Tailoring these

properties can vary the manner by which protons reorient and, thus, can be used to
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enhance differences in intrinsic relaxation material properties without the addition of an
exogenous contrast agent [45, 55]. A non-contrast approach is attractive in that it does
not add the extra variable of using a contrast agent.
This chapter will examine both x-ray and MRI as options to analyze distribution
and volumes of four MeHA formulations with low or high percent modification and low or
high initiator concentration (A/T) in ovine LV explants: low MeHA, low A/T and high
MeHA, low A/T (used by Ifkovits et al.) and low MeHA, high A/T and high MeHA high A/T
(Table 4.2) [1]. The technique that best represents hydrogel volume and distribution in
explants will be used to generate data that will be input into a FE model to evaluate
stress in Chapter 5.

4.2 Materials and Methodology
4.2.1 Synthesis of Methacrylated HA (MeHA) Macromer
MeHA was synthesized as previously discussed and is illustrated in Figure 4.1
[29]. Briefly, methacrylic anhydride (MA) (Sigma) at ~20 fold excess was added to a 1
wt% solution of HA sodium salt (Lifecore, 66kDa) in deionized water on ice. The solution
was titrated to maintain a pH of 8 by adding concentrated sodium hydroxide (NaOH) for
~6 hours or until the pH stabilized. The reaction was stirred overnight at 4 °C and on
day 2 half the amount of MA was added again and reacted by similarly maintaining a pH
of 8 on ice for ~ 4 hours, or until pH stabilization. Excess unreacted MA was removed by
dialysis (MW cutoff 5-8 kDa) against deionized water at room temperature (RT) for at
least 3 days with repeated water changes. The final product was frozen and lyophilized
and stored in powder form at 20 °C until further use. Methacrylate coupling to HA and
macromer purity was assessed via 1H NMR (Bruker, 360 MHz).
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Figure 4.1 Reaction schematic for MeHA synthesis.

4.2.2 Formation and Characterization of MeHA Hydrogels
MeHA hydrogels employed for experimental work were characterized as
previously discussed [1]; gel onset, mechanics, and degradation were assessed in two
formulations of MeHA (~30% and ~60% modified).

Macromers were mixed and

crosslinked at two concentrations of the redox chemical initiators APS (A) (Sigma) and
TEMED (T) (Sigma) (low A/T: 5 mM A and 5 mM T or high A/T: 12.5 mM A and 6.25
mM T) to form the following formulations of 4 wt% hydrogels: (1) low MeHA, low A/T, (2)
high MeHA, low A/T, (3) low MeHA, high A/T, and (4) high MeHA, high A/T. Gelation
was evaluated by monitoring the storage (G’) and loss (G’’) modulus using an AR2000ex
Rheometer (TA Instruments) at 37 °C under 1% strain and a frequency of 1 Hz in a cone
and plate geometry (1°, 20 mm diameter). To evaluate mechanics and degradation,
hydrogels were formed between two glass slides within a teflon mold sealed with
vacuum grease by mixing macromer solutions with APS and TEMED and incubating at
37 °C for 30 minutes. Compressive moduli were determined with a Dynamic Mechanical
Analyzer (DMA) (Q800 TA Instruments) at a strain rate of 10%/ min and moduli were
calculated at a strain from 10-20%. For degradation, samples were incubated at 37 °C
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for 8 weeks with phosphate buffered saline (PBS) changes at weeks 1, 2, and 4.
Degradation was assessed by collecting samples in PBS after 1, 2, 4, and 8 weeks and
performing a uronic acid assay to measure HA content [56].

4.2.3 Imaging HA via X-Ray
4.2.3.1 Synthesis of Radiopaque HA
A schematic depicting the reaction to couple a radiopaque molecule to HA is
illustrated in Figure 4.2.

!
Figure 4.2 Chemical synthesis of HA-GGGG-TIB and intermediate products (GGGGTIBA and HA-TBA).
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Synthesis of Radiopaque Spacer
A spacer group consisting of 4 glycine amino acids (Fmoc-Gly-OH) (Sigma)
(including the resin) was added to 2,3,5, triiodobenzoic acid (TIBA) (Sigma) to limit steric
hindrance and facilitate the attachment of the radiopaque entity to HA. A 0.25 mmol
reaction was run on a peptide synthesizer (Protein Technologies, Inc., PS3) with 4X
excess of the reagents (TIBA and Gly, G) and the coupling agent o-benzotriazoleN,N,N',N'-tetramethyl-uronium-hexafluoro-phosphate (HBTU) (Sigma) to the H-Gly-2ClTrt resin (AnaSpec, Inc.) in dimethylformamide (DMF) (Fisher). A 0.4 M N-methyl
morpholine (Fisher) solution in DMF was used for activation and a 20% piperidine
(Fisher) solution in DMF was used for deprotection. Residual DMF was removed from
the resin by vacuum filtration and was rinsed with dichloromethane (DCM) (Fisher). The
resin was cleaved with DCM and hexafluoroisopropanol (HFIP) (Sigma) (4:1) for 2 hours
and separated from the synthesized peptide by vacuum filtration. Most of the DCM was
removed by rotovap and the final product was precipitated in cold ether (Fisher). Ether
was removed and the peptide was collected, dissolved in deionized water, and frozen for
lyophilization. The final powder was stored at -20 °C until further use. Confirmation of
the final radiopaque spacer (GGGG-TIBA) was assessed via

1

H NMR and mass

spectrometry (Waters SQD with an Acquity UPLC).

Synthesis of HA-TBA
HA-sodium salt (Lifecore, 66 kDa) was converted into a tetrabutylammonium
(TBA) salt by performing an acidic ion exchange with the ion exchange resin (Dowex,
50W x 8-200) (Sigma) at RT for 8 hours.

After filtration for resin removal, the solution

was neutralized by titrating with tetrabutylammonium hydroxide (Sigma) until the desired
equivalent coupling of TBA to HA was reached (pH: 7.02-7.05) [30]. Final products were
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lyophilized and stored at -20 °C until further use. 1H NMR was performed to assess TBA
coupling.

Synthesis of Radiopaque HA
The radiopaque spacer was coupled to HA-TBA via an esterification reaction with
the catalyst dimethylaminopyridine (DMAP) (Sigma) and the coupling agent di-tert-butyl
dicarbonate (BOC2O) (Sigma) in anhydrous di-methyl sulfoxide (DMSO) (Acros) at 45 °C
for 20 hours. GGGG-TIBA and BOC2O were added at a 1:1 ratio to HA-TBA and trace
amounts of hydroquinone were added to the reaction to limit free reaction during
storage.
The synthesis product was dialyzed against deionized water (MW cutoff 5-8 kDa)
at RT overnight. Sodium chloride (NaCl) was added to the solution for exchange of TBA
with Na to facilitate precipitation in acetone.

The final precipitate was collected,

dissolved in water and dialyzed against deionized water at RT for 3 more days.

Final

products were lyophilized and stored at -20 °C until further use. 1H NMR was performed
to assess the degree of GGGG-TIB coupling to HA. (An extensive elaboration on the
optimization of this purification process can be found in Chapter 6).

4.2.3.2 Imaging of Radiopaque HA
The radiopacity of HA was assessed by imaging 4 wt% and 10 wt% solutions of
coupled HA-GGGG-TIB and non-coupled HA with a fluoroscope (Fluoroscan III Imaging
System) at a range of voltages (40-75 kVp).

Radiopaque macromer solutions were

compared to control HA solution (4 and 10 wt %) and a TIBA control.
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4.2.4 Imaging HA via MRI
4.2.4.1 Sample Preparation
Hydrogel distribution and volume within the myocardium was assessed using
explanted ovine myocardial tissue from the LV portion of the heart and simulating the
injection protocol as Ifkovits et al. performed in their experimental in vivo work [1]. In
general, 0.3 mL of the four hydrogel formulations (low or high modified MeHA, with low
(5/5 mM A/T) or high (12.5/ 6.25 mM A/T) initiators) were injected 3 minutes after initiator
addition. After 30 minutes, hydrogel/tissue samples were collected from the LV and
included the transmural injection region from the epicardium to endocardium.

4.2.4.2 MRI with Contrast Agents
Iron oxide nanoparticles (~40 nm, provided by Dr. Andrew Tsourkas and his lab
[53]) were used for preliminary imaging of HA. Electrostatic interactions between iron
oxide nanoparticles and MeHA macromers were confirmed with dynamic light scattering
(DLS) (Malvern Instruments).

Nanoparticles (100 µg/mL) were mixed with 4 wt%

solutions of low and high MeHA macromers for 30 seconds and diluted 1:100 in
deionized water for DLS. Nanoparticle/MeHA samples were compared to iron oxide
(100 µg/mL, 1:100 dilution) and MeHA controls (4 wt%, 1:100 dilution).
Nanoparticles were mixed with MeHA macromer solutions prior to the addition of
A (5 mM) and T (5 mM) initiators at a range of concentrations (10-200 µg/mL) and
injected into LV explants to determine the optimal range needed to accurately represent
hydrogel distribution. (Note: A different high modified version of MeHA (~66% modified)
was used for the pilot nanoparticle concentration study). MR imaging was performed
using a 9.4 Tesla 31 cm horizontal bore MR Spectrometer (Varian) with the following
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parameters: echo time= 5 ms, repetition time= 308 ms, matrix= 256 x 256 x 24, field of
view= 30 x 30 mm2, voxel size= 0.117 x 0.117 x 1.00 mm3. A concentration of 100
µg/mL nanoparticles was selected to image the four hydrogel formulations and a
gradient echo pulse sequence was used to visualize injected explants (n=2/formulation)
with the following parameters: echo time= 5 ms, repetition time= 308 ms, matrix= 256 x
256 x 32, field of view= 40 x 40 mm2, voxel size= 0.156 x 0.156 x 1.00 mm3. Images
were processed with ImageJ software and hydrogel/tissue volumes were calculated
using ITK-SNAP segmentation software [57].

4.2.4.3 MRI without Contrast Agents
Injected explants were imaged without contrast agents by adjusting image
parameters to exploit intrinsic material properties; a spin echo pulse sequence was
employed and the echo time (30-60 ms) was adjusted for optimal contrast. Voxel size
was also altered (0.234 x 0.234 x 1.00 mm3 vs. 0.234 x 0.234 x 0.234 mm3) to optimize
resolution.

After optimization, final settings used for non-contrast imaging were as

follows: echo time= 40 ms, repetition time= 5.8 s, matrix= 128 x 128 x 128, field of view=
30 x 30 mm2, voxel size = 0.234 x 0.234 x 0.234 mm3.
Prior to testing the hydrogel formulations, the non-crosslinked MeHA macromer
(n=3) was injected into myocardial explants to determine whether it could be visualized
at the selected imaging parameters. Non-crosslinked MeHA was injected into explants
identically to hydrogel forming macromers, but the solutions did not contain initiator.
Samples were imaged at days 0, 1, 2, 3, 4, and 5 to examine contrast differences
between the HA injection and background tissue. Explant samples were rinsed 6X at RT
with 50 mL of sterile PBS (1% penicillin streptomycin (P/S)) and overnight at 4 °C in 200
mL of sterile PBS for 2 days; samples were rinsed the final 3 days at 4 °C in 200 mL of
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sterile PBS with daily PBS changes.

Images were converted into NIFTI files using

imageJ software and converted to their correct dimensions with convert3D (c3D
software).

Contrast was quantified using ITK-SNAP after MRI bias correction was

performed with an N4 algorithm [58, 59]; the percent change in intensity between
injected HA and background tissue was quantified over the course of 6 days (i.e., days
0-5).

Five slices in 3 regions of the explant were evaluated (near the epicardium,

myocardium, and the endocardium).
Crosslinked samples (n=4/formulation) were imaged at day 3 (when the average
percent change in intensity between non-crosslinked HA and tissue was ~5%); samples
were washed 6X with 50 mL sterile PBS (1% (P/S)) for 2 days (i.e., day 0 and 1) at RT
and overnight in 200 mL at 4 °C, and 1 day (i.e., day 2) at 4 °C in 200 mL of sterile PBS.
Images were converted to NIFTI files with the correct dimensions and a MRI bias
correction was performed as discussed. Automatic segmentation was performed using
Atropos (an ITK-based multivariate n-class open source segmentation algorithm
distributed with ANTs) [60, 61] to distinguish hydrogel from the background tissue and
for initial segmentation. The input domain component included only the tissue portion of
images, and N4 images were segmented using a smoothing factor of 0.1 (mrf 1.0,
1x1x1) and defining 3 tissues (i.e., 3 distinct regions of segmentation).

A manual

segmentation for hydrogel was subsequently performed; Atropos results were employed
as initial detection criterion and hydrogel was defined as a percent change in intensity
between HA and tissue above 7% (i.e., one standard deviation (SD) above the average
change in intensity at day 3 in non-crosslinked studies).
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4.2.5 Statistical Analysis
Data is presented as mean ± SD or mean ± SEM (standard error of the mean) as
indicated in the figure captions. Differences in composite volumes were assessed using
a one-way ANOVA with Tukey’s post hoc evaluation. For all comparisons p<0.05 was
considered to be statistically significant.

4.3 Results and Discussion
4.3.1 MeHA Hydrogel Formation and Characterization
Two formulations of MeHA (~30% and ~60% modified) were synthesized as
previously described and as shown in Figure 4.1 [1]; their degree of functionalization
was determined via 1H NMR by integrating the acrylate peaks resonating at & ~6.20 ppm
and & ~5.80 ppm with respect to the HA backbone (Figure 4.3A). As discussed by
Ifkovits et al., material properties such as gelation time and mechanics can be tuned by
varying the percentage methacrylation [1].

Additionally, initiator concentrations also

influence hydrogel properties; here, the redox initiators APS (A) and TEMED (T) were
employed for hydrogel generation (Figure 4.3B) where bulk properties (e.g., mechanics
and gelation) were altered by the extent of crosslinking. In this chapter we focus on four
formulations in total with low or high percentage modification and low or high A/T to
explore the influence of initiator parameters on MeHA gelation and distribution and
ultimately stress reduction in the infarcted myocardium.

Gelation was assessed by

performing a time sweep upon mixing of the component solutions, where gel onset was
defined as the intersection of the storage (G’) and loss (G’’) moduli (Figure 4.3C). Gel
onset results for all four formulations are summarized in Table 4.2.
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Figure 4.3 1H NMR spectrum (D2O) of representative MeHA macromer (A). Schematic
of hydrogel formation via redox initiation (B). Representative rheological time sweep,
where the intersection of the storage and loss moduli is defined as the gel onset (C). In
panel A, peak 1= protons on N-acetyl group on HA, peak 2= protons on alkene of
methacrylate group, and peak 3= protons on methyl group on methacrylate.
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Table 4.2 Summary of methacrylate modification, initiator concentration and gel onset
time for all four hydrogels formulations investigated. *= formulations investigated by
Ifkovits et al. [1]. Values presented as mean ± SD.

4.3.2 Imaging HA via X-Ray
4.3.2.1 Synthesis of Radiopaque HA
As discussed in the introduction of this chapter, x-ray visibility is contingent on
the mass attenuation coefficient of the imaged object; thus, groups have incorporated
additional radiopaque chemistries into materials to enhance this property for
visualization [40, 41, 45]. Motivated by the work of Leon et al., we sought to generate a
radiopaque version of HA by covalently attaching an iodinated entity in a similar fashion
(Figure 4.2) where addition should enhance hydrogel contrast.
A spacer group was synthesized to limit steric hindrance between the targeted
acid and the bulky iodinated benzene ring to encourage binding to HA. As described in
Methods, formation of the spacer groups entailed the addition of 4 Gly amino acids to
TIBA and was performed on a peptide synthesizer.

1

H NMR was used to confirm the

successful production of GGGG-TIBA, where protons on the benzene rings (*) resonate
at & ~7.62 and & '8.25 ppm (Figure 4.4A). Mass spectrometry was also performed with
a detected peak of 728.97 g/mol at 720 m/z corresponding to the molecular weight of
GGGG-TIBA (Figure 4.4B).
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Figure 4.4 Chemical structure and 1H NMR spectrum (DMSO) of GGGG-TIBA with
labeled peaks (*) corresponding to the protons on the benzene ring (A). Mass spectrum
confirming the production of GGGG-TIBA (~728 g/mol) at the mass to charge ratio of
~720 m/z (B).

The solubility of the HA sodium salt (Figure 4.5A) is limited to aqueous solvents;
thus, to render it soluble in DMSO for functionalization, the sodium salt was converted to
a TBA salt.

TBA addition to HA was confirmed with 1H NMR by the presence of

additional peaks corresponding to the protons on 4 butyl groups at resonances of &
~3.24 ppm, & ~1.67 ppm, & ~1.42 ppm, and & ~0.98 ppm (corresponding to peaks, 2,
3, 4, and 5, respectively Figure 4.5B). The degree of TBA addition (~1.4 TBA molecules
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per HA repeat unit) was assessed by integrating with respect to the N-acetyl group
corresponding to the HA backbone (resonance of & ~ 2.10 ppm).

!
Figure 4.5 Chemical structure and 1H NMR spectrum (D2O) of HA sodium salt (A) and
HA-TBA salt (B). Peak 1= protons on the N-acetyl group on HA. Peaks 2, 3, 4, 5=
protons on butyl groups of TBA.

HA-TBA was reacted with GGGG-TIBA in DMSO and purified by dialysis and
acetone precipitation.

Coupling of GGGG-TIBA to HA was assessed with 1H NMR

where the protons corresponding to the benzene ring (*) were integrated with respect to
the N-acetyl group corresponding to the HA backbone (peak 1) (Figure 4.6) to confirm
~12% modification.
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Figure 4.6 Chemical structure and 1H NMR spectrum (D2O) for representative HAGGGG-TIB. Peak 1= protons on the N-acetyl group on HA. *= protons on the benzene
ring of GGGG-TIBA.

4.3.2.2 Imaging of Radiopaque HA
After successful coupling of GGGG-TIBA to HA, HA-GGGG-TIB solutions were
imaged and compared to non-coupled HA with a fluoroscope to evaluate their
radiopacity (Figure 4.7).

4 wt% solutions (coupled and non-coupled) were made to

simulate the concentration of hydrogels used in the work by Ifkovits et al. [1]; 10 wt%
solutions (coupled and non-coupled) were also evaluated to increase the concentration
of the groups. Imaging was performed at a range of voltages to best account for iodine’s
K-edge energy. Visually, HA-GGGG-TIB solutions lacked contrast and appeared similar
to non-coupled HA solutions and the PBS control (Figure 4.7B). Whereas, positive TIB
powder was clearly visible (Figure 4.7A). It is important to note that these images are
positive images rather than the negative images typically produced in an x-ray film.
Fluoroscopes commonly convert the transmitted radiation from x-ray into light for real
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time imaging [62]. Overall, these data suggest that 12% modification is not sufficient to
impart radiopaque properties to HA.

!
Figure 4.7 Representative fluoroscopic images (56 kVp and 0.023 mA) of PBS and TIBA
controls (A) and HA controls and HA-GGGG-TIB at 4 wt% and 10 wt% (B).

Past work suggests that higher concentrations (wt% and modification of the
contrast agent) are needed to enhance contrast in radiopaque agents [37, 39, 63].
However, this is not desirable since too much GGGG-TIBA addition could alter the
properties of MeHA hydrogels. For example, excessive addition of GGGG-TIBA could
limit MeHA modification since the methacrylate is also added to the hydroxyl group of
the HA backbone. In this investigation, our goal was to keep material properties of
,%!
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MeHA hydrogels consistent with the work of Ifkovits et al. [1]. This work indicated that xray imaging is insufficient for HA detection for purposes of the current studies and was
not further explored.

Specifically, to circumvent this problem, a different imaging

modality with less dependence on contrast agent concentration was explored.

4.3.3 Imaging HA via MRI
4.3.3.1 MRI with Contrast Agents
Aminated iron oxide nanoparticles are particularly attractive for HA imaging due
to their ability to bind to HA [64]. DLS assessment revealed that positively changed
aminated nanoparticles formed electrostatic interactions with negatively charged HA
(Figure 4.8); for example, the addition of MeHA macromer to iron oxide nanoparticles
resulted in a shift in both the iron oxide and MeHA control curves, corresponding to
increases in particle diameters.

!
Figure 4.8 DLS plot evaluating electrostatic interactions between iron oxide particles
and MeHA macromers.
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As discussed in Methods, for explant work, nanoparticles and initiators were
mixed with MeHA macromers and 0.3 mL of the precursor solution was then injected into
the LV portion of ovine explants 3 minutes after initiator addition. Initial studies entailed
performing a particle concentration (10-200 µg/mL) sweep to determine the optimal
concentration for hydrogel imaging.

Hydrogels (with iron oxide nanoparticles) were

imaged with MRI, and volumes were quantified.

Hydrogel visualization was particle

concentration dependent (Figure 4.9); a drop in signal and detected hydrogel volume
was observed at concentrations lower than 100 µg/mL. At concentrations greater than
100 µg/mL, the detected volumes were comparable, suggesting that they were
accurately representing the entire injection volume.

Thus, for the next study, a

nanoparticle density of 100 µg/mL was selected to examine volume and distribution of
the four hydrogel formulations (Figure 4.10). These preliminary results (n= 2/condition)
indicate that addition of iron oxide nanoparticles in a small quantity is an effective
method to detect hydrogel volume and distribution differences between hydrogel
formulations. While effective, as trends will be confirmed and discussed in more detail in
non-contrast agent studies, the incorporation of particles into hydrogels could potentially
alter their properties; thus, a non-contrast agent approach where image parameters
could be altered without influencing hydrogel properties was explored.
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Figure 4.9 Representative MRI slice after injection of 66% modified MeHA, low A/T
mixed with a range of iron oxide particles (10-200 µg/mL) into the myocardium (A) and
their respective 3-D construction of the injection region (B). Scale bar= 1 cm.
!

!
Figure 4.10 Representative MRI slice after injection of each hydrogel formulation mixed
with iron oxide particles (100 µg/mL) into the myocardium (A) and the respective 3-D
constructions of the injection region (B). Scale bar= 1 cm.
,(!
!
!

4.3.3.2 MRI without Contrast Agents
The proton makeup of a water swollen HA hydrogel is different than that of
tissue; thus, when injected into an explant, the endogenous properties of the composite
hydrogel/tissue region are different than tissue alone. It is not completely understood
how much of this is due to changes in proton density or relaxation times, yet hydrogels
should be detectable without the inclusion of contrast agents. However, the extent of
detectability is dependent on the imaging parameters. For example, when implementing
the imaging parameters used in Section 4.3.3.1, only sporadic detection of portions of
more highly crosslinked networks were observed.

However, by varying image

parameters (type and time of pulse) we were able to more clearly detect and image all
hydrogel formulations. Specifically, a spin echo pulse was implemented and the TE was
altered (Figure 4.11). Images became darker with higher TE (60ms) and lighter with
lower TE (30 ms); for optimal contrast an intermediate TE (40 ms) was selected for
hydrogel imaging.

!
Figure 4.11 Representative MRI slices of high MeHA, low A/T injections into the
myocardium without contrast agent at various TE (30-60 ms). Scale bar= 1 cm.

In addition to altering acquisition parameters to better visualize the hydrogel
within the explant, resolution was also adjusted by altering the voxel size, where a
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smaller voxel size corresponded to thinner slices and better hydrogel image resolution
relative to larger voxels (Figure 4.12). When quantified, volume size decreased with the
smaller voxel size, suggesting that larger voxels overestimated volumes. Based on this
data, a smaller isotropic voxel size (0.234 x 0.234 x 0.234 mm3, Figure 4.12) was
selected for further imaging.

!
Figure 4.12 Representative 3-D construction of high MeHA, low A/T injection into the
myocardium imaged at different voxel sizes (low resolution: 0.234 x 0.234 x 1 mm3 and
high resolution: 0.234 x 0.234 x 0.234 mm3) to assess resolution effects.

Before beginning non-contrast imaging with MRI on hydrogels, initial studies
were performed to better understand what portion of the original injected MeHA solution
(i.e., crosslinked vs. non-crosslinked MeHA) could be visualized using the selected
imaging parameters. To address this, non-crosslinked MeHA was injected into explants,
and the contrast between HA and the tissue was assessed at days 0-5 both visually
(Figure 4.13A) and quantitatively (Figure 4.13B) by calculating the percent change in
intensity between the injection area and background tissue.

Visual and quantitative

assessment revealed that non-crosslinked MeHA could clearly be discerned at day 0 (1,*!
!
!

4 hours following injection).

During the following 5 day time course, the intensity

difference between the non-crosslinked injection and tissue decreased with time with
differences reaching a plateau by day 3 as un-crosslinked material diffused from the
tissue. Thus, this time point was chosen for imaging of hydrogel formulations.

!
Figure 4.13 MRI slice of non-crosslinked MeHA macromer without contrast agent
injected into myocardium and tracked 5 days after injection (day 0) (A).

Quantified

percent change in intensity between non-crosslinked MeHA (n=3) portion and tissue
background over the course of 5 days (B). Data are presented as mean ± SD.
Scale bar= 1 cm.

A summary of volume distributions for low and high MeHA at low and high
initiator concentrations is shown in Figure 4.14. Figure 4.14A illustrates that compared
to minimal contrast observed in control myocardial tissue, all four tissue-embedded
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MeHA formulations were clearly distinguishable. While the geometry of injections varied
both within and between formulations, most injections took on an ellipsoidal shape with
the major axis matching the fiber direction (Figure 4.14A, B). As alluded to in Section
4.3.3.1, the results also revealed a trend in detected volume differences between groups
that were dependent on macromer modification and initiator concentration (Figure
4.14C). Macromer modification had a pronounced influence only at the lower initiator
concentration; in this case lower macromer modification led to smaller volumes. Volume
differences were, however, not significantly different as Ifkovits et al. concluded from
their rheology assessment for gel onset [1]. Furthermore, lower A/T resulted in smaller
volumes compared to higher A/T and was most pronounced in the lower macromer case
where the difference was statistically significant.
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Figure 4.14 Representative MRI slice of each hydrogel formulation without contrast
agent injected into the myocardium (A) and the respective 3-D constructions of the
injection region (B). Quantified volume of the injection region for each MeHA formulation
(n=4) injected into LV explants (C). In panel A, scale bar= 1 cm. In panel C, data are
presented as mean ± SEM. *p<0.05 compared to low MeHA, low A/T.

The smaller volumes observed with low macromer modification and initiator
concentration can be attributed to the lower number of reactive groups and radical
initiators relative to the high groups. When injected into tissue, it is probable that the
precursor solutions of the low macromer/initiator formulations are more susceptible to
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dilution by the fluids within the tissue, leading to inefficient reaction and lower hydrogel
volume relative to the high formulations. It is also important to note that differences were
observed in the distribution of the hydrogel within the myocardial fibers. While hydrogels
formed with low initiators did at times form small hydrogel “plugs” (areas of mostly
hydrogel), these formulations generally dispersed more evenly within the fibers.
Hydrogels formed with higher initiators exhibited more frequent “plugs” in addition to
considerable dispersion. While plugs were observed to an extent in all formulations, in
most cases the calculated volumes were larger than the original 0.3 mL that was
injected, suggesting that the hydrogel is dispersing within the tissue rather than only
forming a plug that displaces the tissue.

4.4 Conclusions
Two imaging techniques (x-ray and MRI) were examined as options to image
MeHA hydrogels and quantify their volume; specifically, four MeHA formulations with low
or high macromer modification and low or high initiator concentration were investigated
to determine the influence of each on hydrogel volume. For x-ray imaging, an iodinated
benzene molecule was successfully added to HA; however, the degree of modification
(~12%) was insufficient to provide radiopacity. Due to its enhanced sensitivity and high
spatial resolution, MRI was explored as an alternative to x-ray for hydrogel imaging both
with and without contrast agents.

While applying iron oxide nanoparticles to MeHA

hydrogel formulations resulted in similar trends as non-contrast approaches, the latter
approach to generate data for FE modeling was pursued further due to similar concerns
regarding the potentially detrimental effects of agent incorporation on hydrogel
properties. Non-contrast MR imaging was performed by adjusting image parameters to
achieve high resolution images of hydrogel dispersion without contrast agent.
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Interestingly, hydrogel volume was influenced by both macromer and initiator
concentration, with significant differences observed with different initiator concentrations.
Smaller volumes in formulations with low A/T were observed and attributed to inefficient
formation of kinetic chains due to the limited presence of free radicals and reactive
groups (in low MeHA), resulting in loss of precursor solution before crosslinking. The
final volumes quantified with non-contrast MR imaging will be applied in Chapter 5.
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CHAPTER 5

A Mechanical and Finite Element Assessment of Methacrylated Hyaluronic Acid
Hydrogels in Treating Left Ventricular Remodeling

5.1 Introduction
In Chapter 4, we employed non-contrast magnetic resonance imaging (MRI) to
visualize methacrylated hyaluronic acid (MeHA) hydrogels in myocardial explants.
Volume data demonstrated that all hydrogels (to a degree) distributed with tissue fibers;
thus, these regions will be referred to as hydrogel/tissue composites for the remainder of
this chapter. As discussed in Section 4.1.1, finite element (FE) models can incorporate
material volume, injection distribution, and mechanical data to generate representative
injections and theoretically assess their influence on stress levels in left ventricular (LV)
remodeling [1, 2].

Here, the goal is to continue acquiring data for FE modeling;

specifically, the same four hydrogel formulations (low MeHA, low A/T, high MeHA, low
A/T, low MeHA, high A/T, and high MeHA, high A/T, where A= ammonium persulfate
(APS) and T= N,N,N,N’,N’-tetramethylethylenediamine (TEMED)) will similarly be
injected into explants and mechanically tested (e.g., compressive and biaxial) to
investigate the mechanical properties of the hydrogel/tissue composites.
With this data and information on composite volumes (from Chapter 4) and
injection distribution (previously reported [3]), the efficacy of each treatment to limit LV
remodeling will be theoretically evaluated in a FE model and compared to no treatment
by quantifying subsequent stress reductions.

As discussed in Chapter 1, increased

stress due to geometric alterations induces a positive feedback loop exacerbating
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remodeling and eventually the potential for heart failure (HF); this work will ultimately
provide more insight on how material treatment specifically mitigates increased stresses.

5.1.1 Mechanical Testing of Myocardial Tissue
The material properties of the myocardium are an important determinant in its
global function. Specifically, studies have demonstrated that both the amount and type
of stiffening (e.g., isotropic, anisotropic), both due to pathological processes and
injection to treat these processes, influence stress and functional outcomes [1, 2, 4-6].
In order to accurately assess these properties in myocardial tissue it is important to
select a model that is representative of the loads that the heart experiences in vivo. To
date, myocardial mechanics have been reported using a variety of techniques including
atomic force microscopy (AFM) [7, 8], compressive testing [3], uniaxial testing [3, 9], and
biaxial testing [9-14]. While methods such as AFM and one-dimensional compressive
and uniaxial testing have contributed to our understanding of fundamental cardiac
mechanics, they are limited in that they only provide information on local (AFM) or
unidirectional mechanics (compressive and uniaxial).

Like many soft tissues, the

myocardium is mechanically anisotropic [10-12, 14-18], being stiffer in the fiber direction
(circumferential) compared to the cross-fiber direction (longitudinal) and is referred to as
transversely isotropic.

Hence, the described unidirectional methods to assess

mechanics are insufficient to evaluate the myocardium’s multiaxial properties.

The

anisotropic nature of the myocardium has been implicated in LV remodeling where
studies have shown that the infarct can heal both in an isotropic and anisoptropic
manner depending on the animal model [4, 6, 10, 13].

Interestingly, in a recent

theoretical study, Fomovsky et al. altered the mechanics of the infarcted myocardium in
an isotropic and anisotropic manner (e.g., increasing the stiffness in either the
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circumferential or longitudinal direction) and demonstrated that directional stiffening
influences the extent of myocardial function with an optimal stroke volume occurring with
longitudinal stiffening [5].

Biaxial testing provides us with the ability to simulate the

multiaxial loading experienced physiologically by the heart so that we can accurately
assess the influence of material injection on its mechanical properties.

5.1.2 Biaxial Testing: Sample and Test Design
Biaxial testing is a versatile technique that has been employed to test numerous
biological tissues [10-14, 19-27].

Sample preparation is generally consistent across

applications; thin tissues (usually 1 mm and no larger than 3 mm in thickness) are
typically tested under strain control (instead of load control) that is optically tracked to
avoid mechanical interferences [17, 18].

Strain control entails optically tracking the

displacement of markers on the tissue (or grips) at a predefined strain rate and range of
strain (or until a maximum load is reached). This will be discussed in more detail later in
this section.
Myocardial tissue is generally tested in trampoline-like fashion, where sutures are
hooked directly through the tissue edge and threads tied on their free ends attach to
motors that apply load to the tissue [11, 12, 17, 18]. Markers to optically control strain
are secured directly onto the center of the tissue (away from the hooks) where the stress
and strain fields are generally considered to be homogenous.

This approach is

advantageous for myocardium testing because it allows for all edges of the sample to
freely expand while accurately controlling the applied strain [17, 18]. In cases where
tissues are heterogeneous, however, markers for protocol optical tracking cannot be
placed on the tissue due to influences on predefined strain control parameters from
variations in the tissue strain.
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As reported in Chapter 4, MeHA hydrogels dispersed throughout myocardial
tissue in an initiator concentration and macromer percent modification (at low initiator)
dependent manner. While trends were observed in hydrogel volumes and most samples
took on an ellipsoidal geometry, observed variations in the distributions could potentially
influence sample testing if tested in the typical trampoline-like manner that is employed
for tissue with homogenous strain fields. Furthermore, hydrogel incorporation made it
difficult to secure sutures onto composites due to the inability of the suture to hook onto
regions where there was prominent hydrogel present. To circumvent these concerns
and ensure that testing of hydrogel/tissue composites was consistent for all groups,
alternative biaxial testing techniques were explored for this investigation.
We specifically explored clamp-like grips that could be directly secured (e.g.,
glued) to the tissue, so that markers could be attached to the grip to provide optimal
strain control.

These types of grips also offered an alternative point of attachment,

obviating concerns of sutures ripping through the hydrogel portion of the composite.
However,

while

clamp-like

grips

could

overcome

problems

such

as

testing

heterogeneous tissues and those susceptible to ripping, they also had drawbacks that
needed to be considered.
A major disadvantage in typical clamp-like grips is that due to their tab-like
geometry, they restrict free expansion of samples edges [28, 29]. To avoid this problem,
a finger-like grip design (developed by Dr. Dawn Elliott’s group at the University of
Pennsylvania) was employed [30]. Typical grip tabs were converted into “fingers” to
allow edges to freely expand at the loads that would be applied to this system.
Additionally, while grip-to-grip strains (i.e., optically computed strain from the markers on
the grips) could be used to provide consistent strain conditions for test protocols, they do
not necessarily represent the strain experienced by the tested tissue. To overcome this,
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we computed tissue strains by performing post-test strain analysis with image correlation
on samples that were speckle coated before testing [20].

Specifically, tissues were

tested by optically tracking markers on grips (grip-to-grip strains); after testing, the
images were analyzed to measure displacements of speckled regions, which were then
used to compute a deformation gradient tensor F for that image [15, 17, 18]. F can then
be used to compute strains, which will be discussed in more detail in Section 5.1.3.

5.1.3 Biaxial Testing: Kinematics and Stresses
*In this section capital letters in bold will be used to define tensors and vectors and
scalars will be represented as normal text.
The computation of strain for biaxial testing is based on the displacement of the
tracked markers and tissue deformation is generally described by the deformation
gradient tensor F.

In general, the bidirectional components for displacements are

described by Equations 5.1 and 5.2 where x and X are the position vectors at the
deformed and reference states, respectively, and (i and )I are components of F that
correspond to the axial stretch ratio and measure of in-plane shear, respectively [17, 18,
21].

x1 = "1 X1 + #1 X 2

(5.1)

x 2 = "2 X 2 + # 2 X1

(5.2)
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The deformation gradient tensor F is dependent on these displacements as shown in
Equation 5.3.

# "x1
% "X
F=% 1
% "x 2
%$"X1

"x1 &
"X 2 ( # )1
(=
"x 2 ( %$* 2
"X 2 ('

*1 &
(
)2 '

(5.3)
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The right Cauchy-Green deformation tensor can be calculated from F and is
defined as C=FT!F. It can be used to calculate the Green-Lagrange strain tensor E,
which is the most common finite strain measure used to analyze soft biological tissues
due to its simple incorporation in constitutive models (E= ! (C-I), where I is the identity
tensor) [17, 18]. E can also be derived directly from the components of F as shown by
the two-dimensional (2-D) Green-Lagrange strain components in Equations 5.4, 5.5, and
5.6 [17, 18, 21].

E11 =

1 2
"1 + # 22 $1)
(
2

(5.4)

E 22 =

1 2
"2 + #12 $1)
(
2

(5.5)

E12 =

1
(" # + "2# 2 )
2 1 1

(5.6)
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To experimentally gain information on the stiffness of the tested specimen, the
first Piola-Kirchhoff stress tensor T can be computed directly from the initial tissue
dimensions (cross-sectional area of each loaded side) and measured axial forces P
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acquired from biaxial testing. The components of T are defined in Equations 5.7 and
5.8, where h is the thickness and Li is the tissue length [17, 18, 21].

T11 =

P1
hL2

(5.7)

T22 =

P2
hL1

(5.8)
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Due to load application being normal to the specimen edges, T12 and T21 are zero. T can
later be employed with F to determine second Piola-Kirchhoff stress S (S=TF-1), which
will be discussed in more detail in the next section where it is implemented in the
development of constitutive models [17, 18].
A similar concept as described in this section is generally applied to calculate
tissue strains; rather than representing displacements from the tracked markers, initial
displacements are computed from speckled regions [20].

5.1.4 Constitutive Modeling of Biological Tissues
In 1974, Lanir and Fung pioneered the field of biaxial testing by performing the
first experimental studies on biological tissues [22, 23]; shortly after, these findings were
employed to develop a constitutive model [31]. From their experimental findings (e.g.,
strain rate independent hysteresis and curve geometry), they determined that a strainenergy function W could be developed to model the stress-strain relationship for
biological tissues [18, 32]. The same group later proposed a simplified exponential form
of W that adequately fits experimental data (Equation 5.9), where C is a constant
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(defined in the next section in terms of the passive myocardium) and Q is a non-linear
function of the Green-Lagrange strain components [17, 18, 33].

W =

C
(exp(Q) "1)
2

(5.9)
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5.1.4.1 Constitutive Modeling of the Myocardium
Passive Myocardium
Early biaxial testing on the ventricular myocardium by Yin et al. confirmed that
the passive (i.e., diastolic, non-contracting) myocardium displayed a similar stress-strain
relationship, anisotropy, and strain-rate independence to characteristic biological tissues
described in the previous section [14, 32]. Modeling the myocardium as transversely
isotropic with respect to the fiber direction (anisotropic), nearly incompressible and
hyperelastic, Guccione et al. later applied these findings to the work of Fung et al. to
derive a version Q to input into the simplified form of W (Equation 5.9).

With the

incorporation of the newly derived Q, the final derivation of W was optimal to represent
the mechanical properties of the three-dimensional (3-D) passive myocardium [32]. The
commonly applied form of Q for recent FE modeling of the passive myocardium [1, 2,
34-36] is depicted in Equation 5.10, where E11 is circumferential strain, E22 is longitudinal
in-plane strain, E33 is radial strain, and the remaining strain components are shear
strains.

The variables bf, bt, and bfs are diastolic myocardial material parameters;

specifically, bf and bt are associated with stiffness in the circumferential and longitudinal
directions, respectively (i.e., material stiffness is directionally increased by increasing bf
or bt) and bfs is directly related to the rigidity of the material under shear.
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Q = b f E112 + bt (E 22
+ E 33
+ E 23
+ E 32
) + b fs (E122 + E 21
+ E132 + E 31
)
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(5.10)

When Equations 5.9 and 5.10 are combined, the constitutive model W can be
employed to describe the passive myocardium where C is also a diastolic material
property that scales the stresses (Equation 5.11) [32, 34].

W =

C
2
2
2
2
2
2
(exp(b f E112 + bt (E 22
+ E 33
+ E 23
+ E 32
) + b fs (E122 + E 21
+ E132 + E 31
)) "1)
2

(5.11)

Active Myocardium

!

The active myocardium (i.e., systolic, contracting) is generally modeled as nearly
incompressible, transversely isotropic (anisotropic with respect to the fiber direction) and
hyperelastic [1, 2, 35-38]. The commonly applied constitutive laws for modeling of the
active myocardium also stem from the work of Guccione et al. [37, 38]. Their work led to
a derivation for systolic contraction, which was modeled as the sum of the passive stress
derived from W (Equation 5.11) and an active fiber directional component T0 and is
defined in Equation 5.12. In the developed model, T0 is a function of time, t, peak
intracellular calcium concentration, Ca0, sarcomere length, l, and the maximum isometric
tension achieved at the longest sarcomere length Tmax. The additional variables in the
equation are as follows: S is the second Piola-Kirchhoff stress tensor (introduced in
Section 5.1.3), p is the hydrostatic pressure as the Lagrange multiplier to ensure
incompressibility, J is the Jacobian of the deformation gradient tensor, C is the right
Cauchy-Green deformation tensor (introduced in Section 5.1.3), Dev is the deviatoric
projection operator, and " is the deviatoric contribution of W.
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(5.12)
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Altering Passive and Active Myocardium Material Properties
As previously described, the constitutive laws for the passive (Equation 5.11) and
active (Equation 5.12) myocardium can be applied to examine the influence of
alterations in mechanical and contractile properties, respectively, on outcomes such as
stress in the myocardium.

Colleagues have varied the diastolic myocardial material

parameters C, bt, bf, and bfs to simulate adjustments in myocardium stiffness [1].
Systolic parameters have also been altered to model variations in contraction due to
both the physiological state of the heart (i.e., normal vs. weakened) or volume additions
to the wall [1, 35, 36].

In 2009, Wenk et al. developed a model that incorporated

polymer inclusions; in addition to their mechanical properties and volume, the number
and distribution of inclusions could also be altered (refer to Chapter 3, Figure 3.2) [2].
This advanced model furthered the field of myocardial modeling by providing control
over more variables to better study the influence of injectable biomaterials.
In this chapter, we will first report the outcomes of mechanical testing
(compressive and biaxial) of MeHA hydrogel/tissue composites.

While compressive

testing has been employed in the past to assess the mechanics of tissue composites [3],
to our knowledge, this is the first study to perform multiaxial testing to evaluate the
influence of an injectable biomaterial on myocardium mechanics. After assessing the
general influence of hydrogel incorporation on moduli, this data will be applied to
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compute the diastolic myocardial material parameters (C, bf, and bt) for each composite
formulation for their theoretical assessment.
The theoretical portion of this chapter will be two-fold. Both portions will employ
a modified version of the already established FE model by Wenk et al. [2], where
hydrogel/tissue composite mechanical parameters, volumes and their distribution [3] can
all be adjusted to better model the influence of MeHA hydrogel treatments on stress
levels in the dilated LV. First, treatment of the MeHA formulations (low and high MeHA,
low A/T) previously studied by Ifkovits et al. will be theoretically modeled to correlate
their influence on stress to their in vivo geometric outcomes [3]. Many studies in the field
assume that experimental outcomes such as decreases in ventricle dilation and
increases in wall thickness directly correlate to reduction in myocardial stress (as per the
Law of Laplace discussed in Chapter 3). Here, we further investigate this paradigm by
evaluating the benefits of two MeHA hydrogel formulations both experimentally (i.e., in
vivo) and theoretically. The second portion of the theoretical assessment in this chapter
will provide more insight on injectable biomaterial design criteria; two additional MeHA
hydrogel formulations with faster gelation (low and high MeHA, high A/T) will be modeled
to further assess the influence of hydrogel mechanics and also distribution on
myocardial stress (limitations in this theoretical model will be discussed in both Methods
and Chapter 9). Here, we demonstrate an innovative approach that incorporates in vitro
hydrogel/tissue composite data into a theoretical model to validate and better
understand the outcomes of in vivo models such as that by Ifkovits et al. [3].
Furthermore, this technique can be employed as a tool to optimize material design,
specifically material properties, for development of better therapies to treat LV
remodeling.
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5.2 Materials and Methodology
5.2.1 Methacrylated Hyaluronic Acid (MeHA) Synthesis, Hydrogel Formation and
Characterization
Two MeHA macromers were synthesized as described in Chapter 4 [39] and
their percent modification (~30% and ~60%) was assessed by 1H NMR (Bruker, 360
MHz). Macromers were crosslinked with the same oxidation-reduction (redox) initiators
introduced in Chapter 4 (APS (A) and TEMED (T)) at either a low or high concentration
(low A/T, 5/5 mM and high A/T 12.5/6.25 mM). Similar to Chapter 4, initial compressive
testing on MeHA hydrogels was performed at a strain rate of 10%/min, and moduli were
calculated as the slope of the stress-strain curve at 10-20% strain.

5.2.2 In Vitro Assessment of Hydrogel/Tissue Composite Mechanics
The influence of hydrogel delivery and addition on the mechanical properties of
myocardium was assessed in explanted ovine myocardial tissue from the LV. Similar to
imaging work, 0.3 mL of precursor solutions were injected in explants 3 minutes after
initiator addition. Thirty minutes after injection, samples were collected for compressive
and biaxial testing.

5.2.2.1 Compressive Testing
For compressive testing, cylindrical (~5 mm diameter) composite samples (n=34/group) were collected via a biopsy punch.

Testing was performed with the same

protocol as non-composite hydrogels as described in Section 5.2.1.
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5.2.2.2 Biaxial Testing
Sample Preparation
For biaxial testing, a total of 5 samples (maximum of 2 per injection) were tested
per group: (1) control myocardium, (2) low MeHA, low A/T, (3) high MeHA, low A/T, (4)
low MeHA, high A/T, and (5) high MeHA, high A/T. Samples were collected from the
myocardial region and trimmed to ~7 X 7 mm2 with a thickness ~2 mm.

Average

thickness values were calculated to compute cross-sectional areas to later determine the
first Piola-Kirchhoff stresses (discussed in more detail in the Experimental Data Analysis
portion of this section). The surface of each sample was speckle-coated with Verhoeff’s
stain for post-test tissue strain analysis with digital image correlation (Figure 5.1A). As a
point of attachment for mechanical testing, finger-like grips were made out of waterproof
sandpaper (T214 Norton) (~75x5 mm2) to allow for free expansion of sample edges.
Slabs were folded in half, and 3, 25x1 mm “fingers” were excised at the free end so that
6 “fingers” in total (3 on the top and 3 on the bottom) were formed. Grips were painted
white to enhance contrast and glued (Locite 454) onto the bottom and top of each side of
the tissue samples with about 1 mm overlap between the grip and tissue. Brass 0.5 mm
markers (Small Parts) were painted black for contrast and placed on the middle “finger”
of each group (4 markers in total) (Figures 5.1A and 5.1B).

Before testing, samples

were equilibrated for ~1 hour in phosphate buffered saline (PBS) at room temperature
(RT).
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Figure 5.1 Representative images of biaxial sample preparation.

Speckle-coated

hydrogel/tissue composite (with finger-like grips and tracking markers) mounted on a
biaxial apparatus at 0 grip-to-grip strain (A). Zoomed out view of specimen ready for
biaxial mounting (B). Scale bar= 1.5 mm (A) and scale bar= 10 mm (B). Representative
sample= low MeHA, high A/T formulation.

Biaxial Testing
In general, grip-to-grip strains were optically tracked by following the 4 markers
and provided consistent strain conditions for testing. Tissue strains were acquired by
tracking the speckle-coat on the tissue surface after biaxial testing. Samples were all
tested in PBS at RT and placed in the same orthogonal (longitudinal and circumferential)
orientation with respect to the myocardium for all testing.
For testing, silk (2-0) sutures were folded in half and secured through the free
end of each sandpaper grip by metal hooks. The looped ends of the sutures were then
hooked around the pulleys attached to the motors of the custom biaxial device [19].
Four independent motors (controlled by LabVIEW software) applied strain to the
myocardial samples in both the circumferential and longitudinal directions, while a highresolution digital camera with a telecentric lens (NT63-730, Edmund Optics) tracked the
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black markers on the middle tabs to track strains. Testing was performed by grip-to-grip
strain control; all samples were preconditioned, exposed to a 1 hour hold, and then
tested. Each sample was preconditioned by pre-straining to 0.01 equibiaxial strain and
then equibiaxially straining to 0.20 for 5 cycles at 0.10 strain/min. Immediately after
preconditioning, samples were subjected to a 1 hour hold where no load was applied
and samples were allowed to freely contract in both directions. The test protocol was
identical to the preconditioning parameters; data and images from the final loading curve
of each test were used for experimental data analysis.

Experimental Data Analysis
All moduli calculations were based on orienting samples for tests according to
their original orthogonal orientation in the myocardium.

For most samples, this

corresponded to the expected fiber direction (e.g., against fibers for longitudinal and with
fibers for circumferential).
Grip-to-grip stress-strain curves were formed from the optically tracked data
collected from the labVIEW interface. Curves and moduli in both the longitudinal and
circumferential directions were determined for three ranges of Green-Lagrange strains
(0.05-0.10, 0.10-0.15, and 0.15-0.20). First Piola-Kirchhoff stresses were determined by
dividing the cross-sectional areas of each sample length by the load values calculated
by labVIEW in the corresponding direction.
To calculate tissue strains, 2-D displacement maps (Figure 5.2) were first
developed using the speckle-coated surface via digital image correlation (Vic2D 2009,
Correlated Solutions). A single deformation gradient tensor F was calculated from the
displacement map of each image by finding the least-squares solution to the system of
equations with a Matlab algorithm developed and described by Szczesny et al. [20]. The
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deformation gradient tensor F for each image was used to compute the tissue GreenLagrange strains (as discussed in Introduction) in both the longitudinal and
circumferential directions at that specific grip-to-grip strain. Stress-tissue strain curves
and moduli were again obtained in three ranges of strains (0.05-0.10, 0.10-0.15, and
0.15-0.20). Stress-tissue strain raw data was applied to derive the parameters for FE
modeling.

!
Figure 5.2 Representative two-dimensional displacement maps at 0.20 grip-to-grip
strain for control myocardium (A) and hydrogel/tissue composites (low MeHA, high A/T)
(B).
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5.2.3 Theoretical Assessment of Hydrogel/Tissue Composites
5.2.3.1 Application and Derivation of Material Parameters
The constitutive model for the passive myocardium (Equation 5.11) was
modified for curve fitting with 2-D data provided from biaxial tests; the E33 term was
included due to incompressibility; however, shear strains were out of the plane of
deformation and therefore these terms were removed. Iterations were performed to
determine the most suitable diastolic myocardial material parameters (C, bf, and bt) for
each MeHA hydrogel/tissue formulation and control myocardium (Table 5.1). The
remaining terms in the original constitutive model (Equation 5.11) were obtained from
previous reports [40]. These material properties were assigned as the material
parameters for each component of the LV model (i.e., either composite injections or
myocardial tissue).

Table 5.1!Summary of diastolic myocardial material parameters derived from biaxial data
for FE modeling. *= formulations investigated by Ifkovits et al. [3].

The systolic myocardial material parameters employed in this model were
previously defined by Wenk et al. [2]. Tested myocardium was normal (not infarcted) and
therefore (to ensure consistency with diastolic myocardial material parameters) selected
systolic parameters assumed that all portions of the modeled heart (i.e., injection sites
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and myocardium) had normal myocardium contractile properties. This limitation will be
described more in Chapter 9 of this dissertation.

5.2.3.2 Finite Element (FE) Model
A 3-D FE model of the dilated LV was generated using a modified version of the
model from Wenk et al. [2]. The injections were modeled as ellipsoidal, rather than
spherical, based on composite geometries obtained from MRI data (Chapter 4) and the
material properties in these regions were assumed to behave as a composite (i.e., the
injection sites are a combination of myocardium and the hydrogel) (Figure 5.3A). A
distribution pattern similar to that employed in previous in vivo studies by Ifkovits et al.
was used (Figure 5.3B) [3]; specifically, there were 20 injection sites, with a pattern of 5
circumferential by 4 longitudinal (Figure 5.3C).

Due to the incompressibility of the

myocardium, to conserve volume with each injection the endocardial wall was thickened
into the LV cavity.

!
Figure 5.3 Representative cross-sectional view of a high MeHA, low A/T composite
injection site in myocardium (A). Representative distribution of 20 injections from in vivo
work by Ifkovits et al. [3] (B) and transparent view of modeled dilated LV with 20
injections (blue) for FE assessment (C).
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Hydrogel/tissue composite volumes were based on the MRI data; however, due
to limitations in the FE model, 20 injections with the calculated average volume of the
high MeHA, low A/T and low and high MeHA, high A/T formulations could not be
achieved. While the FE model mesh will be adjusted to accommodate these volumes for
future analysis, in the context of this dissertation, volumes were adjusted for modeling.
The following cases were considered:
1) For theoretical evaluation of the formulations assessed in the in vivo work of
Ifkovits et al. (i.e., low and high MeHA, low A/T) [3], reported average volumes
from Chapter 4 were decreased by half a standard deviation (SD) for their
simulation. While this adjustment is not ideal, these volumes are still
representative of the volumes injected in vivo and provide applicable information
on the influence of their injection on stress reduction in the dilated LV. Adjusted
volumes are reported in Table 5.2.

Table 5.2!Summary of injection volumes used to validate in vivo work of Ifkovits et al. [3].
Injection volumes equal each formulation’s average volume minus half its SD.

2) The aforementioned solution could not be applied to assess the high initiator
formulations due to their larger volumes. To gain a general idea on the relative
differences between all four formulations, all cases were simulated with volumes
equal to 60% of the average values (Table 5.3).
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Table 5.3! Summary of injection volumes for relative comparisons between all groups.
Injection volumes are equal to 60% of each formulation’s average volume.

5.2.3.3 Stress Assessment
All cases were run on either a 12-core or 32-core computer node. Stress in each
formulation was assessed in the fiber and cross-fiber directions at end-diastole (ED) or
end-systole (ES) and compared to a control simulation of a dilated LV with no treatment.
For all cases, the volume average of these stress components was calculated in the
following regions:
1) Global average over the entire LV, including injection sites.
2) Transmural average of a single injection site at the equator (Figure 5.4A, B).
3) Mid-wall average in a row of injections at the equator (Figure 5.4A, C).
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Figure 5.4 Plane near the equator where transmural and mid-wall stresses were
calculated (A). Representative set of elements where transmural (B) and mid-wall (C)
stresses were calculated.

5.2.4 Statistical Analysis
Data is presented as mean ± SD or mean ± SEM (standard error of the mean) as
indicated in each figure legend. Changes in moduli (for compressive and biaxial testing)
were assessed using a one-way ANOVA with Tukey’s post hoc evaluation.
comparisons, p#0.05 was considered to be statistically significant.
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For all

5.3 Results and Discussion
5.3.1 Compressive Testing of MeHA Hydrogels and MeHA Hydrogel/Tissue Composites
Similar to the previous studies by Ifkovits et al., compressive testing on noncomposite hydrogels and hydrogel/tissue composites was performed to provide
information on MeHA hydrogel behavior in tissue [3]. Non-composite MeHA hydrogels
displayed expected trends, where higher macromer percent modification and initiator
concentration led to higher compressive moduli (Figure 5.5).

Specifically, higher

macromer modification at both low and high A/T resulted in higher mechanics compared
to both low MeHA formulations, indicating that compressive mechanics in these
hydrogels are more dependent on macromer functionalization. Compared to control
myocardial explant tissue, significant differences were observed in all formulations
except for low MeHA, low A/T, which displayed a comparable compressive modulus. As
described in Chapter 4, macromer modification and initiator concentration both influence
the formation of kinetic chains and, consequently, the bulk properties (e.g., mechanics)
of the resulting hydrogels [41, 42]. Increasing either parameter results in more efficient
crosslinking and subsequently higher mechanics [3, 41, 43].

Similar trends were

observed in mechanical testing of composite tissue, but to a lesser degree (Figure 5.5).
Increasing both macromer modification and initiator concentration resulted in higher
mechanics, with higher moduli observed in high MeHA macromers. However, these
differences were less pronounced relative to the MeHA alone groups; a statistically
significant increase in modulus compared to myocardial explant tissue was only
observed in the high MeHA, high A/T formulation. Overall, this work demonstrates that
the addition of MeHA hydrogels to myocardial tissue results in a hydrogel/tissue
composite with its own set of unique mechanical properties.
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Figure 5.5 Compressive moduli for non-composite MeHA hydrogels and composite
formulations compared to control myocardium. Data presented as mean ± SD. *p<0.05
vs. control myocardium.

5.3.2 Biaxial Testing of MeHA Hydrogel/Tissue Composites
5.3.2.1 Optimization of Biaxial Testing Parameters
Biaxial testing was performed as a means to acquire more physiologically
relevant mechanical data for hydrogel/tissue composites.

As discussed in Methods,

composites were preconditioned, subjected to a 1 hour hold to allow for sample
recovery, and then tested. To determine the required sample recovery time, samples
were unloaded immediately after preconditioning and the strain was monitored in both
directions while samples contracted (Figure 5.6A).

A 1 hour hold was selected for

recovery time, since by this time point following unloading, the sample strain reached
equilibrium in both directions. As described in Methods, for preconditioning and testing,
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samples were loaded based on strain (i.e., grip-to-grip strain), which was optically
tracked. As specified by the labVIEW test protocol, samples were always strained to a
reported grip-to-grip Green-Lagrange strain of 0.20 as indicated by the representative
stress-strain curves in Figure 5.6B.

!
Figure 5.6 Representative time sweep of sample recovery (control myocardium) (A) and
representative stress-strain curve for grip-to-grip strains (control myocardium) (B).

5.3.2.2 Grip-to-Grip Strain Analysis
Physiological strain has been reported to range from 0.10 to 0.15 [44-47]; to
account for the lower and higher ends, a mechanical assessment was performed
between 0.05 and 0.10 (Figure 5.7A) and between 0.10 and 0.15 (Figure 5.7B) GreenLagrange strain, where 0.05-0.10 corresponded to the linear toe region in stress-strain
curves. A strain range of 0.15-0.20 (Figure 5.7C), which generally corresponded to the
second linear portion in stress-strain curves, was analyzed as an extreme case that
could potentially simulate a hypertrophied borderzone. Mechanics were most influenced
in the longitudinal direction for all strain ranges (Figure 5.7); in this direction, increases in
macromer percent modification and initiator concentration (particularly at the two lower
strain ranges) resulted in higher moduli compared to control myocardium. Statistically
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significant differences compared to control myocardium were observed in the high
MeHA, high A/T formulations between 0.05-0.10 (high MeHA, high A/T: 32.16 kPa vs.
control myocardium: 11.75 kPa) and 0.10-0.15 (high MeHA, high A/T: 49.32 kPa
vs.control myocardium: 15.10 kPa) strain. Differences in the circumferential direction
were less pronounced; however, similar trends were observed in all groups except low
MeHA, low A/T. The reported decreased modulus (in the circumferential direction) in the
low MeHA, low A/T formulation is not completely understood; however, it may be a result
of the decrease in anisotropy.

!
Figure 5.7 Calculated moduli from grip-to-grip strains in three strain ranges 0.05-0.10
(A), 0.10-0.15 (B), 0.15-0.20 (C), and the calculated anisotropic ratio (D). Data are
presented as mean ± SEM. *p<0.05 vs. control myocardium.
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Interestingly, the hydrogel formulations collectively had a pronounced effect on
the anisotropic nature of myocardial tissue. As discussed in the introduction, healthy
normal myocardial tissue is anisotropic; stiffness in one direction (circumferential) is
higher than the other (longitudinal) direction [14, 32, 46]. The results reported in Figure
5.7 support this trend for normal myocardial tissue; however, when compared to control
myocardium, hydrogel incorporation at all formulations resulted in a larger increase in
the modulus in the longitudinal direction than circumferential direction. Consequently,
this led to a statistically significant decreased anisotropy in all composite groups (at most
strain ranges) compared to control myocardium (Figure 5.7D).

As hydrogels exhibit

isotropic properties alone, this is not entirely unexpected as the composite consists of
both cardiac tissue and hydrogel. Yet, this is interesting considering the recent findings
of Fomovsky et al., which indicated that anisotropic stiffening may be beneficial in
cardiac function [5]. Morita et al. observed a similar trend where treatment with an
injectable dermal filler led to increased stiffening in the longitudinal direction [13]. It
should be noted, however, that both of the aforementioned studies were performed in an
infarct model, while this work was performed in normal myocardial tissue and this could
influence the final outcomes. Regardless, this is an exciting finding and provides insight
on the influence of injectable biomaterials on the mechanical properties (i.e., directional
stiffening) of the myocardium.

5.3.2.3 Tissue Strain Analysis
Tissue strains were quantified as discussed in Introduction and Methods by
computing the deformation gradient tensor F from the local displacements (Figure 5.2) of
each image acquired from grip-to-grip strain analysis. While strains were consistent
between groups due to optical tracking, there was some variability observed as indicated
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by the stress-strain curves in Figure 5.8. Generally, tissue strains remained close to
equiaxial, but some inconsistency in strains within and between conditions were
observed, which could be attributed to sample heterogeneity.

For example, local

displacements in composite samples are dependent on hydrogel distributions, which (as
discussed in Chapter 4) were variable between groups.

Another cause of sample

heterogeneity may be the relatively thick samples used for testing; in thicker samples the
fiber orientation is more likely to change transmurally. While sectioning techniques could
be used to produce thinner samples, this option was not explored due to the potentially
detrimental effects of processing on the properties of embedded hydrogels.
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Figure 5.8 Stress-strain curves for tissue strains for all tested formulations. This data
was applied to derive the diastolic myocardial material parameters for FE modeling.

Tissue strains were analyzed in a similar manner as grip-to-grip analysis where
moduli were calculated in three ranges of strain from stress-strain curves (Figure 5.9).
Overall, when compared to control myocardium, a directionally dependent trend was
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observed where moduli were influenced most in the longitudinal direction.

Data in

Figure 5.9A indicates that from 0.05-0.10 strain, moduli in the longitudinal direction were
higher than control myocardium groups, with more significant increases as the
macromer percent modification and initiator concentration increased.

While similar

trends were observed at 0.10-0.15 and 0.15-0.20 strains, increases in moduli were
limited to low macromer modification and initiator concentration (Figure 5.9B, C). In the
circumferential direction, the modulus of high MeHA, high A/T increased most compared
to control myocardium (Figure 5.9A, B, C).

While only high macromer conditions

resulted in mechanical increases relative to control myocardium in the circumferential
direction, a trend was observed between composite groups that mimicked those of
compressive testing. Specifically, macromer percent modification had a larger influence
on mechanics than initiators did on low percent modified MeHA (Figure 5.9A, B, C).
Overall, tissue strain analysis data indicates that hydrogel incorporation does influence
the stiffness of myocardial tissue. Specifically, high macromer percent modification and
initiator concentration generally lead to higher mechanics compared to control
myocardium in the longitudinal direction and within composites in the circumferential
direction. As with grip-to-grip strain analysis, there was generally a larger mechanical
influence in the longitudinal direction than circumferential direction compared to control
myocardium. Consequently, the anisotropy of all hydrogel formulations compared to
control myocardium was decreased as indicated in Figure 5.9D. Section 5.3.2.2 should
be referred to for a more thorough discussion on this trend.
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Figure 5.9 Calculated moduli from tissue strains in three strain ranges 0.05-0.10 (A),
0.10-0.15 (B), 0.15-0.20 (C), and the calculated anisotropic ratio (D). Data are presented
as mean ± SEM. *p<0.05 vs. control myocardium.

Tissue strain analysis data was chosen for FE modeling instead of grip-to-grip
data because it provided more representative values for strain experienced by
composite formulations, regardless of differences in hydrogel distribution. As discussed
in Methods (Section 5.2.3.1) using a curve fitting scheme with raw stress-strain curves
(Figure 5.8), iterations of the constitutive law for the passive myocardium were
performed to determine the optimal diastolic myocardial material parameters to
represent composite injections and control myocardium.

These parameters were

assigned to represent either injection sites or control myocardium in the FE model.
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5.3.3 Stress Assessment with FE Modeling
.

As discussed in Methods, FE modeling was performed on two sets of injections

and resulting stresses were assessed in three ways: globally, transmurally, and at the
mid-wall. The first set of simulations was performed on the low initiator formulations to
further elaborate on the work of Ifkovits et al. [3] and, specifically, to determine if stress
data between treatments and no treatment control led to similar trends as observed in in
vivo outcomes. Simulation results demonstrated that both treatments generally resulted
in lower stress levels compared to no treatment at ED and ES in the fiber direction;
moreover, high MeHA, low A/T generally resulted in the largest stress reductions
compared to low MeHA, low A/T (Figure 5.10A, B). Both treatments resulted in stress
reductions in the cross-fiber direction with more variability in trends between groups;
however, relative to stress levels in the fiber direction, stress values in the cross-fiber
direction were much lower (Figure 5.10C, D). Overall, these data supported the in vivo
findings since both techniques indicate that high MeHA, low A/T is more effective in
limiting LV remodeling compared to low MeHA, low A/T.
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Figure 5.10 Stress values for low and high MeHA, low A/T treatment and no treatment
control. Global, transmural, and mid-wall stresses at end-diastole (ED) and end-systole
(ES) in the fiber (A, B) and cross-fiber (C, D) directions.

For the second set of simulations, treatment with all four formulations were
simulated and stresses were compared between groups and no treatment control; the
goal here was to assess relative differences between treatments and to assess how
injection mechanical properties and distribution influence reductions in stress. Similar to
the aforementioned simulations, all treatments resulted in lower stresses compared to no
treatment control at ED and ES in the fiber direction (Figure 5.11A, B). Additionally,
treatment with formulations with higher mechanics and larger volume distributions
generally resulted in the largest stress reductions. While treatment generally resulted in
lower stress compared to no treatment controls, trends in stress at ED and ES in the
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cross-fiber direction were more variable and much lower than the fiber direction (Figure
5.11C, D).

!
Figure 5.11 Calculated stresses for all treatments (volume estimated as 60% of
measured mean values) and no treatment control. Global, transmural, and mid-wall
stresses at end-diastole (ED) and end-systole (ES) in the fiber (A, B) and cross-fiber (C,
D) directions.

5.4 Conclusions
To our knowledge this is the first study to a) perform biaxial testing on
hydrogel/tissue composites and b) to apply these data to derive passive myocardial
material parameters to simulate injections to treat a dilated LV.

By performing

compressive and biaxial testing on composites and control myocardium, we
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demonstrated that MeHA hydrogel incorporation into myocardial tissue resulted in
composites with mechanical properties that were dependent on macromer percent
modification and initiator concentration; overall increases in both led to higher moduli.
Interestingly, in biaxial testing, this trend was more pronounced in the longitudinal
direction, suggesting that composite formation directionally influences mechanical
properties of myocardial tissue.

Consequently, anisotropy of all composites was

decreased compared to myocardial control tissue.

Biaxial data was used to derive

diastolic myocardial material properties for control myocardium and composite
formulations. Theoretical outcomes validated previous in vivo findings by Ifkovits et al.
particularly at ED and ES in the fiber direction [3]; treatment with high MeHA, low A/T
was more effective than the low MeHA, low A/T both in vivo (resulting in less dilation)
and in theoretical simulations (resulting in larger stress reductions).

Additionally,

comparisons between all treatments (low or high MeHA and low or high A/T)
demonstrated that higher hydrogel mechanics and greater distribution typically resulted
in larger reductions in stress at ED and ES in the fiber direction. Overall, these data
indicate that FE modeling is an effective technique to employ material properties of
hydrogel/tissue formulations to predict their performance in vivo via stress outputs that
can be correlated to experimental outcomes. Moreover, these data demonstrate that the
magnitude of mechanical support provided by injectable biomaterials influences
myocardial stress (a major contributor in the progression of LV remodeling) and should
be considered when developing materials to treat LV remodeling.
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CHAPTER 6

Synthesis, Purification, and Characterization of Hydrolytically Degradable
Hyaluronic Acid Hydrogels

(Adapted from: E Tous, JL Ifkovits, KJ Koomalsingh, T Shuto, T Soeda, N Kondo, JH Gorman, III,
RC Gorman, JA Burdick, “Influence of Injectable Hyaluronic Acid Hydrogel Degradation Behavior
on Infarction Induced Ventricular Remodeling,” Biomacromolecules, 2011, 12:4127-4135.)

6.1 Introduction
The previous three chapters applied methacrylated hyaluronic acid (MeHA)
hydrogels to demonstrate that mechanics (via experimental/ in vivo [1] and theoretical
assessment) and hydrogel distribution (via theoretical assessment) influence left
ventricular (LV) remodeling.

Here, we introduce hydrolytically degradable hyaluronic

acid (HA) hydrogels to address the time sensitivity of remodeling by investigating the
temporal considerations in material design. Specifically, these hydrogels are used to
examine the temporal role of mechanical support during this process; this will provide
insight to the duration of stability that is required to effectively attenuate LV remodeling.
This chapter will focus on material synthesis and characterization, while Chapters 7 and
8 will apply iterations of these materials to assess their efficacy in limiting these
maladaptive changes in an in vivo ovine MI model.

Overall, the goal is a better

understanding of material design toward the development of more targeted therapies
(injectable biomaterials) to attenuate LV remodeling
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6.1.1 Hyaluronic Acid (HA): Tissue Engineering
As briefly discussed in Chapter 4, HA is a biocompatible linear polysaccharide
comprised of alternating D-glucuronic and "-N-acetyl-D-glucosamine disaccharide
repeat units that is found abundantly throughout the body [2]. HA plays both cellular and
mechanical functions that are essential in maintaining our homeostasis [2-7].
Specifically, HA provides biomechanical integrity by facilitating extracellular matrix
(ECM) organization and also mediates biological processes such as cell proliferation,
morphogenesis, inflammation, and wound healing through three main types of cell
surface receptors: CD44, CD54 (intracellular adhesion molecule-1, ICAM-1), and CD168
(receptor for hyaluronan mediated motility, RHAMM) [2, 4-7]. These attractive qualities
make HA a good candidate for a range of tissue engineering (TE) applications including
cartilage [8-13], valve [3, 14], and cardiac [1, 15, 16] tissues and in controlling stem cell
fate [17-20].

6.1.2 HA: Cardiac Engineering
HA is particularly appealing as a material for cardiac engineering because of its
role in cardiac development and ECM homeostasis [21, 22].

During cardiac

embryogenesis, HA mediates the expansion of the endocardial cushions, which develop
into the valvular and septal portion of the heart by organizing the ECM and hydrating the
cardiac jelly [21].

Experimental work has verified the significance of HA in

morphogenesis; Camenisch et al. reported cardiac abnormalities in mice deficient in HA
synthase 2 (a prominent contributor to HA production) [23].

Additionally, HA-based

scaffolds have been implemented in vitro to investigate their utility in valvular
engineering, where seeded valvular interstitial cells (VICs) demonstrated effective
adherence and proliferation capabilities [3]. The role of HA has also been investigated
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with respect to negative remodeling after MI; the concentration of low molecular weight
(LMW) HA was observed to be greater compared to pre-MI where high molecular weight
(HMW) presence was more dominant [22]. After MI, proteases not only break down
collagen, but can also degrade HMW-HA to LMW-HA, which plays a “wound healing”
role in mediating cell migration and inflammation after MI [24].

Additionally, when

compared to fetal tissues, adult tissues express higher amounts of hyaluronidases that
facilitate the enzymatic break down of HA, rendering HMW-HA in adults more
susceptible to break down into LMW fragments [25]. Overall, these reports demonstrate
the relevance of HA in maintaining a functional myocardium and suggest that HMW-HA
is more relevant in the development and maintenance of ECM structures [21, 22].
Reports also suggest a role of LMW-HA in wound healing applications, mediating
inflammatory activities post-MI and upregulating vascular endothelial growth factor
(VEGF) and promoting angiogenesis and cell proliferation [3, 7], which can be attractive
for treating ischemic tissues such as in the infarct region.

6.1.3 HA: Hydrolytically Degradable Hydrogels
As discussed in Section 4.1.2, HA is readily modified at its carboxyl and hydroxyl
groups with a range of chemistries, including methacrylates [1, 11, 12, 20, 26]. These
groups can undergo radical polymerization at the vinyl group via initiation techniques to
form hydrogels with bulk properties (e.g., mechanics and gelation) that are varied based
on the extent of crosslinking, which can be influenced by extent of macromer
modification, macromer concentration, and initiator efficiency [1, 27]. In addition to their
tunability due to alterations in crosslinking, MeHA hydrogels are generally attractive for
TE applications due to their natural enzymatic degradation.

%(%!
!
!

Most degradable scaffolds applied in TE are designed so that they leave after
providing their structural purpose; however, HA degradable scaffolds are unique in that
their degradation products may also be biologically active.

HA is enzymatically

degradable at its backbone by hyaluronidases naturally found in the body and is broken
down to yield oligosaccharides [2, 4, 6, 7]. Studies with MeHA hydrogels (formed via
photopolymerization) have shown that their degradation kinetics by exogenous
hyaluronidases can be tailored [26]. However, these systems are limited in that they are
only enzymatically degradable; thus, degradation at physiological hyaluronidase
concentrations can take months to years and is dependent on the amount of
hyaluronidases present in vivo. To circumvent these drawbacks, our group has modified
HA with methacrylate-based reactive groups that also introduce hydrolytically
degradable moieties to provide more controlled degradation for TE applications [28, 29].
Like MeHA, these macromers can be crosslinked at the vinyl portion of the
methacrylate to control bulk properties dependent on the efficiency of crosslinking and
are still enzymatically degradable [28, 29]. In addition to these qualities, however, the
inclusion of ester bonds between the HA backbone and the reactive groups provides
enhanced control over hydrogel degradation. Chung, Sahoo and colleagues were the
first to synthesize and characterize these types of HA hydrogels; they achieved this by
including !-hydroxy ester-based chemistries (lactic acid, LA and caprolactone, CL)
between the HA backbone and methacrylate [28, 29]. Using photopolymerization, they
formed hydrogels and demonstrated that, as expected, LA-containing hydrogels
degraded more quickly than CL-containing hydrogels, due to a greater susceptibility to
hydrolysis, and that both degraded much faster than MeHA hydrogels.

In general,

hydrolytic degradation was tailored by either adjusting the number of repeat units within
each added group or the amount added to the HA backbone [28, 29]. While these
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hydrolytically degradable HA hydrogels were successfully synthesized, their synthesis
was tedious and inefficient and they are highly hydrophobic, limiting functionalization and
hydrogel concentrations; hence, here we explore an alternative synthesis and
purification scheme.
In this dissertation, we functionalize HA at the hydroxyl group with a hydroxyethyl
methacrylate (HeMA) group, which is more easily synthesized and results in more
efficient macromer yield.

This chapter will summarize the optimized synthesis and

purification for HeMA-HA macromers of varying extents of modification. While past work
employed photopolymerization techniques to form hydrogels, as discussed in Chapter 4
and as employed by Ifkovits et al. [1], oxidation-reduction (redox) initiation with
ammonium persulfate (APS, A) and N,N,N,N’,N’-tetramethylethylenediamine (TEMED,
T) will be used to initiate hydrogel polymerization in this work [30]. This method of
polymerization facilitates further control of crosslink efficiency and also provides a more
practical means to deliver hydrogels for MI application. Here, HeMA-HA homopolymer
and copolymer (HeMA-HA and MeHA) hydrogels are formed and characterized to
evaluate the influence of the amount of HeMA (percent modification) and type of
copolymer (ratio) on material parameters including gel onset, mechanics, and
degradation.

In general, this work provides insight into the design and material

properties of HeMA-HA hydrogels. Understanding degradation kinetics, in particular, will
allow for the optimal application of this class of materials to treat the evolving
progression of LV remodeling.
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6.2 Materials and Methodology
6.2.1 Synthesis of Hydroxyethyl Methacrylated Hyaluronic Acid (HeMA-HA) Macromer
The reaction scheme for HeMA-HA synthesis is summarized in Figure 6.1. 2hydroxyethyl methacrylate (HeMA) (Acros) was reacted with succinic anhydride (SA)
(Sigma) at 1:1.1 molar ratio via a ring opening reaction that was catalyzed by Nmethylimidazole (NMI) (Sigma) in dichloroethane (DCE) (Fisher) at 65 °C for 16 hours.
A small amount of hydroquinone (Acros) was added to scavenge free radicals and inhibit
their polymerization of the methacrylate groups during storage. The end product of this
reaction was a mixture containing a carboxylic acid terminated HeMA (HeMA-COOH).
HeMA-COOH was purified and isolated from impurities by undergoing several washes
with aqueous hydrochloric acid to remove excess SA and with deionized water to
remove water-soluble impurities. The mixture was dried by adding magnesium sulfate
(MgSO4) (Fisher) and filtration was performed to remove MgSO4. The filtered solution
was rotovapped to concentrate the final product by minimizing the volume of DCE and
stored at 4 °C.

1

H NMR (Bruker, 360 MHz) was performed to confirm HeMA-COOH

formation and purity.
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Figure 6.1 Chemical synthesis of HeMA-HA intermediate products (HeMA-COOH and
HA-TBA) and final product (HeMA-HA).
!
HA-tetrabutylammonium salt (HA-TBA) was synthesized as described in Section
4.2.3.1

where

HA-sodium

salt

(Lifecore,

66

kDa)

was

converted

into

a

tetrabutylammonium (TBA) salt by performing an acidic ion exchange followed by
titration [29].
HeMA-COOH was coupled to HA-TBA via an esterification reaction where
dimethylaminopyridine (DMAP) (Sigma) activated the carboxylic acid on HeMA-COOH
and the coupling agent di-tert-butyl dicarbonate (BOC2O) (Sigma) mediated the
attachment of HeMA-COOH to HA-TBA in anhydrous di-methyl sulfoxide (DMSO)
(Acros) at 45 °C for 20 hours.

Trace amounts of hydroquinone were added to the
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reaction to prevent free radical polymerization. HeMA addition to the HA backbone was
altered by adjusting the concentration and molar ratios of HeMA-COOH and the coupling
agent BOC2O and confirmed via 1H NMR.

6.2.2 Purification of HeMA-HA Macromer
A variety of purification techniques were explored to obtain a pure form of HeMAHA from the reaction mixture. Three specific approaches were examined (all dialysis
was performed against deionized water at 4 °C and a MW cutoff 5-8 kDa): 1) only
dialysis for 1 and 5 days, 2) acetone precipitation followed by overnight dialysis, and 3) 1
or 5 days of dialysis followed by acetone precipitation and dialysis again. After all forms
of purification, the HeMA-HA final products were lyophilized and stored at -20 °C prior to
use. The degree of purification was assessed via 1H NMR.

6.2.3 Synthesis of Methacrylated HA (MeHA) Macromer
Methacrylated HA was synthesized as discussed in Methods of Chapter 4
(Section 4.2.1) [26] where methacrylic anhydride (MA) (Sigma) was reacted in excess
with HA sodium salt (Lifecore, 66kDa) and modification was assessed via 1H NMR.

6.2.4 Formation and Characterization of Hydrogels
Gelation, mechanics and degradation were evaluated to assess hydrogel
tunability based on HeMA-HA modification (~10%, ~30%, and ~60%) and MeHA
inclusion at 5 ratios (100:0, 75:25, 50:50, 25:75, 0:100, HeMA-HA (~20% modified):
MeHA (~100% modified)). Macromers were crosslinked through radical initiation with
APS (5 mM) (Sigma) and TEMED (5 mM) (Sigma) to form 4 wt% hydrogels. Gel onset
and compressive moduli were generally assessed as in Section 4.2.2. Gelation was
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assessed by monitoring the intersection of the storage (G’) and loss (G’’) moduli using
an AR2000ex Rheometer (TA Instruments) at 37 °C under 1% strain and a frequency of
1 Hz in a cone and plate geometry (1°, 20 mm diameter). To examine mechanics and
degradation, hydrogels (~50 µL) were formed between two glass slides within a teflon
mold sealed with vacuum grease by mixing macromer solutions with APS and TEMED
and incubating at 37 °C for 30 minutes. Compression testing was performed on samples
immediately after gelation with a Dynamic Mechanical Analyzer (DMA) (Q800 TA
Instruments) at a strain rate of 10%/ min and moduli were calculated at a strain from 1020%. For HeMA-HA homopolymers, degradation was assessed by incubating hydrogels
in phosphate buffered saline (PBS) at 37 °C and changing solutions at 1, 7, 14, 28, 56,
63, 70, 77, and 84 days or until hydrogels were completely degraded. Degradation
assessment was performed for copolymers by incubating hydrogels in PBS at 37 °C,
collecting samples at 1, 7, 14, 28, 42, 49, and 56, and quantifying percent (%) HA
release using a uronic acid assay [31]. Hyaluronidases (Sigma) were added to PBS
solutions to completely enzymatically degrade hydrogels after 8 weeks if necessary.

6.2.5 Statistical Analysis
Data is presented as mean ± SD (standard deviation). Differences in gel onset,
moduli, and percent mass loss were assessed using a one-way ANOVA with Tukey’s
post hoc evaluation.

Differences in mass loss between copolymer and MeHA at 8

weeks were assessed using the Student’s T-Test. For all comparisons, p<0.05 was
considered to be statistically significant.
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6.3 Results and Discussion
A hydrolytically degradable HeMA-COOH group was added to the enzymatically
degradable HA backbone to provide more precise control of degradation. While our
group has previously designed hydrolytically degradable hydrogels with the inclusion of
!-hydroxy esters (e.g., lactic acid and caprolactone) [28, 29], the macromer synthesis
employed was time consuming and inefficient. Instead of performing two reactions to
obtain a hydrolytically degradable carboxylic acid terminated moiety, the HeMA-HA
synthesis combines these two steps by directly converting the HeMA hydroxyl group into
a carboxylic acid via the ring opening reaction with SA (Figure 6.1). This new synthesis
allows for a more convenient and efficient synthesis of tunable hydrolytically degradable
HA-based macromers.

6.3.1 Synthesis of HeMA-HA Macromer
The hydroxyl groups of HeMA were first converted to carboxylic acids as
described in Methods. The conversion from hydroxyl to carboxyl terminated chemistry
was confirmed with 1H NMR with the detection of a peak at & ~2.70 ppm corresponding
to the protons added from the addition of SA (4, 5, Figure 6.2). The presence of minimal
impurities is also supported by the relatively clean 1H NMR spectrum.
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Figure 6.2 Chemical structure and representative 1H NMR spectrum (CDCL3) for HeMACOOH with labeled peaks corresponding to the protons on the intermediate product.
Peak 1= protons on alkene group. Peak 2, 3= protons corresponding to portion from
HeMA. Peak 4, 5= protons corresponding to SA addition. Peak 6= protons on methyl
group.

HA-TBA (characterization described in Chapter 4, Section 4.3.2.1) was reacted
as discussed in Methods with HeMA-COOH to synthesize HeMA-HA (Figure 6.1).
HeMA-HA was purified via several techniques to evaluate the most efficient and effective
method for pure HeMA-HA Figure 6.6.

6.3.2 Purification of HeMA-HA Macromer
As briefly discussed in Methods, HeMA-HA purification was analyzed in three
primary ways. In all cases, dialysis against deionized water was performed at 4 °C to
minimize hydrolytic degradation of the HeMA groups; purification optimization indicated
that dialysis at 4 °C did not influence the modification (Figure 6.5). Acetone precipitation
entailed the addition of NaCl to the reaction solution for exchange of TBA with Na so that
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TBA salts dissolved in the organic acetone solvent, while the Na and HA products
precipitated. The NaCl mixture was dripped into a solution of stirring acetone on ice that
was 10X the reaction volume to ensure efficient precipitation. Reaction solutions were
precipitated no more than 100 mL at a time to prevent crosslinking; precipitating large
amounts of HA at once resulted in unwanted polymerization, possibly due to the close
proximity of HA macromers in the polar acetone solvent. The HA-based precipitate was
collected, dissolved in water and then dialyzed to remove soluble impurities.
At day 1 the extent of purification by dialysis alone could not be assessed
because of the high content of impurities, likely due to high levels of DMSO; this
prevented lyophilization and salvage of the macromer. Immediate acetone precipitation
followed by overnight dialysis decreased the impurities (e.g., cloudiness of the solution);
however, 1H NMR revealed that DMSO and excess TBA salts were still present (Figure
6.3A).

Dialysis, followed by acetone precipitation and further dialysis produced the

purest product at day 1, with minimal DMSO and TBA (Figure 6.3B). These results
suggest that initial dialysis is important for DMSO removal; excess DMSO may hinder
precipitation as suggested by data from immediate acetone precipitation studies.
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Figure 6.3 Representative 1H NMR spectrum (D2O) for HeMA-HA macromer after 1 day
of purification.

Acetone precipitation followed by overnight dialysis (A) or overnight

dialysis followed by acetone precipitation and further dialysis (B).

At day 5, groups 1 (dialysis alone) and 3 (5 days of dialysis, acetone
precipitation, and further dialysis) were evaluated. After 5 days of dialysis, DMSO was
no longer present; however, TBA salts (although in smaller quantities then in group 2 at
day 1) remained (Figure 6.4A). In contrast, significant reduction of DMSO and TBA salt
impurities were observed in group 3 at day 5 (Figure 6.4B).

While impurities were

significantly minimized, several macromers after acetone precipitation followed by an
overnight dialysis displayed an abnormal HA backbone as shown in Figure 6.4B. This
may be due to residual acetone remaining in the final product after precipitation. A
%)%!
!
!

normal HA backbone was restored after an additional 3 days of dialysis following
acetone precipitation (Figure 6.5A and 6.5B). Also, prolonged dialysis at 4 °C did not
alter the macromer modification (~30%) (Figure 6.5).

!
Figure 6.4 Representative 1H NMR spectrum (D2O) for HeMA-HA macromer after 5 days
of purification. 5 days of dialysis alone (A) or 5 days of dialysis followed by acetone
precipitation and further dialysis (B).
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Figure 6.5 Representative 1H NMR spectrum (D2O) for HeMA-HA macromer assessing
its purity immediately after acetone precipitation (A) or 3 days of dialysis after acetone
precipitation (B).

Taking into consideration the aforementioned studies, the purification protocol
was finalized as follows: a 1 day dialysis to remove DMSO for precipitation, acetone
precipitation to remove most of the TBA salts, and a 3 day dialysis to remove leftover
salts and acetone impurities to ensure a normal HA backbone after precipitation.
Employing this purification technique resulted in a pure HeMA-HA macromer (Figure
6.6).
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6.3.3 Alteration of HeMA-HA Functionalization
The amount of HeMA added to the HA backbone (e.g., percent modification/
methacrylation) was tuned by varying the concentration of HeMA-COOH and BOC2O in
the same ratio (1.4: 1.2, HeMA-COOH: BOC2O) with excess HeMA-COOH (Figure
6.6B). Syntheses performed with the same or excess amounts of BOC2O to HeMA were
prone to crosslinking both within the reaction vessel and during acetone precipitation.
Modification was assessed by 1H NMR; percent methacrylation was determined by
integrating the methacrylate peaks on the HeMA (peaks 2, & ~6.20 ppm and & ~5.80
ppm) with respect to the N-acetyl group on HA, or peak 1 at a resonance of & ~2.10 ppm
(Figure 6.6A, C).
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Figure 6.6 Chemical structure for HeMA-HA (A), the relationship between final
methacrylation (modification) and HeMA-COOH to BOC2O ratio during synthesis, n=4
(B), and representative

1

H NMR spectrum (D2O) of HeMA-HA macromer (~10%

modification) after finalized purification method (C). Peak 1= protons on the N-acetyl
group on HA. Peak 2= protons of alkene on methacrylate group. Peak 3= protons of
methyl group on HeMA moiety. Data presented as mean ± SD.

6.3.4 Formation of HeMA-HA and Copolymer Hydrogels
APS and TEMED redox reaction initiation was employed to polymerize
macromers into hydrogels. As discussed in Section 4.1.3, this type of polymerization is
most practical to facilitate delivery of the pre-polymer solution (ideally via catheter) to the
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heart for MI repair. Furthermore, gelation times can be adjusted by altering initiator
concentrations, providing enhanced control for delivery [1].
Specifically, either HeMA-HA alone or HeMA-HA/MeHA macromer solutions
were mixed with APS and TEMED initiators to form homopolymer or copolymer
hydrogels, respectively. Kinetic chains form through the reactive methacrylate groups to
generate a network where bulk properties are dependent on the macromer percent
modification, macromer concentration, and initiator concentration.

In addition to the

similar mechanical tunability and enzymatic degradation of MeHA hydrogels, HeMA-HA
hydrogels are also susceptible to hydrolysis of the HeMA side groups, which break down
into poly(methacrylic acid) kinetic chains and HA fragments. Here, we investigate the
influence of the degree (i.e., HeMA percent modification) and type (i.e., HeMA/MeHA
macromer ratio) of modification on gelation, mechanics, and degradation of HeMA-HA
and copolymer hydrogels.

6.3.5 Characterization of HeMA-HA and Copolymer Hydrogels
HeMA-HA hydrogel characterization was performed to evaluate the influence of
HeMA modification (~10%, ~30%, ~60%) on material properties including gelation,
mechanics and degradation. Gelation was examined as described in Section 4.3.1 by
performing a time sweep and defining the gel onset time as the intersection of the
storage (G’) and loss (G’’) moduli.

Increases in HeMA-HA methacrylation led to

significantly shortened gel onset times (Figure 6.7A), potentially due to changes in
reactive group concentration with HeMA-HA modification.

As expected, increased

methacrylation led to significantly increased compressive moduli and degradation time
due to the greater crosslink density and number of bonds needing to hydrolyze for
complete hydrogel degradation (Figure 6.7B).
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Figure 6.7 Gel onset, n=3-4, (A) and degradation time (black) and compressive modulus
(white), n=3-4, (B) as a function of HeMA-HA modification, gelled at 5 mM APS/TEMED.
Data are presented as mean ± SD. All groups are statistically significant (p<0.05).

Past work by our group with MeHA and !-hydroxy ester block copolymers has
demonstrated that material properties such as mechanics and degradation can be
tailored by adjusting the ratio of the MeHA block to the hydrolytically degradable block
[28].

Here, we performed similar characterization with HeMA-HA (~20% modified) and

MeHA (~100% modified) hydrogels formed at 5 copolymer ratios (HeMA-HA:MeHA,
100:0. 75:25, 50:50, 25:75, and 0:100) and a constant concentration (4 wt%). MeHA
alone (0:100) displayed higher mechanics compared to HeMA-HA alone (100:0) and for
copolymer groups the mechanics also increased with increased MeHA amount (Figure
6.8A). One copolymer formulation was selected for additional characterization (e.g.,
HeMA-HA:MeHA, 75:25); this formulation contained the greatest number of hydrolytically
degradable groups, allowing for the most thorough assessment of degradation (via
hydrolysis) on hydrogels.
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Figure 6.8 Compressive moduli of hydrogels formed from HeMA-HA:MeHA (H:M)
copolymers at various ratios (n=4-5) (A). Gel onset times (n=4-5) (B) and degradation
(n=3) (C) of HeMA-HA, selected copolymer (75:25, H:M), and MeHA. Data are
presented as mean ± SD. For A, all groups are statistically different from each other
except for 50:50 compared to 25:75 and 75:25 (p<0.05). All groups are statistically
significant in B (p<0.05). For C: *p<0.05 HeMA-HA vs. MeHA, #p<0.05 copolymer vs.
MeHA, $p<0.05 between all groups.
!
Gel onset time for copolymer hydrogels was assessed as in homopolymer
studies and results indicate that increased MeHA addition relative to HeMA-HA
corresponds to accelerated gelation times (Figure 6.8B). Due to the extensive amount
of time required for MeHA degradation, degradation for copolymer studies was
evaluated with a uronic acid assay for 8 weeks, at which point hydrogels were degraded
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via the addition of exogenous hyaluronidases.

Figure 6.8C demonstrates that HA

release from MeHA alone hydrogels was minimal throughout the 8 weeks and
statistically lower than the copolymer and HeMA-HA hydrogels at all time points.
Conversely, percent mass loss and degradation rate between the copolymer and HeMAHA alone hydrogels were similar for about 6 weeks until a burst of HA release was
observed in HeMA-HA hydrogels; this observation is likely due to the bulk degradation
exhibited by hydrolytically degradable hydrogels, which is dependent on hydrogel
swelling, where once a threshold of broken crosslinks is reached an exponential
increase in mass loss follows.

Copolymer degradation by 8 weeks was still

comparatively low; however, a similar burst release as observed in HeMA-HA alone
hydrogels may have been observed in a prolonged study since the copolymer is
composed of primarily HeMA-HA compared to MeHA.

6.4 Conclusions
In this section, the synthesis and purification of a hydrolytically degradable HA
macromer (HeMA-HA) with tunable functionality was achieved. Various hydrogels of
varying composition were formed via redox chemical initiation by altering the amount of
HeMA on the HA backbone and/or by forming copolymers with MeHA. Characterization
of HeMA-HA hydrogels was performed for gel onset, initial mechanics and degradation.
Altering the HeMA addition influenced all these parameters, confirming the tunability of
hydrogel properties based on HeMA modification. Copolymers were also evaluated as
an alternative approach to form hydrogels with tunable properties.

This chapter

illustrates the versatility of HeMA-HA hydrogels; by altering both functionalization and
incorporating MeHA macromers, several combinations of initial mechanics and
degradation can be achieved depending on the desired application. While the use of
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copolymers was also effective in tuning degradation properties, the remainder of this
dissertation will employ solely HeMA-HA homopolymers for simplicity in experimental
design and the desire for accelerated degradation behavior.

The next chapter will

explore the application and influence of temporal degradation of HeMA-HA hydrogels to
attenuate LV remodeling.
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CHAPTER 7

Hydrolytically Degradable Hyaluronic Acid Hydrogels to Assess the Influence of
Temporal Mechanical Support on Left Ventricular Remodeling

(Adapted from: E Tous, JL Ifkovits, KJ Koomalsingh, T Shuto, T Soeda, N Kondo, JH Gorman, III,
RC Gorman, JA Burdick, “Influence of Injectable Hyaluronic Acid Hydrogel Degradation Behavior
on Infarction Induced Ventricular Remodeling,” Biomacromolecules, 2011, 12:4127-4135.)

7.1 Introduction
As reviewed in Chapter 1, myocardial infarction (MI) results from the occlusion of
a coronary artery, leading to the depletion of oxygen and nutrients and resulting in
cardiomyocyte necrosis and extracellular matrix (ECM) break down. As the ECM is
disrupted, the myocardium is susceptible to geometric changes that subsequently
increase stress throughout the injured and healthy regions of the heart [1-4]. These
maladaptive responses lead to a series of biological and mechanical changes that cause
further cell death and increase myocardial instability, which contribute to contractile
dysfunction and can progress into a positive feedback loop that ultimately leads to heart
failure (HF) [5-8]. The strategy in this investigation was to target these initial geometric
alterations, which have been identified as the initiator of the maladaptive events
associated with adverse post-MI remodeling [9-11].
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7.1.1 Injectable Biomaterials for Myocardial Infarction (MI)
As has been discussed throughout this dissertation, numerous theoretical [2, 12,
13] and experimental models [14-32] have shown that limiting infarct expansion with the
introduction of injectable materials into the infarct can attenuate the remodeling process,
primarily through bulking (thickening) and stabilizing (stiffening) the infarct zone. While
these reports have demonstrated the benefits of these injectable agents, the materials
tested to date have had a wide range of properties, including the method of gelation,
bulk mechanical properties and degradation behavior [14-16, 18-32]; consequently the
mechanism behind their efficacy is unclear.

Few studies have been performed to

determine the optimal mechanical and degradation properties of the injected material;
although, based on theoretical analyses both parameters should affect their efficacy [12,
13].

(Refer to Chapter 5 for theoretical assessment on the influence of mechanical

factors).

7.1.2 Injectable Biomaterials for MI: Tunable Systems
Tunable hydrogel systems provide an important experimental tool to help identify
optimal material properties of the injectate, since material properties (gelation, stiffness,
and degradation) can be independently manipulated and examined.

Ifkovits et al.

recently used a mechanically tunable injectable material system where the influence of a
mechanics on negative remodeling could independently be assessed [17]. Chapters 3,
4 and 5 already thoroughly discussed and referred to the mechanically tunable
methacrylated hyaluronic acid (MeHA) hydrogels employed in that work. Briefly, two
variations of MeHA were explored, where crosslink density (i.e., mechanics) was
adjusted by varying the amount of methacrylation (low and high), yet gelation behavior
and mass loss were similar [17].
!

This work concluded that high MeHA was more
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effective in attenuating LV remodeling and motivated the importance of material
mechanical properties in bulking agents and in stabilizing the myocardial wall post-MI.
In this case both hydrogels were stable and still present after 8 weeks in an ovine MI
model.
This chapter will further discuss properties for injectable hydrogels, with a focus
on the timing of the material degradation.

HA was functionalized with hydroxyethyl

methacrylate (HeMA), to yield a macromer (HeMA-HA) that crosslinks similar to MeHA,
yet has additional ester bonds that provide further control over hydrogel degradation.
Initial HeMA-HA hydrogel characterization (gel onset, mechanics, and degradation) was
performed in Chapter 6, and demonstrated that these properties could be tailored based
on HeMA modification in a controlled manner.

Here, we specifically compare the

previous experimental work [17] of two versions of MeHA hydrogels (low and high
mechanics) with the newly synthesized HeMA-HA hydrogels, where initial mechanics are
matched and degradation timing was varied to evaluate the influence of temporal
changes with HeMA-HA hydrogels. This system is the first to examine the temporal
dependency of mechanical stabilization during the progression of LV remodeling, and
provides insight into how long mechanical support must be applied to attenuate the
aftermath of MI.

7.2 Materials and Methodology
The animals studied in this investigation received care in compliance with the protocols
from the University of Pennsylvania that were approved by the Institutional Animal Care
and Use Committee in accordance with the guidelines for humane care (National
Institutes of Health Publication 85-23, revised 1996). All materials were purchased from
Sigma-Aldrich unless otherwise indicated.
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7.2.1 Synthesis of Hydroxyethyl Methacrylated Hyaluronic Acid (HeMA-HA) Macromer
Variations of HeMA-HA were synthesized by coupling HA-tetrabutylammonium
salt (HA-TBA) with HeMA-COOH as discussed in Chapter 6.

(For a more detailed

description on HeMA-HA synthesis and purification refer to Sections 6.2.1 and 6.3.2,
respectively). Briefly, HA-TBA coupling to HeMA-COOH was performed in di-methyl
sulfoxide (DMSO) (Acros) for 20 hours and purified overnight by dialysis against
deionized water at 4 °C, precipitation in acetone, and dialysis for 3 additional days
against deionized water at 4 °C. Methacrylation was adjusted by varying the amount of
HeMA-COOH and di-tert-butyl dicarbonate (BOC2O) and all products were assessed
with 1H NMR (Bruker, 360 MHz).

More details on tuning coupling are described in

Section 6.3.3.

7.2.2 Synthesis of Methacrylated Hyaluronic Acid (MeHA) Macromer
MeHA was synthesized as described in Section 4.2.1 through the reaction of HA
with methacrylic anhydride (Sigma) at pH 8.0 for 24 hours followed by dialysis and
lyophilization [33]. Methacrylation was altered by varying the amount of methacrylic
anhydride relative to HA and was assessed with 1H NMR.

7.2.3 Formation, Characterization, and Selection of HeMA-HA Hydrogels
HeMA-HA hydrogel characterization was performed in Chapter 6 to examine the
influence of varying degrees of HeMA functionalization on material properties (gel onset,
initial mechanics and degradation). To compare HeMA-HA efficacy to that of MeHA in
attenuating LV remodeling, two HeMA-HA variations (low and high) were selected based
on this initial characterization.

The chosen formulations were normalized to their

respective MeHA (low and high) initial mechanics and gel dispersion by adjusting the
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efficiency of crosslinking via alteration of the concentration of the oxidation-reduction
(redox) initiators ammonium persulfate (APS, low: 8 mM, high: 7 mM) and N,N,N,N’,N’tetramethylethylenediamine (TEMED, low: 4 mM, high: 7 mM) (Table 7.1).
As described in Section 6.2.4, 4 wt% hydrogels were formed through a redox
radical polymerization reaction with APS and TEMED [34]. Gelation was assessed, as
in Section 6.2.4, by monitoring the storage (G’) and loss (G’’) moduli using an AR2000ex
Rheometer (TA Instruments) at 37 °C under 1% strain and a frequency of 1 Hz in a cone
and plate geometry (1°, 20 mm diameter). Gel dispersion was also evaluated in ovine
explants by injecting 0.3 mL at either 2 or 3 minutes (depending on gel onset rheology
data) to evaluate time dependent influences in high HeMA-HA compared to low HeMAHA hydrogels.
To evaluate mechanics and degradation, hydrogels were formed between two
glass slides within a teflon mold sealed with vacuum grease by mixing macromer and
initiator solutions. To assess temporal mechanics, compression testing was performed
on samples immediately after gelation (Day 0) or at desired time points throughout
degradation (as in Section 6.2.4) with a Dynamic Mechanical Analyzer (DMA) (Q800 TA
Instruments) at a strain rate of 10%/ min; moduli were calculated as the slope of the
stress-strain curve at 10-20% strain. For degradation assessment, gels were incubated
in phosphate buffered saline (PBS) at 37 °C and samples were collected at various time
points and percent mass loss was quantified using a uronic acid assay [35].

7.2.4 In Vivo Evaluation in MI Model
Low and high HeMA-HA macromers were sterilized under germicidal ultraviolet
(UV) light for 30 minutes on each side, and all solutions were filter sterilized. An
established reproducible in vivo ovine MI model was employed to assess their efficacy in
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limiting LV remodeling [28]. Twenty-one adult male Dorset sheep (35-40 kg) (n=6 low
HeMA-HA, n=8 high HeMA-HA, n=7 infarct control) were anesthetized, underwent a left
thoracotomy to expose the heart, and were monitored for arterial, ventricular, and
pulmonary artery pressure and electrocardiogram throughout the surgery.

Baseline

echocardiographic and hemodynamic data were first obtained and then followed by
infarction, induced via ligation of the left anterior descending (LAD) and second diagonal
coronary artery to create an infarct that was ~40% of the distance from the apex to the
base of the heart and included ~20% of the LV mass at the anteroapex [36].
Thirty minutes post-MI, HeMA-HA treatment sheep received 20 0.3 mL injections
in the infarct area of the pre-polymer solution that was mixed for 2 to 3 minutes,
depending on the polymer, before injection and gelation. Hemodynamic data and realtime three-dimensional echocardiographs (3DE) were collected before infarction, 30
minutes post-MI, 30 minutes post-injection, and 2 and 8 weeks after therapy. 3DE was
used to quantify the extent of global LV remodeling by measuring LV end diastolic and
systolic volumes at each time point. All volume measurements were normalized to preinfarction values [17].

Functional outcomes were analyzed by evaluating ejection

fraction (EF) at 2 and 8 weeks and with dobutamine (DoB) (2.5 and 5.0 mg kg-1 min-1)
stress testing. EF was evaluated by comparing baseline values to outcomes at 2 and 8
weeks post-MI and values under stress to no stress at 8 weeks. Animals were sacrificed
at 8 weeks, and morphometric and histologic evaluations were performed on the excised
hearts. Results were compared to controls consisting of infarct controls and previously
published MeHA work (low MeHA (n=5) and high MeHA (n=7)) [17] to determine the
efficacy of this system in limiting global LV remodeling.
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7.2.4.1 In Vivo Evaluation in MI Model: Immunohistochemistry
Due to the potential influences of degradation on biological activity, both vessel
formation and inflammation were evaluated in all groups in paraffin embedded sections
at the 8 week time point. Vessels were stained with anti-!-smooth muscle actin (!-SMA,
mouse anti-human, Dako, MO851), and examined at the apical, middle, and basilar
infarct regions (one section per animal for each region). Vessel density was calculated
in three fields of view at 20X magnification at the apical and basilar infarct regions and in
nine magnification views in the middle infarct area of each section.

Vessels were

identified by positive !-SMA staining and were quantified in three ways: 1) all vessels
greater than 10 µm, 2) all vessels with visible lumen greater than 10 µm, and 3) all thick
vessels (vessels with more than one cell layer comprising the lumen) greater than 10
µm.
The

inflammatory

response

was

investigated

by

performing

immunohistochemical (IHC) staining with major histocompatibility complex (MHC) class
II (mouse anti-sheep, Serotec, MCA901).

Staining was evaluated both near the

biomaterial and in the surrounding tissue. Briefly, for IHC staining, paraffin sections
were deparaffinized, hydrated and quenched for endogenous peroxidase activity for 5
minutes in 4% H2O2 in deionized water. After quenching, samples were washed 3X in
Dako 1X wash buffer and primary antibody was applied at appropriate dilutions in Dako
diluent (!-SMA: 1:500, MHC class II: 1:10) at room temperature (RT) for 30 minutes in a
humidified chamber. After incubation, 3 washes in wash buffer were performed and
samples were incubated with HRP labeled polymer (Dako, K4000) for 30 min at RT in a
humidified chamber.

After washing 3X in wash buffer, sections were incubated in

diaminobenzadine substrate (Vector, SK-4100) at RT. Samples were then washed in
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deionized water to stop the reaction, counterstained in hematoxylin stain, dehydrated
and cover slipped.

7.2.5 Statistical Analysis
Data is presented as either mean ± SD (standard deviation) or mean ± SEM
(standard error of the mean) as indicated in figure legends. All changes in data were
assessed using a one-way ANOVA with Tukey’s post hoc evaluation to account for
differences between groups or time points.

p<0.05 was considered statistically

significant for all comparisons.

7.3 Results and Discussion
7.3.1 Selection and Characterization of HeMA-HA Hydrogels: Mechanics and Gelation
We previously synthesized MeHA macromer and injected two hydrogel
formulations with varying mechanics in vivo into infarcted myocardium and observed
mechanically-dependent outcomes [17].

Here, we address another property,

degradation, by employing a new HA macromer that contains additional ester bonds
between the HA backbone and reactive methacrylate that are susceptible to hydrolysis;
similar to MeHA, HeMA-HA modification (percent) was assessed by 1H NMR (Section
6.3.3).
HeMA-HA was reacted into hydrogels using redox initiation by mixing solutions of
HeMA-HA containing either APS or TEMED to form kinetic chains and generate a
network with bulk properties (e.g., mechanics) dependent on the crosslink density, which
was influenced by factors including modification. Unlike MeHA hydrogels, HeMA-HA
hydrogels are susceptible to both enzymatic degradation of the HA backbone and
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hydrolysis of the side groups; thus, as demonstrated in Section 6.3.5, in addition to
mechanical tunability, HeMA-HA also allows for enhanced tunability of degradation.
To address how both mechanics and degradation influence adverse LV
remodeling, we investigated two variations (low and high) of two different macromers
(HeMA-HA and MeHA) (four hydrogel groups in total), where two hydrogels with low
mechanics were compared and two hydrogels with high mechanics were compared,
each having variable degradation behavior. Specifically, the HeMA-HA tunability was
used to identify two formulations for direct comparison to low and high MeHA from a
previous study [17], where the initial material properties (i.e., initial mechanics and gel
onset) were similar, but degradation was more rapid than their respective MeHA
counterpart (i.e., low HeMA-HA vs. low MeHA and high HeMA-HA vs. high MeHA)
(Table 7.1).

Table 7.1 Summary of the material properties of HeMA-HA and MeHA formulations
evaluated in an in vivo ovine MI model.
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As demonstrated in Chapter 6, HeMA-HA material properties including
mechanics and gelation behavior are both dependent on methacrylation; conversely,
other work has shown that, while MeHA hydrogel mechanics are influenced by
modification, gel onset properties (evaluated via rheometry) are not significantly affected
[17].

To compensate for this discrepancy, initiator concentrations were tailored for

HeMA-HA formulations (Table 7.1) to achieve gelation and mechanical properties that
were similar to MeHA hydrogels. Previous work by Ifkovits et al., as well as data in
Sections 5.3.1, have shown that material properties such as gel dispersion and bulk
mechanics can be tuned by varying initiator concentrations [17].

While altering the

initiator concentration was sufficient to normalize low HeMA-HA gelation to that of
MeHA, high HeMA-HA gelation was more accelerated, according to rheometry
assessment, despite adjustments of initiator concentration (Figure 7.1A).

This was

accounted for in in vivo work by injecting high HeMA-HA at 2 minutes, while low HeMAHA and low and high MeHA were injected at 3 minutes. Gel dispersion of HeMA-HA
was additionally examined in myocardial explants before in vivo work was performed to
confirm that the delay in injection resulted in similar gel dispersion (Figure 7.1B).
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Figure 7.1 Gel onset time evaluated via rheometry for all four hydrogel formulations
studied in in vivo MI work (n=3) (A) and representative images of low and high HeMA-HA
dispersion in ovine explanted myocardial samples to validate similar dispersion at
injected times (B). Data presented as mean ± SD. *p<0.05 vs. high HeMA-HA. Scale
bar= 10 mm.

7.3.2 Characterization of HeMA-HA Hydrogels: Degradation
As previously discussed, HA is enzymatically degradable at its backbone;
however, this is dependent on the availability of hyaluronidases [33, 37, 38]. Although
MeHA does have an ester bond where the methacrylate attaches to HA, accessibility to
this bond is sterically hindered and hydrolytic degradation is minimal; therefore, MeHA
degradation is primarily dependent on an enzymatic mechanism and will be referred to
as having stable degradation for the remainder of this chapter. HeMA-HA, however, has
additional ester bonds that are accessible for hydrolytic degradation. Thus, in addition to
the enzymatic mechanism of the HA backbone, HeMA-HA hydrogels undergo hydrolytic
bulk degradation due to the availability of water throughout the gels. As seen in the
degradation profiles (Figure 7.2A), both MeHA formulations lose little mass throughout
the 8 week period, while both HeMA-HA formulations degraded within 8-10 weeks,
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depending on the extent of modification. Since the HA is reacted via many groups into
the kinetic chains, there is minimal mass loss at early time periods even with crosslink
hydrolysis, which accelerates at late times when the HA chains can be released from the
network, and eventually completely converts to soluble products.

!
Figure 7.2 MeHA and HeMA-HA degradation, n=3-4, (A) and temporal mechanics
profiles, n=3-4 (B). Data are presented as mean ± SD. *p<0.05 low HeMA-HA vs. low
MeHA, +p<0.05 high HeMA-HA vs. high MeHA, $p<0.05 low HeMA-HA vs. all
treatments, #p<0.05 high HeMA-HA vs. all treatments.

This hydrolysis also leads to exponential decreases in HeMA-HA mechanics,
even more rapidly than mass loss, since hydrolysis can cleave the crosslinks and lead to
decreases in mechanics prior to releasing mass into the surroundings (Figure 7.2B) [3943]. MeHA hydrogel degradation profiles showed an initial minimal burst response that
is commonly observed in hydrogels due to a soluble fraction, followed by stable, or
minimal, degradation. Slight mechanical decreases in MeHA hydrogels were observed
over this period. Overall, it is evident from degradation and mechanical temporal profiles
that hydrolytic degradation was more influential in HeMA-HA hydrogels compared to
%+*!
!
!

MeHA hydrogels. Importantly, release of HA may also have some biological function; as
discussed in Section 6.1.2, HA plays an active role in wound healing by promoting cell
migration and differentiation and angiogenesis and is involved in heart morphogenesis
and development [44-48]. The influence of all treatment groups on local vessel density
and inflammation will be discussed in more detailed in the in vivo portion of this chapter
(i.e., Sections 7.3.3.4).

7.3.3 In Vivo Evaluation in MI Model
As previously discussed, LV remodeling refers to the complex series of events
that occur post-MI.

Briefly, initial ECM break down triggers infarct dilation that

propagates throughout the borderzone (BZ) and remote region of the myocardium [1-4]
leading to thinning of the myocardial wall and in global geometric changes that cause the
heart to be susceptible to increased stress [5-7, 9, 10]. Although bulking agents are
becoming an attractive therapy to stabilize the myocardium and deter geometric
changes [14-32], there is still a lot that remains to be elucidated towards optimal
properties of the injected material.

Towards the importance of degradation, LV

remodeling is a time sensitive process that can be broken down into three main periods
of necrosis and acute inflammation, fibrosis, and remodeling. In humans, necrosis and
acute inflammation occur within the first week, followed by fibrosis for approximately
three additional weeks and finally by remodeling for approximately four more weeks [1].
Thus, it is of great importance to understand how the material presence during these
various periods after infarction plays a role in the progression of LV remodeling; this is
performed here with four material formulations.
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7.3.3.1 In Vivo Evaluation in MI Model: Thickness
Thinning of the infarct region is an important contributor to increased wall stress
both within the infarct and in the perfused regions of the heart and has been identified as
a precipitating and sustaining phenomenon that drives adverse remodeling after MI.
Infarct thickness was analyzed to evaluate the efficacy of the four treatment groups in
preventing remodeling. Specifically, thicknesses in the apical infarct, basilar infarct, BZ,
and in the remote myocardium were measured for each treatment group, normal (noninfarcted) and for infarct controls (Figure 7.3A, B). As expected, 8 weeks post-MI, infarct
control animals displayed a significantly thinner myocardial wall in the apical and basilar
infarct (apical: 2.2 mm, basilar: 4.6 mm) regions compared to normal non-infarct animals
measured at areas corresponding to infarct regions in treatment animals (apical: 6.1
mm, basilar: 8.5 mm). As previously shown, MeHA treatment was able to maintain
thicknesses in the apical and basilar infarct at levels similar to normal tissue (low MeHA:
apical: 6.5 mm, basilar: 7.0 mm, high MeHA: apical: 7.0 mm, basilar: 7.2 mm) [17]; this is
likely due to the stability and minimal degradation behavior of these polymers.
Interestingly, despite their susceptibility to hydrolytic degradation, treatment with both
HeMA-HA polymers increased the myocardium thickness compared to infarct controls,
with significant increases observed in high HeMA-HA treatments in the apical infarct
region but no significant increases in either polymer in the basilar infarct region (low
HeMA-HA: apical: 3.5 mm, basilar: 6.0 mm, high HeMA-HA: apical: 4.1 mm, basilar 6.1
mm). The mechanism behind HeMA-HA thickness increases, particularly for low HeMAHA, are not completely understood, but are thought to be due to a biological role of the
material and degradation products (including vessel formation and inflammation) [24].
Similar increases in myocardial thickness relative to infarct controls have been observed
following injection of fibrin, which also degrades in several weeks [14, 21].
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Figure 7.3 Myocardium thickness of normal myocardium, infarct controls, and HA
treatment groups (A: quantified, B: images) 8 weeks post-MI. Data are presented as
mean ± SEM. *p<0.05 vs. infarct control. Scale bar= 10 mm.

Histological analysis of the tissue at 8 weeks provided insight into the amount of
remaining gel at this time post-MI (Figure 7.4). As expected from the in vitro degradation
assays, hydrogel was present in both MeHA formulations and to a minimal extent in the
high HeMA-HA treatment group, primarily in the apical infarct regions. In contrast, no
gel was observed at all locations at 8 weeks for the low HeMA-HA groups.

This

observation supports in vitro trends as well as the limited enzymatic degradation that
occurs to break down the MeHA hydrogels. Generally, extensive collagen staining was
observed in all groups, with more prominent staining in the low HeMA-HA formulations,
potentially due to the released degradation products and changes in the inflammatory
response.
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Figure 7.4 Histological evaluation (Masson’s Trichrome stain) and representative
images of treatment groups at the apical, middle, and basilar infarct regions 8 weeks
post-MI. Scale bar= 500 µm. G= Gel.

7.3.3.2 In Vivo Evaluation in MI Model: End Diastolic and Systolic Volume
In addition to thickness increases, the extent of LV dilation in treatment groups
was compared to infarct control data by quantifying normalized end diastolic and systolic
volumes (NEDV and NESV) from 3DE data 2 and 8 weeks post-MI. As expected from
previous studies [17] both low polymers were ineffective in preventing volume increases
(Figure 7.5). Conversely, treatment with high polymers revealed promising results at 2
weeks where both high polymers limited LV increases to similar degrees (high HeMAHA: NEDV: 1.61 and NESV: 1.96, and high MeHA: NEDV: 1.62 and NESV: 1.89);
however, at 8 weeks it was evident that the high MeHA was more effective (high HeMAHA: NEDV: 1.98 and NESV: 2.46, and high MeHA: NEDV: 1.70 and NESV: 1.98).

In

vitro mechanical data supported these findings; while both high polymers had higher
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mechanics than myocardial tissue (~6 kPa) at 2 weeks [17], high HeMA-HA mechanics
were reduced to values lower than initial low values (~2 kPa) by 8 weeks. This finding
supports the importance of the timing of mechanical support and suggests that
myocardium stabilization is required for a longer period of time (at least 8 weeks) to be
most effective in attenuating LV dilation.

!
Figure 7.5 End diastolic and systolic volumes normalized to each treatment’s respective
baseline (NEDV and NESV) 8 weeks post-MI. Data presented as mean ± SEM. *p<0.05
vs. infarct control.

7.3.3.3 In Vivo Evaluation in MI Model: Infarct Area
As discussed, post-MI the ischemic infarcted region can spread and further the
progression of maladaptive LV remodeling. Treatment with both HeMA-HA polymers
significantly decreased the infarct area compared to infarct controls (Figure 7.6). These
improvements could be due to the biological role of soluble HA, which has shown to
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promote wound healing as well as angiogenesis [24, 49]. While biological factors are
thought to contribute to this finding, Ifkovits et al. demonstrated that mechanical factors
also play a role in decreasing infarct area [17]. It is, thus, likely that both these factors
influence remodeling; additional investigation (e.g., on the biological role of HA in MI)
would be beneficial to fully elucidate the mechanism behind this finding.

!
Figure 7.6 Infarct area of each group along side their respective initial infarct length
compared to infarct control. Data are presented as mean ± SEM. *p<0.05 vs. infarct
control.

7.3.3.4 In Vivo Evaluation in MI Model: Immunohistochemistry
Vessel Formation: !-SMA
MI results from the occlusion of an artery and leads to the depletion of oxygen
and nutrients to the heart. To remedy this and salvage viable myocardium, groups have
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focused on restoring blood flow to ischemic tissue by stimulating vessel formation.
While this has been successful via delivery of pro-angiogenic growth factors such as
FGF [50-53], VEGF [54, 55] and PDGF [54], and molecules such as pleiotrophin [56],
other groups have also shown that biomaterials without angiogenic stimulants also hold
the potential to promote neovascularization [57]. In this investigation, IHC staining for !SMA was performed to assess the ability of our HA hydrogels to induce vessel
formation.
At 8 weeks post-MI, treatment with all four HA hydrogel groups resulted in an
increase in vessel density in the apical, middle, and basilar infarct regions of the heart
compared to infarct controls (Figure 7.7), suggesting a role of HA hydrogel treatment in
stimulating neovascularization.

Significant improvements were observed when

evaluating all vessels (Figure 7.7C) and thick vessels greater than 10 µm (Figure 7.7E)
between HeMA-HA hydrogel groups and infarct controls in the middle region of the
infarct.

In addition, both high mechanics hydrogel groups demonstrated significant

increases in vessel density in the basilar infarct region compared to infarct controls. No
significant differences were observed when examining vessels with visible lumen (Figure
7.7D).

In general, vessel quantification showed that HA treatment resulted in a similar

degree of vessel formation in degradable and stable gels. !-SMA positive staining in
non-vessel forming cells was also observed, potentially indicative of myofibroblasts.
While all treatment groups demonstrated more positive staining than infarct controls,
groups with hydrogel remaining 8 weeks post-MI (high HeMA-HA, low MeHA, and high
MeHA), particularly MeHA hydrogels, exhibited more pronounced staining around
biomaterial implants (Figure 7.7A).
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7.7

Immunohistochemical

evaluation

of

!-SMA

for

vessel

formation.

Representative images of myocardium cross-section in middle region of infarct (scale
bar= 500 µm) (A), and zoomed in representative images of vessels (scale bar= 100 µm)
(B) in each group. Quantified vessel density of all vessels over 10 µm (C), all vessels
with lumen over 10 µm (D), and all thick vessels over 10 µm (E). Data are presented as
mean ± SEM. *p<0.05 vs. infarct control. G= Gel.
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Inflammation: MHC Class II
Inflammatory responses play a large role in tissue remodeling, which is important
in the context of biomaterials for cardiac repair [58, 59].

To address this, an IHC

evaluation with anti-MHC class II was performed to assess the degree of inflammation
resulting from degradable and stable HA hydrogel treatments. MHC class II proteins are
expressed on antigen presenting cells, which include macrophages, dendritic cells and B
lymphocytes. These cells present digested fragments of foreign extracellular antigens
on their surface and are able to interact with helper T cells to stimulate an adaptive
immune response [60, 61]. Examination of MHC class II expressing cells, thus, provides
a general idea of the inflammatory response to various hydrogels.
MHC class II staining was analyzed in both the surrounding tissue and at the
biomaterial interface, in groups where biomaterial was still present at 8 weeks. Staining
in the surrounding tissue was generally limited to areas with vessels and as a result, all
treatment groups displayed more positive MHC class II staining in this region (Figure
7.8). Although all groups exhibited more staining, treatment with both HeMA-HA groups,
particularly high HeMA-HA, appeared to result in more prevalent staining in the
surrounding tissue (Figure 7.8A). A similar observation was observed at the biomaterial
interface, where high HeMA-HA resulted in more positive MHC class II staining around
the hydrogel compared to stable degrading MeHA hydrogels (Figure 7.8B). According to
in vitro work, high HeMA-HA hydrogels degrade within approximately 10 weeks; thus, it
is expected that they are undergoing degradation and release degradation products,
which stimulate MHC class II expression, compared to MeHA gels, which have limited
degradation at 8 weeks.
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Figure 7.8 Immunohistochemical examination of inflammation with MHC class II.
Representative images in surrounding tissue in all groups (A) and representative images
at biomaterial interface in all groups with biomaterial present at 8 weeks (B). Scale bar=
50 µm. G=Gel.

7.3.3.5 In Vivo Evaluation in MI Model: Ejection Fraction
Functional improvements of ejection fraction (EF) were evaluated by comparing
baseline to 2 and 8 weeks post-MI. All groups displayed lower EF at 2 and 8 weeks
post-MI compared to baseline; however, all treatment groups resulted in smaller
decreases in EF than infarct controls (Figure 7.9A). In addition to comparing EF at 2
and 8 weeks, EF was also evaluated during stress testing. Stress testing, which can be
implemented via exercise or intravenous pharmacological simulation [62, 63], is often
used for diagnostic purposes to evaluate how the heart responds to external stress by
comparing blood flow before and after exertion. Examining the heart during exertion
allows clinicians to better pinpoint any abnormalities and determine the patient’s
prognosis that may not have been obvious before testing. Stress testing was used in
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this study as a more sensitive technique to detect functional improvements from
treatments. Cardiac function was evaluated upon stress testing with dobutamine (DoB)
(2.5 and 5.0 mg·kg-1min-1), which was conducted before sacrifice at 8 weeks. EF values
of all groups increased with stress compared to no stress at 8 weeks (Figure 7.9B), with
most improvement in the high MeHA hydrogel treatment group (Figure 7.9B). These EF
trends verify previous work [17], in that that highest mechanical support did result in the
largest functional improvement under stress. While some improved trends were also
observed in the high HeMA-HA treated group, they were lower than high MeHA. These
findings suggest that while HeMA-HA initial support at 2 weeks did provide subtle
improvements seen under stress, treatment with the high MeHA is more effective in
promoting functional improvements under stress. Further functional evaluation at longer
time points may provide more information on the observed trends as well as more insight
into long-term improvements.

!
Figure 7.9 Ejection fraction of treatment groups compared to their respective baseline
values (A) and under dobutamine stress testing compared to no stress at 8 weeks (B).
Data are presented as mean ± SEM. *p<0.05 vs. respective baseline.
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As previously discussed, hydrogels were injected 30 minutes post-MI and
evaluated at 2 and 8 weeks. Treatment was employed early to reduce the number of
surgical interventions to limit animal mortality. Other studies have injected materials as
early as immediately after MI [25] and as late as two months [18]; most have shown
improvement, with earlier injections before potential irreversible processes resulting in
more effective attenuation in LV remodeling [18]. Despite this, the appropriate time for
injection it is still not clear. The average time between MI symptom onset to hospital
prevention is 2-6 hours [64, 65], thus, a 30 minute injection time is not clinically feasible.
Another implication to consider is the progression of the remodeling process; in this
report, hydrogels were injected during the onset of necrosis and acute inflammation.
The specific stage during which the hydrogel is injected, as well as the temporal
properties from that injection point, may play a role in the overall outcomes.

7.4 Conclusions
The overall goal of this chapter was to gain a better understanding on the
significance of the duration of mechanical support in attenuating LV remodeling. This
was achieved by employing hydrolytically degradable hydrogels (HeMA-HA) with tunable
degradation and temporal mechanics.

Specifically, two formulations of HeMA-HA

hydrogels were selected to compare to two MeHA hydrogels, with similar initial
mechanics and gel dispersion, in their efficacy to limit negative remodeling.

When

injected into early infarct tissue in an ovine model, HeMA-HA hydrogels demonstrated a
similar vascular response to their MeHA gel counterpart; however, they also induced a
stronger inflammatory response that may be associated with their degradation. Along
similar lines, HeMA-HA hydrogels also revealed that HA may play a biological role in
limiting spreading of ischemic tissue. Most interestingly, however, studies with HeMA%,,!
!
!

HA revealed that geometrical improvements (e.g., limited chamber dilation) are
dependent on the duration of mechanical support with best outcomes resulting from high
MeHA treatment.

High MeHA treatment also showed the most improved trends in EF

under stress testing. Overall, these results demonstrate the utility of tunable hydrogel
systems in probing the influence of material properties on adverse remodeling outcomes
after infarction. Specifically, they implicate a significant role in the duration of mechanical
support (e.g., temporal mechanics) and the potential biological function of HA.

%,-!
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CHAPTER 8

Attenuation of Left Ventricular Remodeling via Natural Bulking with Hyaluronic
Acid Hydrogel and Poly(lactide-co-glycolide) Microsphere Composites

(Adapted from: E Tous, HM Weber, MH Lee, KJ Koomalsingh, T Shuto, N Kondo, JH Gorman,
III, D Lee, RC Gorman, JA Burdick, “Tunable Hydrogel-Microsphere Composites that Modulate
Local Inflammation and Collagen Bulking,” Acta Biomater, 2012, in press.)

8.1 Introduction
Chapter 7 employed a hydrolytically degradable hydrogel system to evaluate the
relevance of temporal mechanics in limiting left ventricular (LV) remodeling. This study
demonstrated that treatment with longer-lasting stiff hydrogels is most effective in limiting
LV remodeling (i.e., limiting myocardial wall thinning and ventricle dilation). The benefits
in this system, as well as most injectable acellular materials, are related to the stability
directly provided by the injected material; consequently, after material degradation,
support may be minimized and LV remodeling may continue its course. This chapter will
explore an alternative strategy to temporally target LV remodeling; instead of enhancing
myocardial stability with only the injected material, in this case, stability will also be
provided by collagen bulking induced as a result of the body’s natural foreign body
response (FBR) to a stimulatory composite material.

The goal is that collagen

production will provide enhanced natural long-lasting support during and after material
degradation.
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These types of composite systems are commonly used for various biomedical
and cosmetic applications and are referred to as dermal fillers [1-5]. Originally, most
fillers, as with most injectable biomaterial approaches for myocardial infarction (MI)
repair, were volumizing replacements; however, these approaches have evolved beyond
this towards the design of stimulatory composites that promote a transient tissue filling
effect by inducing a FBR. This promotes collagen production and a gradual increase in
tissue bulking, resulting in a natural filling effect over time [1-5]. Most stimulatory fillers
are comprised of two main components: 1) a particle that determines the type of FBR
and bulking that is endured and 2) a carrier material that delivers the particle and is
subsequently resorbed [1-5].

The mechanism behind this response relies on the

activation and “crosstalk” between macrophages and fibroblasts, which is mediated by
particle and carrier design.

8.1.1 The Foreign Body Response: Pro-inflammatory versus Pro-Healing Responses
When a foreign object is implanted into the body, proteins immediately adsorb to
its surface and activate an inflammatory cascade that determines the cellular response
and extent of tissue remodeling [6-10]. This entails an initial innate response comprised
of neutrophil infiltration and macrophage phagocytosis, followed by a more specialized
response that relies on macrophage plasticity [11, 12].

Macrophages have recently

been loosely characterized as having M1 (pro-inflammatory) and M2 (pro-healing)
phenotypes [13-17]. Classically activated (M1) macrophages are induced by IFN-%, LPS,
and TNF-!, and play a dominant role in the initial inflammation, and are characterized as
inducing a chronic inflammatory response [14, 15].

Alternatively activated (M2)

macrophages are stimulated by Il-4, Il-10, and Il-13 cytokines and are anti-inflammatory
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because of their ability to facilitate tissue remodeling [13-15]. It is thought that these
macrophages, in particular, play a large role in secreting TGF-"s to stimulate fibroblasts
to produce collagen for constructive tissue repair [8, 14, 18-22].

One approach to

mediate a specific biomaterial response is to direct this macrophage response by
controlling the initial protein adsorption to the biomaterial [23-25]; however, there is
overlap and switching between the M1 and M2 pathways, making it difficult to clearly
distinguish and selectively activate one or the other [13]. Regardless, advances have
been made in understanding tissue responses to materials and have led to the improved
design of dermal fillers for constructive remodeling.

8.1.2 Design Criterion for Induction of Pro-Healing (M2) Responses
Towards strategies to induce a constructive healing response via particle design,
specific focus has been placed on particle chemistry, geometry, and size. Hydrophilicity
[4, 13], crosslinking [26], and biodegradability [4] all influence the degree of
inflammation, and have impacted the material selection for particle stimuli.

Particle

geometry and size have also been extensively studied; generally, smooth surfaces and a
smaller area for a given volume induce a macrophage mediated constructive collagen
bulking.

Although irregularly shaped particles do induce inflammation, they elicit a

macrophage mediated chronic healing response leading to inconsistent collagen
distribution [4, 27, 28]. Microsphere size is also an important design parameter; particles
should be small enough for injectable delivery and to prevent fibrous capsule isolation
(typically < ~100 µm), but large enough to avoid macrophage phagocytosis (> ~10 µm),
which can amplify an undesired chronic inflammatory response [5-7, 27, 29].
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8.1.3 Dermal Fillers as Bulking Agents for Myocardial Infarction (MI)
Dermal fillers have been studied as bulking agents to prevent maladaptive LV
remodeling post-MI [30, 31]. Specifically, Radiesse is an FDA approved stimulatory
dermal filler comprised of a suspension of 30% calcium hydroxyapatite (CaHA)
microspheres (25-45 µm) in a 70% aqueous gel carrier of water, glycerin, and
carboxymethylcellulose [1-5]. As a stimulatory filler, Radiesse induces cells to infiltrate
the carrier portion and fibroblasts to produce collagen around the microspheres. Morita
et al. recently demonstrated that Radiesse injection into the infarcted myocardium
thickened the myocardium and resulted in geometric and functional improvements [30].
Here we strive to further understand and improve on work such as this by investigating
how material design parameters within a composite system influence tissue outcomes.
In this investigation, we developed a tunable and biodegradable composite
comprised of a hyaluronic acid (HA) hydrogel carrier containing poly(lactide-co-glycolide)
(PLGA) microspheres. Previous work by Kang et al. demonstrated successful bulking
via delivery of a suspension of PLGA microspheres in high-molecular-weight HA [32];
motivated by their work, this crosslinkable system will provide the addition of tunable
control over microsphere presentation through an actual HA hydrogel with controlled
degradation. Due to its natural benefits in vivo [33], HA is commonly used in dermal
fillers [1-5] and, furthermore, can be functionalized to form hydrogels with controlled
properties [34, 35]. As in the preceding chapters (Chapters 6 and 7) [35], HA was
modified with a hydroxyethyl methacrylate (HeMA) group to tailor hydrogel gelation,
degradation, and mechanics, as well as microsphere temporal presentation via
crosslinking. PLGA particles have been used extensively in tissue engineering [36-38]
and, as briefly discussed, even to promote bulking [32].
&.%!
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Here, smooth PLGA

microspheres (20-60 µm) were fabricated and encapsulated at varying concentrations
(0, 10, 75, 300 mg/mL) in two formulations of the HeMA-HA (low and high percent
modified) carrier to examine material design considerations on local and temporal
bulking.

Composites were evaluated in vivo in a subcutaneous murine model and,

similar to the work of Morita et al. [30], in an ovine MI model to determine how controlled
microsphere presentation influences collagen bulking and attenuates negative
remodeling, respectively.

8.2 Materials and Methodology
All animals studied in this work received care in compliance with protocols from the
University of Pennsylvania that were approved by the Institutional Animal Care and Use
Committee according to the guidelines for humane care. Materials and reagents were
purchased from Sigma Aldrich and used without further purification unless otherwise
specified.
8.2.1 Synthesis of Hydroxyethyl Methacrylated Hyaluronic Acid (HeMA-HA) Macromer
The two same formulations of HeMA-HA (low and high, Table 7.1) used in
Chapter 7 were synthesized as previously described [35].

For a more detailed

explanation on HeMA-HA synthesis and purification, refer to Sections 6.2.1 and 6.3.2,
and for more details on the specific HeMA-HA formulations employed in this chapter
refer to Sections 7.3.1 and 7.3.2. Briefly, HA/sodium salt (HA-Na, Lifecore, 66 kDa) was
converted to HA-tetrabutylammonium salt (HA-TBA) and coupled to HeMA-COOH by
reacting at 45 °C for 20 hours.

The product was dialyzed, purified by acetone

precipitation, and further dialyzed. Methacrylation (percent) was adjusted by varying the
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ratio of HeMA-COOH and di-tert-butyl dicarbonate (BOC2O) and assessed with 1H NMR
(Bruker, 360 MHz) (Section 6.3.3).

8.2.2 Fabrication of Poly(lactide-co-glycolide) (PLGA) Microspheres
8.2.2.1 Fabrication via Homogenization
PLGA (Lactel Absorbable, 50:50, 0.41dL/g) microspheres were initially fabricated
using conventional homogenization to form oil-in-water emulations (O/W). One mL of 10
wt% PLGA in dichloromethane (DCM) (Fisher) was slowly dripped into a solution of 100
mL of 0.5 wt% polyvinyl alcohol (PVA) with stirring. After complete addition of PLGA, the
mixture was homogenized for 15 min at 1000 rpm. The solvent was evaporated by
stirring 2 hours, microspheres were washed 3X in deionized water, lyophilized, and
stored at -20 °C until use.

Microspheres were imaged with an upright microscope

(Olympus BX51) and a scanning electron microscope (SEM, JEOL 7500F HRSEM,
Penn Regional Nanotechnology Facility).

Light micrographs were used to evaluate

microsphere size using ImageJ software.

8.2.2.2 Fabrication via Microfluidic Device
PLGA microspheres between 20-60 µm were fabricated by forming oil-in-water
(O/W) single emulsions in a glass microfluidic device [39]. The inner phase (O) was 4
wt% PLGA (Lactel Absorbable Polymers, 75:25, 0.71 dL/g) in dichloromethane (DCM)
and the outer phase (W) was a 2 wt% polyvinyl alcohol (PVA, 13,000-23,000 g/mol)
aqueous solution. The outer phase hydrodynamically focused the inner fluid stream into
the collection channel, leading to the formation of single emulsions. DCM was removed
by rotovap at 37 °C and 398 mbar, microspheres were washed 3X in deionized water
and then lyophilized for storage. Emulsion formation was monitored on a Nikon Diaphot
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300 and a Nikon TMD/TME automated stage microscope with Vision Research Phantom
V7.1. Microsphere size was quantified using light micrographs and ImageJ software.
For morphological evaluation with degradation, microspheres (75 mg/mL) were
incubated in phosphate buffered saline (PBS) at 37 °C, and samples were removed at
pre-defined time points and imaged under SEM. In addition to topography, SEM images
also provided information on the size of microspheres with time via analysis using
ImageJ software.

Degradation was also assessed by monitoring the pH of

microsphere/PBS solutions (75 mg/mL) incubated at 37 °C at the same time points as
morphology studies.

8.2.3 Formation and Characterization of Hydrogel Composites
Microspheres were mixed (0, 10, 75, 300 mg/mL) and crosslinked within the HA
hydrogels (either low or high HeMA-HA, 4wt%) via oxidation-reduction (redox) reactions
with ammonium persulfate (APS, low: 8 mM, high: 7 mM) and N,N,N,N’,N’tetramethylethylenediamine

(TEMED,

low:

4mM,

high:

7

mM)

to

form

hydrogel/microsphere composites. Hydrogels without microspheres will be referred to
as empty hydrogels throughout this chapter and were formed similar to those used in
Chapters 6 and 7 (described in Section 6.2.4). For in vitro characterization and in vivo
subcutaneous evaluation, hydrogel composites were formed between two glass slides
within a Teflon mold sealed with vacuum grease at 37 °C for 30 minutes.
Gelation was evaluated by monitoring the storage (G’) and loss (G’’) moduli after
mixing using an AR2000ex Rheometer (TA Instruments) at 37 °C under 1% strain and a
frequency of 1 Hz in a parallel plate geometry (20 mm diameter).

A parallel plate

geometry was employed due to microsphere addition, and thus, the need for a larger
geometry gap for testing.
!

Gelation onset time of composites was normalized to empty
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hydrogels (i.e., composite gel onset time was divided by empty hydrogel gel onset time)
to determine the influence of microsphere addition on polymerization. Degradation of
the hydrogel portion of the composites was examined at 37 °C in PBS with a uronic acid
assay [40]. Hydrogel and composite mechanical properties were assessed initially and
with degradation (PBS at 37 °C) via compressive testing using a Dynamic Mechanical
Analyzer (DMA) (Q800 TA Instruments) at a strain rate of 10%/ min and moduli were
calculated between 10-20% strain.

8.2.4 In Vivo Evaluation in Subcutaneous Model
Microsphere/PBS solutions were sterilized under germicidal ultraviolet (UV) light
for 1 hour. HeMA-HA macromer was similarly sterilized for 30 minutes on each side,
and all solutions were filter sterilized. Hydrogel composites (~50 µL, n=3 per group)
were formed ex vivo, sterilized under germicidal UV light for 30 minutes on each side,
and implanted subcutaneously into dorsal pockets of rats. The animals were euthanized
and explants were collected at 1, 2, and 4 weeks, fixed in 4% formalin overnight and
paraffin embedded using standard histological techniques. Samples were processed
into 7 µm sections and stained with hematoxylin and eosin (H&E) and Masson’s
Trichrome (MT) to evaluate the extent of tissue (primarily collagen) integration.

8.2.4.1 In Vivo Evaluation in Subcutaneous Model: Immunohistochemistry
For immunohistochemical (IHC) analysis, all PBS was filtered and all washes
were 2 minutes. IHC staining was performed on low HeMA-HA composites at the 4
week time point to evaluate the phenotypic macrophage response by targeting surface
markers: CD68 (general), CCR7 (pro-inflammatory, M1), and CD163 (pro-healing, M2).
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Primary antibodies used were mouse anti-rat CD68 (Serotec, MCA341R) at 1:100, rabbit
anti-CCR7 (Cell Applications Inc., CA0710) at 1:200, and mouse anti-rat CD163
(Serotec, MCA342R) at 1:50; all were incubated with 1% normal horse serum (Vector, S2000) (CD68 and CD163) or 1% goat serum (Vector, S-1000) (CCR7).

Secondary

antibodies used were biotinylated horse anti-mouse IgG (CD68 and CD163, Vector, BA2000) at 1:100 and goat anti-rabbit IgG (CCR7, BA-1000) at 1:200, all incubated with
1.5% normal horse serum (CD68 and CD163) or 1.5% goat serum (CCR7).
Sections were deparaffinized with citrisolv and hydrated with a graded series of
ethanol solutions ranging from 100% to 50%. Slides were immersed in boiling antigen
retrieval buffer (10 mM citric acid monohydrate, pH 6) for 20 minutes and allowed to cool
in the buffer. They were washed 2X in tris buffer (tris buffered saline/ tween 20, pH 7.4)
and 3X in PBS. Samples were blocked in 1.5% normal horse serum (CD68 and CD163)
or 1.5% normal goat serum (CCR7) for 45 minutes at room temperature (RT). After
removing blocking solution, samples were directly incubated with primary antibody
(CD68, CCR7, or CD163) for 15 minutes at RT and overnight at 4 ˚C in a humidified
chamber. Following primary incubation, samples were washed 3X in PBS, quenched in
3% H2O2 in methanol for 30 minutes, and washed again 3X in PBS. Secondary antibody
incubation was performed for 30 minutes at either RT (CD68) or at 37 ˚C (CCR7 and
CD163). Samples were washed 3X with PBS (CD68 and CD163) or 7X (CCR7) and
incubated with Vectastain ABC reagent (Vector) for 1 hr (CD68 and CD163) or 30 min
(CCR7) in a humidified chamber at 37 ˚C. Samples were washed 3X with PBS and
incubated with diaminobenzadine substrate for 1 minute (Dab, Vector, SK-4100) at RT.
The reaction was stopped by washing 3X with deionized water.

Slides were

counterstained with hematoxylin (Gill No. 2) for 2 minutes, dehydrated and cover
slipped.
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The phenotypic macrophage response due to microsphere concentration was
analyzed in low HeMA-HA composites at week 4 by counting positively stained cells for
each marker (CD68, CCR7, CD163) in each explant of each group (0, 10, 75, and 300
mg/mL, n= 3). Six fields of view (FOV) at 400X magnification were analyzed; three FOV
were counted at the biomaterial/tissue interface and in the surrounding tissue, with the
latter defined as tissue >25 µm from the biomaterial. In samples where the composite
was no longer present, six FOV of the tissue representing the area where the material
was implanted were counted. Tissue area in each FOV was calculated by excluding
microsphere and hydrogel area using ImageJ software, and cell number in each FOV
was normalized by tissue area (mm2).

8.2.5 In Vivo Evaluation in MI Model
Microspheres, macromer, and all solutions were sterilized as described in the
subcutaneous studies. The same established in vivo ovine MI model used in Chapter 7
was used to evaluate the efficacy of the selected composite in attenuating LV
remodeling [31].

For a more detailed description refer to section 7.2.4 in this

dissertation. Thirty minutes post-MI, six adult male Dorset sheep (30-50 kg) underwent
composite treatment; the composite (macromer/ microsphere) pre-polymer solution was
mixed for 3 minutes and injected into the infarct (20 0.3 mL injections). Hemodynamic
data and real time three-dimensional echocardiographs (3DE) were collected, animals
were sacrificed at 8 weeks, and histological evaluation was performed (H&E and MT
staining). Wall thicknesses in the apical infarct, basilar infarct, and borderzone (BZ)
regions were normalized to remote myocardium. Ejection fraction (EF) as a functional
outcome was assessed at 2 and 8 weeks by comparing to baseline values, and also by
comparing before and after dobutamine (DoB) (2.5 and 5.0 mg kg
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-1

min-1) stress testing.

Composite treated sheep were compared to infarct and low HeMA-HA controls (e.g.,
empty hydrogel) from the study described in Chapter 7 [35].
Vessel density and inflammation were both evaluated by staining for anti-!smooth muscle actin (!#SMA) and major histocompatibility complex (MHC) class II,
respectively. For details on the IHC staining that was performed refer to Section 7.2.4.1.

8.2.6 Statistical Analysis
Data is presented as either mean ± SD (standard deviation) or mean ± SEM (standard
error of the mean) as indicated in the figure captions. All changes were assessed using
a one-way ANOVA with Tukey’s post hoc evaluation to account for differences between
groups. p#0.05 was considered statistically significant for all comparisons.

8.3 Results and Discussion
8.3.1 Fabrication and Characterization of PLGA Microspheres
PLGA microspheres were fabricated with a glass capillary microfluidic device to
guarantee a smooth surface and high uniformity in size (Figure 8.1C, D) [39], as
opposed to standard homogenization techniques that resulted in undesired variations in
size and topography (Figure 8.1A, B). To form microspheres, the dispersed phase (4
wt% PLGA) and continuous phase (2% PVA) were delivered from opposite sides of the
square outer capillary at adjusted flow rates until solutions formed a cone at the orifice of
the collection tube and pinched off to form microspheres. The majority of microspheres
obtained after solvent removal, were smooth and between 20-60 µm, meeting the criteria
for bulking agents (Figure 8.1D) [5, 27-29].
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Figure 8.1 PLGA microsphere fabrication using standard homogenization techniques,
representative SEM image (A) and microsphere size distribution (B). PLGA microsphere
fabrication in glass capillary microfluidic device (C), post-purification microsphere size
distribution, and SEM image (inset) (D). In panel A, scale bar= 150 µm. Scale bar= 250
µm in C and scale bar= 40 µm in D.

In addition to being FDA approved and used for numerous tissue engineering
applications [36-38], PLGA was selected because of its biodegradable nature. While it is
desirable for microspheres to eventually degrade, it is also important that they remain
stable and maintain a smooth geometry to promote constructive collagen remodeling.
PLGA microsphere surfaces and diameters remained unchanged after 8 weeks (Figure
8.2A, B) and minimal changes in pH were observed during degradation (~7.4 to 7.2)
(Figure 8.2C) suggesting insignificant degradation throughout the 8 weeks. In addition
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to this work, others have shown that while the molecular weight (MW) of PLGA
decreases in 8 weeks, the mass of the microspheres changes very little [41]. Thus,
there is likely little release of acidic byproducts during the span of 8 weeks.

!
Figure 8.2 Microsphere SEM images after incubation in PBS up to 8 weeks (A).
Microsphere diameter quantification (B) and variation in pH (C) to investigate
degradation with time (8 weeks). Data are presented as mean ± SD. *p<0.05 vs. PBS.
Scale bar= 40 µm.

8.3.2 Formation and Characterization of Composites
HeMA-HA was synthesized as described in Sections 6.3.1-6.3.3 to yield
macromers with a low (~10%) or high degree (~30%) of modification.

HeMA-HA

undergoes a radical polymerization via the redox initiators APS and TEMED at the
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methacrylate groups to form hydrogels that undergo either enzymatic degradation
through the HA backbone or hydrolytic degradation through the esters on the HeMA
groups [35]. Variation in the extent of modification leads to changes in the crosslinking
density, which alters the gelation, mechanics, and degradation behavior of these
hydrogels. In this work, the rate of degradation also alters how fast the microspheres
are released from the carrier hydrogel.
Composites were formed by crosslinking HeMA-HA formulations (low or high) in
the presence of 0, 10, 75, or 300 mg/mL of PLGA microspheres (Figure 8.3).

As

discussed in Methods, gel onset time was defined as the intersection of G’ and G’’.
Rheometry showed that microspheres did not affect gel onset in most composites with
only the gelation of low HeMA-HA at 300 mg/mL significantly increased (~40% slower
than empty hydrogels, Figure 8.4).

!
Figure 8.3 Cross-sectional views of low (A) and high (B) HeMA-HA composites at the
four microspheres concentrations. Scale bar= 500 µm.
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Figure 8.4 Gel onset for composites normalized to low or high HeMA-HA, 0 mg/mL
formulations. Data are presented as mean ± SD. *p<0.05 vs. low HeMA-HA 0 mg/mL.

Composite hydrogel mass loss in both low and high HeMA-HA hydrogels were
influenced slightly by microsphere concentration; however, degradation trends remained
generally comparable (Figure 8.5A, B). In low HeMA-HA hydrogels, concentrations of
10 and 75 mg/mL significantly decreased the amount of mass loss compared to empty
hydrogels; yet, their degradation rate was similar until the final week when they
accelerated to compensate for initial lower mass losses (Figure 8.5A).

While these

results indicate that a concentration of 300 mg/mL did not affect mass loss, this is likely
due to incomplete gelation as suggested by slower gel onset. High HeMA-HA hydrogel
mass loss was predominantly influenced at 10 and 300 mg/mL, being significantly lower
at all time points compared to empty hydrogels except for at week 8 where only 10
mg/mL was affected (Figure 8.5B). Significant differences in degradation rates were
only observed at 7 days (300 mg/mL) and at 8 and 10 weeks (10 mg/mL), as in low
hydrogels.
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The presence of microspheres only increased the compressive modulus of
hydrogels at the initial time points (Figure 8.5C, D). Specifically, significant increases in
moduli were observed at 75 and 300 mg/mL in low HeMA-HA composites at day 0
compared to empty hydrogels (Figure 8.5C) and at days 0 and 1 for 300 mg/mL in high
HeMA-HA composites (Figure 8.5D). Thus, in vitro characterization demonstrated that
microspheres had minimal influences on composite material properties (particularly
degradation and mechanics) and that differences are likely due to initial changes in the
gelation around the microspheres. Nonetheless, composite material properties should
be characterized when selecting a formulation for implantation.
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Figure 8.5 In vitro characterization of low HeMA-HA (A) and high HeMA-HA (B) hydrogel
composite degradation and low HeMA-HA (C) and high HeMA-HA (D) hydrogel
composite mechanics with degradation. Data are presented as mean ± SD. *p<0.05 for
10 mg/mL vs. 0 mg/mL, $p<0.05 for 75 mg/mL vs. 0 mg/mL, +p<0.05 for 300 mg/mL vs.
0 mg/mL.
!
8.3.3 In Vivo Evaluation in Subcutaneous Model
8.3.3.1 Macroscopic and Histological Evaluation
Macroscopic evaluation of subcutaneous explants demonstrated a temporal
correlation in bulking with hydrogel formulation (low HeMA-HA vs. high HeMA-HA
composites). Differences in explants were observed 1 week post-treatment, with tissue
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integration beginning in low HeMA-HA composites and delayed in high HeMA-HA
composites until week 2.

Furthermore, at 4 weeks, low HeMA-HA hydrogels were

explanted as a mass of tissue, whereas the more slowly degrading high HeMA-HA
hydrogels remained primarily as hydrogel disks, surrounded by tissue (Figure 8.6). This
is likely due to the slower hydrogel degradation behavior in the high formulations, limiting
initial interactions of the material and microspheres with local tissue; in contrast, the low
formulation degrades within a few weeks, allowing cells and tissue to interact more
quickly with the microspheres. While gross evaluation revealed distinct differences in
bulking with polymer modification (low vs. high), there did not appear to be a
macroscopic response based on the microsphere introduction or concentration.

!
Figure 8.6 Gross evaluation of bulking in low and high HeMA-HA hydrogel composites
at 1 day (D1), 1 week (W1), 2 weeks (W2) and 4 weeks (W4) after subcutaneous
implantation and containing 0, 10, 75, or 300 mg/mL of microspheres. Scale bar= 5 mm.

MT staining was performed to validate macromer influences and address
microsphere effects on bulking by assessing collagen infiltration within and surrounding
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each composite (Figure 8.7).

Collagen integrated at the edge of low HeMA-HA

composites by 1 week and into composites by 2 weeks; in contrast, minimal collagen
was observed within the slowly degrading high HeMA-HA composites and was limited to
the edge of the hydrogel. In contrast to low HeMA-HA, which showed tissue integration
within the composite, slower degradation of the high HeMA-HA composites resulted in
the formation of a fibrous capsule at 4 weeks, limiting microsphere presentation. Due to
negligible microsphere exposure in high HeMA-HA, the effects of microsphere
incorporation on collagen bulking could only be assessed in low HeMA-HA composites.
This highlights the importance of the design of the carrier material when designing
bulking formulations. At week 4 in the low formulations, it was evident that microsphere
concentration influenced the tissue response with increasing collagen integration from 0
to 75 mg/mL in low HeMA-HA composites (Figure 8.7) with primarily adipose tissue
(determined by pathological assessment) in the 0 and 10 mg/mL groups.

The high

concentration of 300 mg/mL microsphere composites presented primarily aggregates of
microspheres throughout the gel, limiting tissue and cellular interactions in some areas.
Interestingly, in contrast to in vitro degradation results, while empty hydrogels
and 10 mg/mL composites appeared completely degraded by week 4, 75 and 300
mg/mL composites still had remnants of hydrogel composite present between infiltrated
tissue. This observation may be due to a combination of the influence of the local tissue
response on degradation and the suspected microsphere hydrophobic interactions.
Staining showed that as tissue infiltrated the edge of the hydrogel, the hydrogel broke
into smaller pieces. Composites with more microspheres may further decrease the rate
of tissue infiltration due to additional hydrophobic interactions.
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Figure 8.7 Masson’s Trichrome staining of explants 1 week (W1), 2 weeks (W2) and 4
weeks (W4) after subcutaneous implantation and containing 0, 10, 75, or 300 mg/mL of
microspheres. Scale bar= 500 µm. Red circles and red positive signs represent gel and
adipose tissue respectively.

8.3.3.2 Immunohistochemical Macrophage Evaluation
IHC staining for general, M1 (pro-inflammatory), and M2 (pro-healing)
macrophages was performed to determine the influence of hydrogel/microsphere
composites on the type of inflammatory response (Figure 8.8). As an overall trend,
staining for all markers indicated that macrophage presence was highest in the 75 and
300 mg/mL formulations, suggesting that macrophage infiltration is dependent on
microsphere concentration. 75 mg/mL composites elicited the largest response, with a
statistically significant increase in general macrophage response compared to empty
hydrogels (641 ± 113 vs. 93 ± 28 macrophages/ mm2) (Figure 8.9A). Lower numbers in
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300 mg/mL composites could be due to observed microsphere aggregation limiting their
cellular interactions. In contrast, in 75 mg/mL composites, cells and tissue were able to
penetrate the hydrogel and readily access microspheres (Figure 8.8).

!
Figure 8.8 Immunohistochemical evaluation of macrophage phenotype in composites at
week 4. Top row is Masson’s Trichrome stain, scale bar= 200 µm. Other rows are
general (CD68) and M1 (CCR7) and M2 (CD163) macrophage stains, scale bar= 50 µm.
Red circles represent gel.

Red stars and red arrows indicate representative

microspheres and macrophages respectively.

Treatment with composites of 75 mg/mL microspheres resulted in greater M1 (0
mg/mL: 41 ± 10, 10 mg/mL: 61 ± 6, 75 mg/mL: 171 ± 55 macrophages/mm2) and M2 (0
mg/mL: 25 ± 14, 10 mg/mL: 24 ± 14, 75 mg/mL: 80 ± 16 macrophages/mm2) responses
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compared to the less concentrated composites (Figure 8.9B, C). The presence of fewer
macrophages in empty hydrogel and 10 mg/mL composites is likely due to complete
hydrogel degradation by week 4, suggesting that they do not stimulate a sufficient
inflammatory response to bulk.

Low HeMA-HA 300 mg/mL composites elicited the

largest M2 response (300 mg/mL: 130 ± 25 macrophages/mm2) with statistically
significant higher numbers than empty hydrogels and resulted in a slightly greater M2
responses compared to their respective M1 (300 mg/mL: 99 ± 20 macrophages/mm2)
response (Figure 8.9B, C). This finding is not completely understood; however, it could
be attributed to the plasticity of M2 macrophages [13], the time point investigated, and
the nature of collagen distribution at the implant. As a general observation, more M2
macrophages were observed in the surrounding tissue, while M1 macrophages were
more prominent in areas with tissue and biomaterial contact. It is speculated that this
may be because M1 macrophages initiate a response with the composite as it is
degrading; HA fragments have also been shown to induce a strong pro-inflammatory
response [42].

Following material degradation and acute inflammatory activity, M2

macrophages may also play a role in remodeling [20]. As discussed, in 300 mg/mL
composites, there was a tendency to wall off composites and limit tissue penetration.
Consequently, this restricted analysis in most samples to tissue interaction at the edge
as opposed to within composites of infiltrated tissue regions. Prolonging this study may
provide more information on long-term macrophage polarization with time after complete
hydrogel degradation. However, this analysis supports a phenotypic dependence on
composite design and the presence of microspheres. Due to the above results, we
chose the low HeMA-HA containing 75 mg/mL composite formulation for application as a
bulking agent in cardiac repair.
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Figure 8.9 Quantification of general (A), M1 (B) and M2 (C) macrophage phenotype in
low HeMA-HA composites at week 4 from immunohistochemistry. Data are presented
as mean ± SEM. *p<0.05 vs. 0 mg/mL.

8.3.4 In Vivo Evaluation in MI Model
Subcutaneous work validated the ability of composites to temporally and locally
control remodeling by varying hydrogel crosslinking and microsphere concentration,
respectively.

Exploiting these tunable properties may be beneficial in treatment of

injuries, such as MI, where bulking may improve outcomes, but where more control is
necessary to effectively attenuate maladaptive geometric changes that occur [43]. In
particular, the timing of treatment is critical due to the time dependent remodeling
observed in MI where necrosis dominates for the first week and the overall process can
extend for 8 weeks and beyond [44]. Previous work described in Chapter 7 with the
empty low HeMA-HA hydrogel formulation revealed that compared to the empty high
HeMA-HA group it did not provide sufficient stability to attenuate long-term negative
remodeling, which was attributed to its accelerated degradation and subsequent
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decrease in mechanics with time [35]. Other agents that have been investigated range
from synthetic and natural materials; however, most of their bulking capacity relies on
their ability to physically support the damaged myocardium, and few directly stimulate
and control natural thickening [43].

As discussed, Morita et al. applied the FDA

approved dermal filler, Radiesse, to induce bulking in the myocardium post-MI and
demonstrated its efficacy in limiting geometric changes [30].

This study and the

temporal nature of MI remodeling provide motivation to improve on our previous
approach by implementing low HeMA-HA composites, where hydrogels carry
microsphere stimuli to control delivery (avoiding prime necrosis 1 week post-MI) and
potentially induce natural bulking for enhanced stability during (as the tissue penetrates
the hydrogel) and after hydrogel degradation.
The low HeMA-HA, 75 mg/mL composite formulation was selected for this work
because of its similar material properties (gelation, degradation and compressive moduli
trends) to empty hydrogels and its ability to induce collagen bulking and a macrophage
response in subcutaneous studies. At this formulation, material properties can for the
most part be decoupled from microsphere effects enabling direct evaluation of
microsphere presentation (e.g., composite vs. empty low HeMA-HA treatments) in
attenuating LV remodeling.

8.3.4.1 In Vivo Evaluation in MI Model: Thickness
LV remodeling leads to a series of adverse changes (thinning of the myocardial
wall, dilation and infarct expansion) that can negatively affect function and lead to heart
failure [45-48]. When analyzing normalized thickness, both composite and hydrogel
alone treatments significantly thickened the apical infarct region compared to infarct
controls (composite: 0.40, empty: 0.29, infarct control: 0.18, normal: 0.52) (Figure
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8.10A); however, the composite also resulted in a statistically significant increase in
thickness compared to empty hydrogels. Increased thicknesses were also observed
within the basilar infarct region for both hydrogel groups (composite: 0.51, empty: 0.51,
infarct control: 0.38, normal: 0.72).

All groups were similar in the BZ region.

MT

staining in the apical, middle, and basilar infarct regions demonstrated cellular infiltration
around microspheres surrounded by a collagen network (Figure 8.10B).

!
Figure 8.10 Myocardial wall thickness in apical infarct, basilar infarct, and borderzone
(BZ) regions normalized to remote healthy myocardium (A) and Masson’s Trichrome
staining in the basilar, middle, and apical infarct regions (B). Data presented as mean ±
SEM.

All groups are significantly different from normal control in apical and basilar

infarct regions and from infarct control in the apical infarct region. *p<0.05 vs. empty low
HeMA-HA. Scale bar= 100 µm.
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8.3.4.2 In Vivo Evaluation in MI Model: End Diastolic and Systolic Volume
LV volumes were measured to assess the extent of their dilation with and without
treatment; composite hydrogels showed trends in decreasing normalized end diastolic
volume (NEDV) and normalized end systolic volume (NESV) at 2 and 8 weeks
compared to infarct controls and empty hydrogels, particularly at 2 weeks (composite
2W NEDV: 1.63, composite 2W NESV: 1.94, composite 8W NEDV: 1.98, composite 8W
NESV: 2.50 vs. empty 2W NEDV: 1.85, empty 2W NESV: 2.22, empty 8W NEDV: 2.15,
empty 8W NESV: 2.61 vs. infarct 2W NEDV: 1.75, infarct 2W NESV: 2.21, infarct 8W
NEDV: 2.31, infarct 8W NESV: 3.02) (Figure 8.11).

This suggests that, compared to

empty hydrogels, composites were more effective in attenuating geometric changes
associated with MI, specifically by enhanced bulking and stabilizing the myocardial wall.

!
Figure 8.11 Normalized end diastolic volume (NEDV) and normalized end systolic
volume (NESV) at 2 and 8 weeks (2W NEDV and NESV and 8W NEDV and NESV).
Data presented as mean ± SEM.
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8.3.4.3 In Vivo Evaluation in MI Model: Infarct Area
Post-MI, the area of non-viable myocardium increases as remodeling
progresses; consequently, several groups have used infarct area as a metric to evaluate
treatment efficacy [42]. In our case, infarct area was statistically significantly decreased
by both composite and empty low HeMA-HA treatment compared to infarct controls
(composite: 22.9%, empty: 22.5%, infarct control: 29.0%) (Figure 8.12); yet there was no
statistically significant difference between hydrogel groups. As reported in Chapter 7,
both degradable systems prevented the spreading of the infarct region, suggesting a
beneficial biological influence from HA; however, further investigation is needed to
confirm this hypothesis.

!
Figure 8.12 Initial infarct length and infarct area at week 8. Data presented as mean ±
SEM. *p<0.05 vs. infarct control.
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8.3.4.4 In Vivo Evaluation in MI Model: Immunohistochemistry
Vessel Formation: !-SMA
Another important parameter in infarct remodeling and repair is the supply of
nutrients to myocardium through vessel growth in ischemic tissue [49-55]. In this study,
infarct control (Figure 8.13A), empty hydrogel (Figure 8.13B) and composite (Figure
8.13C) treated infarct tissues were stained for !-SMA to identify vessels. Quantification
revealed increases in all vessels over 10 µm (Figure 8.13D), with lumen (Figure 8.13E),
and thick vessels (Figure 8.13F) in both composite and empty cohorts.

Overall,

treatment with composites tended to result in the highest vessel number, with significant
increases in thicker vessels compared to infarct controls; however, there were no
significant differences compared to empty hydrogels. Interestingly, composite stimulated
vessel development was prominent at the apex region, agreeing with thickness data that
indicated that composite therapy significantly bulked this region.

Overall, vessel

assessment suggests that both biological and mechanical factors play a role in
attenuating LV remodeling. In particular, increased vessel density could be due to a
combination of the mechanical support provided by composites and the biological effects
of HA, which may affect vessel development and be the contributing stimulator in both
treatments [32, 33, 56].
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Figure 8.13 Staining for !-SMA to identify vessels in infarct controls (A) and empty (B)
and composite hydrogels (C). Quantification of all vessels greater than 10 µm (D), all
vessels greater than 10 µm with lumen (E), and all thick vessels greater than 10 µm (F).
Scale bar= 100 µm. Data are presented as mean ± SEM. *p<0.05 vs. infarct control.
Red arrows= representative thick-walled vessels. Black arrows= representative thinwalled vessels.

Inflammation: MHC Class II
MHC class II was performed to assess inflammation at 8 weeks post-MI,
particularly in empty and composite hydrogel treatment to assess inflammation after
hydrogel degradation. MHC class II proteins are expressed on antigen presenting cells
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such as macrophages, dendritic cells, and B lymphocytes, which later present foreign
digested fragments to stimulate an adaptive immune response [57, 58].

Thus,

investigating MHC class II expressing cells provides a general view of the degree of
inflammation induced by each group. As shown in staining in Chapter 7, both treatments
resulted in more positive staining for MHC class II compared to infarct controls. While a
few samples displayed positive staining around microspheres, empty and composite
hydrogels generally induced a similar inflammatory response (Figure 8.14).

!
Figure 8.14 Representative images for MHC class II staining to evaluate inflammation at
8 weeks in empty hydrogel and composite treated cohorts. Scale bar= 50 µm. Black
arrows= representative positive staining.

8.3.4.5 In Vivo Evaluation in MI Model: Ejection Fraction
Ejection fraction (EF) was evaluated to assess the performance of heart
contraction. EF at 2 and 8 weeks decreased less relative to infarct controls in both
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treatments; however, no noteworthy improvements were observed between treatments
(Figure 8.15A). EF after stress testing did not improve with either treatment relative to
infarct controls (Figure 8.15B). This may be because the functional benefits come over
time or after myocardial wall stabilization from composite treatment. To further explore
this it would be valuable to perform a functional evaluation at a time point after 8 weeks.

!
Figure 8.15 Functional assessment for MI work. Ejection fraction at 2 weeks (2W) and 8
weeks (8W) compared to baseline (A) and at 8W following dobutamine stress (2.5 and
5.0 mg kg-1 min-1) echocardiographic testing compared to no stress (B). Data are
presented as mean ± SEM. *p<0.05 vs. baseline, +p<0.05 vs. 8W no stress.

MI work agrees with Radiesse studies by Morita et al., confirming similar
geometric trends [30]. While composite design enhanced low HeMA-HA treatment, it is
important to place this work in perspective with the rest of the field, and note that other
stable agents (e.g., high MeHA, as discussed in Chapter 7) with proven high mechanics
have provided higher degrees of prolonged support in MI [34]. As previously discussed,
the benefits from treatment with hydrogel/microsphere composites could potentially be
improved upon by tailoring composite design (e.g., microsphere concentration and HA
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crosslinking) and material properties to alter the degree of bulking and presentation of
microsphere in the progression of remodeling. These modifications could lead to further
material myocardial wall stability and possible functional improvements with time.

8.4 Conclusions
A composite hydrogel microsphere system was developed with tunable material
properties (gelation, degradation, and mechanics) to adjust the extent and timing of
collagen bulking to treat negative LV remodeling.

Subcutaneous in vivo work

demonstrated a temporal dependence of tissue response on macromer functionalization
and a local dependence on microsphere concentration. Composites improved on the
design of empty low HeMA-HA hydrogel (evaluated in Chapter 7) for MI repair by
stimulating myocardial bulking and providing enhanced stability to attenuate maladaptive
geometric changes.

This investigation with tunable HeMA-HA/PLGA microsphere

composites demonstrated the ability to present stimulatory bulking agents in a controlled
manner after MI and showed promise for the application of stimulatory fillers as an
alternative natural treatment for MI repair.
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CHAPTER 9

Limitations, Future Directions, and Conclusions

9.1 Summary
Myocardial infarction (MI) initiates left ventricular (LV) remodeling which is
associated with a series of subsequent maladaptive alterations that can compromise
heart function and result in heart failure (HF). Chapter 1 described the pathological
alterations that occur due to LV remodeling both on the cellular and tissue scale.
Current clinical treatments for MI are often either invasive or insufficient to limit its
repercussions, and while numerous cellular-based tissue engineering (TE) strategies
have demonstrated a degree of efficacy in animal models, they are limited by concerns
including optimal delivery for cell survival and engraftment, cell source, and “cell dosage”
to impart function.
Consequently, the use of acellular materials has become a more attractive
approach to treat MI; the goal is to impart stability to counteract geometric changes
rather than direct regeneration of the infarct. Injectable biomaterials offer a minimally
invasive alternative to physical restraints, since the material may be delivered directly to
the myocardial tissue to provide mechanical support and limit LV remodeling. Chapter 3
summarized a range of natural and synthetic hydrogels that have been investigated for
this purpose, and concluded that while treatment with many of these materials has
attenuated LV remodeling, the mechanism behind their success is not clear.

This

dissertation aimed to elaborate on the work of Ifkovits et al., which addressed these
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concerns by employing a tunable methacrylated hyaluronic acid (MeHA) hydrogel to limit
LV remodeling [1].
The overall goal of Chapters 4 and 5 was to assess stress reduction in the
dilated LV due to treatment with various MeHA hydrogel formulations formed via
oxidation-reduction (redox) initiation. Hydrogels had low or high macromer modification
(percent) and low or high initiator concentration (ammonium persulfate (APS, A) and
N,N,N,N’,N’-tetramethylethylenediamine (TEMED, T)) (e.g., low MeHA, low A/T, high
MeHA, low A/T, low MeHA, high A/T, high MeHA, high A/T).

An established finite

element (FE) model developed by our collaborator, Dr. Jonathan Wenk, that allowed
variation of the hydrogel/myocardial tissue composite mechanical properties, volume,
and injection distribution was implemented. To acquire data for FE model analysis in
vitro assessment of both hydrogel volume and hydrogel/tissue mechanical properties
were performed.

In Chapter 4, the volume of each MeHA hydrogel formulation in

myocardial explant tissue was quantified via non-contrast magnetic resonance imaging
(MRI); data indicated that volume distribution was especially dependent on initiator
concentration, and to a lesser degree, on macromer modification (at lower percent
modifications). Higher initiator concentration and higher macromer modification (at low
initiator concentration) resulted in larger volumes.
In Chapter 5, biaxial testing was performed on each MeHA/tissue formulation;
composites generally exhibited stiffer moduli in the longitudinal direction compared to
control tissue (myocardium alone) and mechanics generally increased directly with
macromer modification and initiator concentration. Composite anisotropy decreased
compared to normal myocardium controls.

These mechanical data (i.e., tissue

stress/strain curves) were used to generate diastolic myocardial material parameters for
each composite formulation. Mechanical and volume data were incorporated into a FE
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model to simulate treatment with each formulation in a dilated LV.

Comparisons

between the low A/T formulations previously studied by Ifkovits et al. revealed that global
and regional stresses in the fiber direction generally decreased most with the stiffer
hydrogel (i.e., high MeHA), which correlated with previously reported in vivo geometric
outcomes [1]. Relative comparisons between all MeHA formulations revealed that stress
in the fiber direction was generally dependent on the mechanics and volume of the
injections with the greatest stress reductions observed as both were increased.
Two approaches were explored to evaluate the temporal significance of
mechanical support in attenuating LV remodeling.

Chapter 6 introduced the

hydrolytically degradable HA hydrogel system that would be employed for both
strategies.

Macromers with a range of modification extents were synthesized by

coupling hydroxyethyl methacrylate (HeMA) to HA. The material properties of HeMA-HA
hydrogels formed by redox initiation were altered by varying the modification percent; in
particular, higher modification resulted in faster gelation, higher mechanics, and slower
degradation. In Chapter 7, to assess the importance of degradation, two HeMA-HA
modification percentages were selected, and by varying APS and TEMED initiator
concentrations, low and high mechanics HeMA-HA hydrogels were designed with similar
gelation and mechanics, but differing degradation kinetics as those of low and high
mechanics MeHA hydrogels investigated by Ifkovits et al. [1]. In an in vivo ovine MI
model, HeMA-HA hydrogel treatment (particularly the high formulation) increased the
thickness of the myocardium compared to infarct control, though to a lesser extent than
either MeHA treatment. Volume data provided the most interesting information; at 2
weeks, high HeMA-HA and MeHA treatment were most effective in preventing
normalized end diastolic (NEDV) and normalized end systolic volume (NESV) increases;
however, by 8 weeks, only high MeHA limited volume dilation. This was attributed to the
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decreased mechanics (from in vitro data) of high HeMA-HA hydrogels at 8 weeks and
suggests that the duration of mechanical support is significant in treating LV remodeling.
Despite the lack of mechanical support, treatment with both HeMA-HA formulations was
effective in limiting expansion of the infarct area compared to controls. This finding may
have to do with the biological role of soluble HA released from degraded HeMA-HA.
Chapter 8 introduced an alternative system to assess temporal mechanical
support on LV remodeling; here, the weakened infarct wall was stabilized by natural
collagen produced as a result of a controlled foreign body response (FBR) to a
stimulatory composite material.

The same low and high HeMA-HA formulations

employed in Chapter 7 were implemented as the carriers for poly(lactide-co-glycolide)
(PLGA) microsphere stimuli.

Macromers were mixed with microspheres (0, 10, 75, or

300 mg/mL) and hydrogel composites were formed similarly to Chapter 7 via redox
initiation. Composites were characterized for mechanics, gelation, and degradation to
assess microsphere influences on hydrogel material properties.

An in vivo

subcutaneous assessment was performed to determine the type of tissue response each
composite elicited; a histological evaluation via Masson’s Trichrome (MT) staining
demonstrated that the timing and extent of collagen bulking induced by composites was
dependent on macromer formulation (i.e., degree of crosslinking), which influenced the
presentation of microspheres to the in vivo environment, and microsphere concentration,
respectively. An immunohistochemical (IHC) assessment was performed only on low
HeMA-HA composite explants due to minimal tissue infiltration into the slowly degrading
high HeMA-HA composites.

A macrophage dependent response was observed in

composites with higher concentrations of microspheres; the largest general and M1
macrophage response was induced by 75 mg/mL composites and largest M2 response
was induced by 300 mg/mL composites. Based on these findings, the low HeMA-HA, 75
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mg/mL composite was selected for assessment in an in vivo ovine MI model. Composite
treatment data was compared to a previously studied treatment with empty low HeMAHA hydrogels to determine if microsphere incorporation prolonged the lack of stability
imparted by empty low HeMA-HA and attenuated LV remodeling. Composite treatment
increased the thickness of the apical infarct region and decreased ventricle dilation,
particularly at 2 weeks when compared to empty low HeMA-HA hydrogels. These data
suggest that prolonging mechanical support by natural collagen bulking enhances
treatment. Infarct area was statistically significantly decreased to a similar extent by
both low HeMA-HA and composite treatment and may be due in part to the bioactive role
of HA.
When comparing in vivo outcomes (Table 9.1) between all five hydrogel
treatments discussed in this dissertation, this work demonstrates that stiffer, longer
lasting biomaterials are most effective in attenuating LV remodeling.

Interestingly,

although not as effective in limiting geometric changes, degradable HA systems (i.e., low
and high HeMA-HA and low HeMA composites) are more effective in limiting infarct size,
suggesting an additional biological mechanism in HA injectable materials. Overall, this
work supports that material design criterion is important to consider when developing
treatments to attenuate LV remodeling.
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Table 9.1 Summary of in vivo outcomes for infarct control and all five hydrogel
treatments: normalized thickness (to remote myocardium) at 8 weeks (8W) post-MI,
infarct area at 8W post-MI, normalized end diastolic and end systolic volumes (to
baseline volumes, NEDV and NESV) at 2W and 8W post-MI, and ejection fraction (EF)
at baseline, 2W, and 8W and after dobutamine (DoB, 2.5 and 5.0 mg kg-1 min-1) stress
testing post-MI. Data are presented as mean ± SEM.

9.2 Limitations and Future Directions
9.2.1 Specific Aim 1
To theoretically examine different formulations of MeHA hydrogels with various
mechanics and volume distributions to determine their influence on stress reduction in a
FE model of the dilated LV.
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9.2.1.1 Limitations
Limitations in In Vitro Data Acquisition
A general limitation to the explant work performed in this dissertation was that
explant myocardial tissue used was 1) from normal myocardium (not infarct) and 2)
thawed from frozen explants. Studies have shown that infarcted tissue has different
mechanical properties than normal myocardium [2-5]; thus, the tissue used could
influence FE input values. Additionally, most biaxial testing on myocardium uses fresh
tissue [4, 6, 7]. While to our knowledge a direct comparison between the mechanical
properties of thawed and fresh myocardium has not been performed, comparisons with
other tissues have shown that freezing and thawing may alter mechanical properties [8,
9].

Ideally, to circumvent these limitations, biaxial testing should be performed by

injecting MeHA formulations into an infarcted heart in vivo and later sacrificing the
animal and performing biaxial testing on the tissue
In this work, samples were only subjected to equibiaxial testing; typically, biaxial
testing is performed at numerous ratios to generate several sets of data to fit the
constitutive equation to generate a unique set of parameters. While this would have
been ideal, the diastole passive mechanical parameters reported here for control
myocardium are similar to parameters that have been previously reported for large
animals [10-12]. Another limitation concerning biaxial testing was that grip strains did
not completely match with tissue strains, possibly due to the heterogeneous nature of
injection throughout the tissue and to the transmurally dependent changes in fiber
orientation.
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Limitations in Finite Element Model
As discussed in the previous section, normal myocardial explant tissue rather
than infarcted tissue was used in this work. Consequently, to maintain consistency with
the acquired material parameters it was assumed that contraction at the injection sites
was similar to normal myocardium and active systole parameters were selected to
simulate these properties. Another limitation in the FE model was its inability to replicate
the exact geometry of injections; thus, an ellipse was selected as the best approximation
to represent all formulations (depending on their volume).
Finally, the FE model itself was limited in that it could not accommodate 20
injections at the calculated average volumes for most groups (i.e., high MeHA, low A/T,
low MeHA, high A/T, high MeHA, high A/T). As discussed in Section 5.2.3.2, volumes
were decreased systematically for initial FE analysis to make relative comparisons
between groups.

Despite these adjustments, this data may not accurately reflect

specific stress reductions from modeling with the average calculated volumes. Related
to the aforementioned limitation, the distribution of injections was modeled as a 5 by 4
grid, and, while a good approximation, is not completely representative of the pattern
employed in in vivo studies, which follows more of a tapering of injections as they
approach the apex of the heart [1].

9.2.1.2 Future Directions
To better understand stress reduction due to hydrogel treatment, the FE model
should be adjusted to incorporate larger volumes and an injection distribution that more
closely matches previous in vivo work [1]. Simulations should be performed using the
calculated average injection volumes to achieve stress data that corresponds to the
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exact formulations studied. These stress data would provide valuable insight on future
hydrogel formulations to implement and test in vivo.
Future work should also evaluate the influence of hydrogel volume, in hydrogels
with similar mechanics, on stress reductions. This would be accomplished by varying
hydrogel properties by altering initiator concentration, macromer percent modification,
and weight percent to design different hydrogel formulations with similar volumes and
different mechanics.

Similar in vitro characterization (i.e., MRI imaging and biaxial

testing) would be performed to acquire hydrogel volume and mechanical data for FE
model simulation to determine stress reductions.
Overall, in addition to stress, global pump function should also be theoretically
assessed. Others have demonstrated (via theoretical modeling) that reductions in stress
do not necessarily translate to improvements in global functionality (e.g., stroke
volume/end diastolic pressure relationship) [13]; thus, the influence of material treatment
on these functional metrics should be further assessed (pending the appropriate model).

9.2.2 Specific Aim 2
To synthesize and characterize hydrolytically degradable HA hydrogels and select
formulations to assess the temporal role of mechanical support in attenuating LV
remodeling in an in vivo ovine MI model.

9.2.2.1 Limitations
Limitations in In Vitro Characterization
In this section, the distribution of HeMA-HA hydrogels was normalized to MeHA
hydrogels by altering APS and TEMED concentrations to achieve a similar gel onset
time (assessed via rheometry) as MeHA hydrogels. While gel onset has been assessed
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this way in previous reports [1], MRI studies from Chapter 4 demonstrated that despite
exhibiting similar gel onset times, hydrogels of differing methacrylation may not distribute
similarly.

This was particularly seen in formulations with low modification and low

initiator concentrations; however, gel onset trends seemed to correlate well with MRI
data when comparing between hydrogels with higher macromer modifications and
initiator combinations. MRI imaging may be a better assessment of material distribution
in tissue. Yet, the work in this Aim was performed before MRI data was used for volume
calculations.

Limitations in In Vivo MI Model Assessment
The extent of remodeling in this study was evaluated by injecting the hydrogel
treatment into the infarct region 30 minutes post-MI in an in vivo ovine MI model. While
this model has been used in several previous studies to evaluate the efficacy of material
treatment in limiting LV remodeling, this time-frame is not necessarily clinically relevant
[1, 14-16].

Material delivery to the infarct region should be evaluated at other time

points. Furthermore, most in vivo metrics were assessed utilizing three-dimensional (3D) echocardiography, which was unable to provide data on resulting myocardial strain in
infarct control and hydrogel treatment cohorts; hence, employment of other tools (i.e.,
imaging modalities) should be considered to provide more information with regard to
tissue properties.
Studies have demonstrated that treatment with HA can increase angiogenesis,
and in a MI model it has shown regenerative capabilities [17, 18]. However, in this work,
the delivery of HA is coupled to mechanical and degradation behavior.

In order to

completely understand the role of HA in this study, biological and mechanical influences
would need to be decoupled; this could be done by assessing treatment with a non&(*!
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bioactive hydrogel with tunable mechanics and degradation that matched HeMA-HA
formulations.

9.2.2.2 Future Directions
To determine the optimal duration of mechanical support that is required to limit
LV dilation, future investigation should entail designing HeMA-HA hydrogels with higher
mechanics and longer degradation times.

This may be accomplished by varying

macromer modification, macromer weight percent, and initiator concentrations.

In

addition to improving material design, future studies should be performed in an in vivo
model where geometric and functional outcomes can be measured via MRI instead of
echocardiography. This type of assessment has been performed in the past and would
provide more informative outcomes for this work including strain data that could be
directly input into a FE model to determine stresses without the need for additional
biaxial testing [19]. In addition to being a more efficient model for data acquisition at any
given time point, MRI assessment allows for strain data acquisition throughout the study.
Thus, temporal stress profiles could be acquired and directly correlated to geometric and
functional improvements using this type of method.

9.2.3 Specific Aim 3
To design various hydrogel/microsphere composites to evaluate their influence on
collagen production and macrophage response in a subcutaneous model, and to identify
an optimal composite formulation to attenuate LV remodeling in an in vivo ovine MI
model.
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9.2.3.1 Limitations
Limitations in In Vitro Characterization
The same limitations concerning the correlation of gel onset and gel distribution
are relevant to this Aim and should be addressed as discussed in Aim 2.

Limitations in In Vivo Subcutaneous Model Assessment
While subcutaneous results indicated a clear dependence of bulking on
microsphere concentration and macromer modification, the macrophage phenotypic
response was only investigated at a single time point. Specifically, subcutaneous work
was only assessed for 4 weeks, because hydrogels degraded in vitro by 3 weeks.
Longer implantation could provide more information on general composite degradation
and on macrophage phenotype with time.

Limitations in In Vivo MI Model Assessment
As in Aim 2, the efficacy of the selected composite to attenuate LV remodeling
was assessed in an in vivo ovine MI model via 3-D echocardiography. Thus, the same
concerns regarding injection 30 minutes post-MI and limitations with the employed
imaging modality remain for this Aim. IHC for specific macrophage phenotypes was not
performed in this study because, to our knowledge, anti-M1 macrophage antibodies for
sheep are not available. To better characterize macrophage phenotypic responses to
composite treatment in MI, an alternative animal model could be explored.
limitations to Aim 2 regarding the biological role of HA also apply here.
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Similar

9.2.3.2 Future Directions
Future work should entail performing studies to better understand the FBR
induced by composites and to further increase the induced collagen bulking to enhance
stability following MI.

The former could be accomplished by prolonging the in vivo

subcutaneous studies to at least 8 weeks; tissue responses could then be directly
compared to results observed at 8 weeks in the employed MI model. MT staining would
be performed to assess collagen infiltration and IHC for general, M1 and M2
macrophages should be performed to gain insight on the macrophage-phenotypicspecific response.
To further understand the FBR and determine if the observed responses in these
studies are PLGA-dependent, alternative microsphere stimuli (i.e., of similar size and
concentration but synthesized from a different polymer) could be incorporated into
HeMA-HA hydrogel carriers. Examples of alternative microsphere candidates include
less degradable poly-lactic acid or polymethylmethacrylate microspheres, which have
already been extensively used in dermal fillers [20]. Induced tissue responses could be
assessed in a subcutaneous in vivo model and explants analyzed via MT and IHC (e.g.,
general, M1 and M2 macrophage) staining.
To further enhance bulking, alternative concentrations of PLGA microspheres
within HeMA-HA hydrogels could be evaluated. A concentration of 300 mg/mL was
originally selected as the extreme case for this work to match the concentration of
calcium hydroxyapatite microspheres that comprise Radiesse (the dermal filler employed
by Morita et al. to treat LV remodeling [14]). A microsphere concentration between 75
and 300 mg/mL was not assessed in this work; it is possible that an intermediate
composite may provide optimal bulking both subcutaneously and after MI.

Tissue

responses could be initially assessed in an in vivo subcutaneous model and evaluated
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!

via MT and IHC staining on explants.

Following validation of bulking in the

subcutaneous model, the composite treatment could be evaluated in an in vivo ovine MI
model to assess its ability to attenuate LV remodeling with evaluation metrics including
thickness, chamber volume, and infarct area.
In addition to adjusting the type and concentration of particle stimuli, stimulatory
proteins and/or cytokines including TGF-", Il-10, and Il-4 could be encapsulated within
microspheres to induce the desired M2 inflammatory response.

ELISA would be

performed to optimize factor release from microspheres for in vivo application.
Subsequently, composites with stimulatory factors could be implanted subcutaneously to
examine their induced biological response by performing MT staining and IHC for
general, M1 and M2 macrophages.

9.3 Conclusions
Geometric alterations in LV remodeling are thought to be the main contributor in
the onset of HF, but are not adequately addressed by current therapies. The goal of this
dissertation was to understand the influence of material properties of acellular injectable
biomaterials as a minimally invasive strategy to stabilize the myocardial wall and limit LV
remodeling.

This was accomplished by employing tunable HA-based hydrogels that

were formed via redox initiation. Overall, in addition to the importance of higher initial
mechanical support for stress reduction in the dilated LV, the data presented in this
dissertation indicates that temporal considerations are critically important in material
design and that longer mechanical support results in the largest benefits towards
attenuating LV remodeling. The findings of this dissertation represent advancements in
material design and will be beneficial in developing more effective injectable material
treatments to better target LV remodeling and prevent the onset of HF.
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